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The emergence and spread of carbapenem-resistant organisms (CRO) is a 
global public health threat in healthcare settings, resulting in high mortality, 
prolonged healthcare and increased costs. In the last two decades, many 
papers aiming to identify individuals at high risk of acquiring CRO have been 
published. However, the results reported across these studies are inconsistent 
and there are no studies systematically summarising those findings. 
Carbapenem resistance is mediated by multiple mechanisms. 
Carbapenemase production is the most concerning as the encoding genes of 
carbapenemases are located on mobile genetic elements, facilitating 
horizontal genetic exchange and therefore promoting the acquisition and 
spread of resistance genes. Examination of the epidemiology of 
carbapenemase-producing organisms (CPO) will inform local infection 
prevention and control strategies.  
This thesis has two main parts. The aim of the first part is to systematically 
summarise risk factors for CRO infection and colonisation in healthcare 
facilities worldwide and identify study characteristics contributing most to the 
heterogeneity across studies. In the second part I focused on CPO in Scotland 
to investigate the incidence, microbiological characteristics and outcomes of 
CPO and determine risk factors associated with CPO among hospitalised 
patients. 
In the first part, I conducted a systematic review and meta-analysis to evaluate 
risk factors associated with infection and/or colonisation of CRO in healthcare 
facilities. In total, 227 papers published between 1986 and 2016 were 
identified. Using pooled odds ratio estimates and the likelihood of statistical 
significance as criteria, prior carriage of multidrug-resistant organisms, prior 
antibiotics usage (carbapenem or oxazolidinone), prior provision of medical 
devices (mechanical ventilation or nasogastric tube) and prior healthcare 
exposure (intensive care unit ICU stay, and longer hospital stay) were most 
consistently found to be leading risk factors for CRO infection and/or 
colonisation. Additionally, decubitus ulcer was a specific leading risk factor for 
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CRO infection, and prior antibiotics usage (polymyxin or cefepime) and steroid 
treatment were specific for hospital acquired CRO infection. However, prior 
provision of some medical devices (parenteral nutrition or gastrostomy or 
urinary catheter) were only leading risk factors for CRO colonisation. Study 
organism, case-control selection, study population, sample size, study setting 
and specialty (ICU or non-ICU) were the characteristics accounting for most 
heterogeneity across the published studies examined. 
In the second part of this thesis, I focused on CPO in Scotland using data 
extracted from several national datasets. I performed a retrospective analysis 
on all CPO from clinical and screening cultures in 2003-2016 using generalised 
linear models and survival analyses, and then conducted a matched case-
control study to determine risk factors for CPO infection and colonisation 
among hospitalised patients using conditional logistic regression models. In 
total, 243 CPO isolates were identified in 214 individuals from 13 of 14 NHS 
Boards. The overall incidence of CPO cases increased significantly (P<0.001), 
from 0.02 to 1.38 per 100,000 population. The case fatality rate was 5.6%. 
Enterobacteriaceae isolates predominated (84.8%) and increased significantly 
faster than non-fermenters. Community-associated CPO were more likely to 
be colonisations while healthcare-associated CPO were more likely to be 
infections. The ‘big 5’ carbapenemases (VIM, NDM, KPC, OXA-48 and IMP) 
predominated (96.7%). Awareness is required that older patients, with 
systemic infection or organ failure or presenting non-fermenters are at higher 
30-day mortality risk from CPO. Patients with CPO infection had higher 
hospital mortality and longer hospital stay. A history of prolonged 
hospitalisation, prolonged ICU or high dependency unit (HDU) stay and being 
immunocompromised all independently increased the risk of CPO infection, 
while a history of HDU stay and ‘endocrine, nutritional and metabolic diseases’ 
were independent risk factors for CPO colonisation. 
In conclusion, this thesis sheds light on patients at high risk of being infected 
or colonised by CRO including CPO in healthcare facilities. Pre-emptive 
management should be prioritised for these patients. The findings also 
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demonstrate the necessity of continuing the existing acute hospital admission 
screening programme for carbapenemase-producing Enterobacteriaceae in 
Scotland. Future efforts are required to understand underlying factors 





Since their discovery 90 years ago, antibiotics have saved countless lives from 
infections. Due to extensive usage, resistance to antibiotics emerged, 
including the last resort antibiotics-carbapenems. Increasing numbers of 
carbapenem-resistant organisms (CRO) have been found globally over the 
past decade. Studying CRO worldwide and locally will help healthcare 
professionals and policy makers to address key questions of infection 
prevention and control of CRO. 
To determine who is likely to acquire CRO in healthcare facilities, I summarised 
the findings from published papers on this topic worldwide in the last 30 years. 
The results highlight the leading risk factors, such as prior treatment with 
specific antibiotics and medical devices. I identified some study-design 
characteristics that warrant more careful consideration in future studies. 
Carbapenem resistance arises from multiple mechanisms, but 
carbapenemase-producing organisms (CPO) are the most concerning due to 
their easy transferability. I conducted a retrospective epidemiology study of 
CPO since its first report in 2003 until the end of 2016 using data in Scotland. 
My results show that the incidence of CPO is relatively low but increasing 
rapidly. CPO infections are more likely to be healthcare-associated while 
community-associated CPO is associated with colonisation. Mortality for 
individuals in Scotland with CPO is low but CPO infections result in prolonged 
hospital stay. A history of (prolonged) healthcare exposure and being 
immunocompromised were independently associated with CPO infections. 
Also, a subgroup of patients that are at a higher risk of death from CPO were 
identified.  
These findings highlight the importance of CPO surveillance in both hospitals 
and the community. Knowledge of risk factors for acquiring CRO including 
CPO will help policy makers to develop more effective strategies for the 
prevention and control of carbapenem resistance, and encourage healthcare 
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Chapter 1 Introduction 
1.1 Emergence of carbapenem resistance 
1.1.1 Development of carbapenems 
Bacterial β-lactamases emerged and threatened the use of penicillin in the late 
1960s (Cole, 1980; Rolinson, 1991). In 1976, scientists discovered the first β-
lactamase inhibitors, olivanic acids, a natural product of Streptomyces 
olivaceus. However, they had poor chemical instability and penetration into the 
bacterial cell (Hood et al., 1979). Searches for other β-lactamase inhibitors 
identified two agents: clavulanic acid and thienamycin. Thienamycin was the 
first “carbapenem”, naturally generated from Streptomyces cattleya (Birnbaum 
et al., 1985). It is not clinically useful due to instability in aqueous solution, 
sensitivity to mild base hydrolysis (above pH 8.0), and highly reactive to 
nucleophiles (Kahan et al., 1979), but it serves as the parent or model 
compound for all carbapenems. After that, clinically useful carbapenems were 
developed. Structurally, carbapenems are similar to penicillins but have some 
unique substitutions (Knapp and English, 2001), which confer enhanced 
Gram-negative coverage and activity as compared with other β-lactams as well 
as stability against extended-spectrum β-lactamases (ESBL) which are 
capable of hydrolysing almost all β-lactam antibiotics. Carbapenems have 
been proven to have low oral bioavailability and must be administered 
intravenously or intramuscularly because they cannot cross the 
gastrointestinal membranes readily (Papp-Wallace et al., 2011). 
Carbapenems currently on the market are imipenem-cilastatin, meropenem, 
ertapenem, doripenem, biapenem and panipenem/betamipron (Codjoe and 
Donkor, 2018). Additionally, novel carbapenems such as razupenem, 
tebipenem, tomopenem and sanfetrinem are under development. Due to lack 
of the 1-β methyl group which confers resistance to renal hydrolysis by 
dehydropeptidase I (Knapp and English, 2001), imipenem must be 
administered with dehydropeptidase I inhibitor cilastatin. Panipenem is more 
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stable than imipenem against hydrolysis by dehydropeptidase I; however, it is 
still susceptible to hydrolysis by dehydropeptidase I, and is therefore 
administrated with a dehydropeptidase I inhibitor, betamipron. Carbapenems 
exhibit broad spectrum activity against Gram-negative bacilli and somewhat 
narrower activity against Gram-positive bacteria. In general, imipenem, 
panipenem and doripenem are effective against Gram-positive bacteria while 
meropenem, ertapenem, biapenem and doripenem are more potent against 
Gram-negative bacilli. In the UK, imipenem-cilastatin, meropenem and 
ertapenem are licensed in clinical practice. 
 Imipenem was the first carbapenem developed in 1979 and was 
approved for clinical use in the United States in 1985 and in the United 
Kingdom (UK) in 2009 (Medicines and Healthcare products Regulatory 
Agency) (Figure 1-1). It is available in both intravenous and 
intramuscular formulations. Imipenem-cilastatin is particularly important 
for its activity against Pseudomonas aeruginosa, however, it is not 
active against Methicillin-resistant Staphylococcus Aureus (MRSA) 
(Papp-Wallace et al., 2011). 
 Meropenem was approved for clinical use in the United States in 1996 
and in the UK in 2010 (Medicines and Healthcare products Regulatory 
Agency) (Figure 1-1). It is just available in intravenous formulations. 
Meropenem is not as potent as imipenem or doripenem against 
Acinetobacter baumannii (Papp-Wallace et al., 2011).  
 Ertapenem was launched in the United States in 2001 and in the UK in 
2004 (Scottish Medicines Consortium) (Figure 1-1). It has longer 
elimination half-life than imipenem-cilastatin and meropenem, so is 
used as a long-acting carbapenem. It can be administered either 
intravenously or intramuscularly. Notably, ertapenem has limited activity 
against Pseudomonas aeruginosa, Acinetobacter spp., MRSA and 
Enterococci (Di Modugno et al., 1994). 
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 Doripenem was launched in Japan in 2005 and approved for in the 
United States in 2007 (Figure 1-1). In the UK, doripenem was granted 
marketing authorisation in 2009, however, it was withdrew in 2014 due 
to lower cure rates and higher death rates compared with imipenem-
cilastatin (Scottish Medicines Consortium, 2014; European Medicines 
Agency, 2014). It has similar activity as imipenem against Gram-
positive bacteria and meropenem against Gram-negative bacilli, but it 
has lower minimum inhibitory concentration and higher blood 
concentration and longer half-life than imipenem and meropenem 
against Pseudomonas aeruginosa and Acinetobacter baumannii 
(Mandell, 2009; Bassetti et al., 2009). Additionally, doripenem is the 
carbapenem least susceptible to hydrolysis by carbapenemases 
(Queenan et al., 2010). 
Due to the low activity of ertapenem against Pseudomonas spp., the 
antipseudomonal carbapenems in clinical use worldwide comprise imipenem, 
meropenem and doripenem. 
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Figure 1-1. Timeline of introduction of carbapenems and first report of carbapenemases worldwide. The flags indicate 
the countries where carbapenems were first approved for clinical use worldwide, and the countries where 
carbapenemases were first reported from. The year in which each carbapenem was first licensed in the United Kingdom 
is also shown in this figure. 
Source: (Medicines and Healthcare products Regulatory Agency; Scottish Medicines Consortium) 
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1.1.2 Mechanisms of carbapenem resistance 
Due to their potent antibacterial activity, stability against β-lactamases, fewer 
adverse effects and concentration-independent killing effect, carbapenems are 
utilised as the last line agents for treating severe infections caused by 
multidrug-resistant organisms. In clinical practice, carbapenem resistance in 
Gram-negative bacilli comprising Enterobacteriaceae (e.g. Escherichia coli, 
Klebsiella pneumonia) and non-fermenters (non-glucose-fermenting Gram-
negative bacilli, e.g. Pseudomonas aeruginosa, Acinetobacter baumannii) is 
of greatest concern. Of note, carbapenem resistance is intrinsic in some 
bacteria (Stenotrophomonas spp., Proteus spp., Providencia spp. and 
Morganella spp.) (Clinical and Laboratory Standards Institute, 2019). These 
bacteria are opportunistically pathogenic and not common among species of 
clinically importance. Stenotrophomonas maltophilia that possesses the 
endogenous metallo-beta-lactamases L1 is the only organism occasionally 
associated with hospital acquired infections (Sanchez, 2015). In addition, 
Morganella morganii, Proteus spp. and Providencia spp. have intrinsic 
imipenem resistance. 
In general, resistance to carbapenems arises from two mechanisms: 
enzymatic or non-enzymatic. The enzymatic mechanism is production of 
carbapenemases. Non-enzymatic mechanisms include decreased outer 
membrane permeability or over-expression of efflux pumps with or without 
production of an ESBL and/or AmpC. Several studies have suggested that 
carbapenem resistance introduced by porin (components of outer membrane) 
defects is unstable. This could result from lower fitness and decreased growth 
ability of strains with an outer membrane permeability defect (Doumith et al., 
2009). Additionally, carbapenem resistant strains that do not produce 
carbapenemases are usually less resistant to other antibiotics (Nordmann et 
al., 2012a) and their carbapenem resistance trait is not transferable. For this 
reason, carbapenem resistance arising from a non-enzymatic mechanism are 
considered of less clinical concern than carbapenemase production. 
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1.1.2.1 Carbapenemase mediated carbapenem resistance 
Carbapenemases are able to inactivate carbapenems together with other β-
lactam antibiotics, conferring high level resistance to most clinically used 
antibiotics. Carbapenemases are encoded by genes frequently carried on 
horizontally transferable mobile genetic elements such as plasmids and 
transposons that also carry genes encoding for other resistance determinants. 
Carbapenemase producers have largely been responsible for the rapid 
worldwide spread of carbapenem resistance (Nordmann, 2014). 
According to Ambler’s structural classification based on analogies of the 
peptide sequence (Ambler, 1980), β-lactamases are classified in 4 groups, A 
to D. Enzymes of groups A, C, and D are serine enzymes, while group B 
enzymes are metallo-beta-lactamases. Carbapenemases belong to group A, 
B, and D. Ambler class A carbapenemases consist of Klebsiella pneumoniae 
carbapenemase (KPC), Serratia marcescens enzyme (SME), non-
metalloenzyme carbapenemase (NMC)/imipenem-hydrolyzing β-lactamase 
(IMI) and Guiana extended spectrum (GES). Ambler class B carbapenemases 
include imipenemase (IMP), Verone integron-encoded metallo-β-lactamase 
(VIM), New Delhi metallo-β-lactamase (NDM), German imipenemase (GIM), 
Sao Paulo metallo-β-lactamase (SPM), Seoul imipenemase (SIM), Australia 
imipenemase (AIM) and Kyorin University Hospital imipenemase (KHM). 
Ambler class D carbapenemases are the oxacillinase (OXA) β-lactamases, 
consisting of many variants. Although class C enzymes are not 
carbapenemases per se as their hydrolytic activity against carbapenems is 
very weak or non-existent, they can play a role in resistance to carbapenems 
in the context of permeability defects (Meletis, 2016). The principal 
characteristics and geographical epicentres of carbapenemases according to 
Ambler class are listed in Table 1-1. 
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1.1.2.2 Non-carbapenemase mediated carbapenem resistance 
In contrast to carbapenemase production, the non-enzymatic mechanism of 
carbapenem resistance is frequently associated with a loss in fitness to the 
organism and reduced transmissibility. These mechanisms include loss of 
expression of porin-encoding genes, mutations in chromosomally encoded 
porin genes, and overexpression of genes encoding efflux pumps. There are 
some differences of non-carbapenemase mediated carbapenem resistance 
between Enterobacteriaceae and non-fermenters. 
For non-carbapenemase producing carbapenem resistant 
Enterobacteriaceae, the mechanisms include production of ESBL and/or 
AmpC in conjunction with outer membrane alterations. ESBL and AmpC could 
hydrolyse carbapenems at low levels, but in conjunction with decreased 
membrane permeability or efflux pump over-expression, these enzymes are 
more effective at preventing carbapenems from reaching their binding targets 
at sufficient concentrations to exert their antibacterial effect (Livermore and 
Woodford, 2006; Poirel et al., 2004a; Oteo et al., 2008). For non-
carbapenemase producing carbapenem resistant non-fermenters, the 
mechanisms often work synergistically, consisting of efflux pumps, target 
modification and porin deficiency. The efflux pump associated with 
carbapenem resistance in Acinetobacter spp. is the chromosomally encoded 
AdeABC. Synergy between AdeABC and oxacillinases has been reported to 
result in higher levels of resistance to carbapenems (Heritier et al., 2005). 
MexAB-OprM is the most common pump system conferring intrinsic resistance 
in P. aeruginosa. It works together with other pump systems, like MexCD-OprJ, 
MexEF-OprN, MexJK-OprM and MexVW-OprM, to cause resistance to 
carbapenems (Poole, 2001). 
Arranged by resistance mechanisms, the terms used to describe carbapenem 
resistance in Gram-negative bacilli are summarized in Table 1-2. 
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1.2 Epidemiology of carbapenem resistance 
An increased consumption of carbapenems has been reported worldwide in 
recent years (Klein et al., 2018; Rhodes et al., 2019; European centre for 
Disease Prevention and Control, 2018). As a result, there is an emerging 
global public health threat of CRO, leaving few effective therapeutic options 
available for multidrug-resistant organisms infections and ultimately causing 
high mortality and increased healthcare costs. In 2017, the World Health 
Organization (WHO) published a list of antibiotic-resistant bacteria that are of 
global priority which included carbapenem-resistant Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacteriaceae (World Health 
Organization, 2017b). Therefore, some countries and/or regions have set up 
surveillance systems for CRO. Recent reviews of the epidemiology of CRO 
have found that the epidemiology varies geographically (Gniadek et al., 2016; 
van Duin and Doi, 2017), and there is still a scarcity of accurate and reliable 
data on CRO prevalence, outcomes, detection and infection prevention and 
control. 
1.2.1 Prevalence and disease burden 
Different methodologies used to detect carbapenem resistance and resistance 
mechanisms, and various antimicrobial administration and infection control 
and prevention measures and/or policies in both healthcare facilities and 
communities might account for the geographical diversity in epidemiology and 
disease burden of CRO. Despite these differences, it is widely reported that 
CRO are increasing globally and are associated with higher mortality rates, 
prolonged healthcare and increased healthcare costs (Falagas et al., 2014; 
Zilberberg et al., 2017). Moreover, in most regions carbapenem-resistant non-
fermenters are the most problematic pathogens, carbapenem-resistant non-
fermenters generally accounting for a higher proportion of CRO and higher 
resistance rates to carbapenems than CRE (Nordmann and Poirel, 2019). 
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1.2.1.1 North America 
The 2019 report entitled ‘Antibiotic Resistance Threats in the United States’ 
listed CRE and carbapenem-resistant Acinetobacter spp. as urgent threats 
(Centers for Disease Control and Prevention, 2019). KPC is the most common 
carbapenemase while NDM, VIM and OXA-48 are also reported. The highest 
prevalence of carbapenem resistance among Gram-negative health care-
associated infections in the United States, as reported by the National 
Healthcare Safety Network, was observed among Acinetobacter baumannii 
(62.6%) and Pseudomonas aeruginosa (26.1%). Among CRE, carbapenem 
resistance was highest among Klebsiella pneumoniae, at 12.8% (Sievert et al., 
2013).  
Compared with data in an earlier report (Centers for Disease Control and 
Prevention, 2013), the burden of CRE in the United States increased from 
11,800 cases and 1,000 deaths in 2012 to 13,100 cases and 1,100 deaths in 
2017. Infection with CRE was associated with a four-fold increased risk of 
receiving inappropriate empiric antimicrobial treatment, which in turn increased 
mortality (12%), the length of hospital stay (>5.2 days) and healthcare costs 
(extra $10,312) (Zilberberg et al., 2017). Furthermore, the cost associated with 
CRE is higher than the cost of many chronic and acute diseases, and costs 
rise proportionally with the incidence of CRE, increasing by 2.0 times, 3.4 
times, and 5.1 times for incidence rates of 6, 10, and 15 per 100,000 persons 
respectively (Bartsch et al., 2017). Unlike CRE the burden of carbapenem-
resistant Acinetobacter spp. decreased from 11,700 cases and 1,000 deaths 
in 2012 to 8,500 cases and 700 deaths in 2017. Despite the decline, the threat 
level for carbapenem-resistant Acinetobacter spp. was escalated to urgent 
because of the lack of antibiotics, both in clinical use and in development, 
available to treat these infections (Centers for Disease Control and Prevention, 
2019). 
Epidemiological data on CRO in Canada is quite limited. According to the 
report of the Canadian Nosocomial Infection Surveillance Program conducted 
between 2011-2015 in 64 acute-care hospitals (Government of Canada, 
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2016), the number and incidence rate of CPO infections were 16-27 and 0.033-
0.041 per 10,000 patient-days while the number and incidence rate of CPO 
colonisations were 21-36 and 0.032-0.087 per 10,000 patient-days. All-cause 
30-day mortality rate was 12.5-27.3 per 100 CPO cases. The most common 
carbapenemases were KPC (66.9% per year) and NDM-1 (17.3% per year), 
with a significant increase in OXA-48 between 2010 and 2014 (Mataseje et al., 
2016). 
1.2.1.2 Europe 
Data from the European Antimicrobial Resistance Genes Surveillance Network 
and its predecessor the European Survey of Carbapenemase-Producing 
Enterobacteriaceae show that the situation for CPE worsened between 2010 
and 2018 (Brolund et al., 2019). Increases in the epidemiological stage (stage 
0-5: no case reported, sporadic occurrence, hospital outbreaks, regional 
spread, interregional spread and endemic) between 2015 and 2018 were 
observed in 11 out of the 37 participating countries, with 15 countries reporting 
interregional spread or an endemic situation (Brolund et al., 2019). KPC, NDM, 
OXA-48 and VIM were widely distributed carbapenemases. However, 29.3% 
(353/1203) of Klebsiella pneumonia and 60.3% (117/194) of Escherichia coli 
(E. coli) isolates were confirmed to have other resistance mechanisms as well 
(Grundmann et al., 2017). E. coli with resistance to carbapenems remained 
rare but showed a significantly increasing trend in Europe, ranging from 0% to 
2.0% between countries. For Klebsiella pneumoniae, the national percentages 
of resistant isolates ranged from 0% to 63.9 % while for Pseudomonas 
aeruginosa and Acinetobacter spp. percentages of resistant isolates ranged 
from 0% to 55.1% and from 0% to 95.5% respectively in 2018 (European 
Centre for Disease Prevention and Control, 2019c). One survey conducted 
between May 2015 and June 2017 including 211 laboratories in 20 European 
countries and showed that 60 laboratories (36%) reported an outbreak of CRE 
during one of the two years preceding the completion of the survey. Rates of 
carbapenem resistant Acinetobacter spp. above 50% were reported by 74 
laboratories (47%), particularly in the Western Balkan countries where the 
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rates were higher than 90% (Kostyanev et al., 2019). The highest percentages 
of carbapenem resistance were reported from southern and south-eastern 
European countries, a pattern that has also been reflected by point prevalence 
survey of healthcare-associated infection (HCAI) and antimicrobial use in 
European acute care hospitals (Plachourasi et al., 2018; Cassini et al., 2019). 
According to the European Centre for Disease Prevention and Control study 
of the disease burden of antimicrobial resistance, CRO accounted for 16.0% 
(107,801 of 671,689) of infections caused by antibiotic-resistant bacteria, 26.5% 
(8,777 of 33,110) of attributable deaths and 31.5% (53.5 of 170) of the total 
disability-adjusted life-years per 100,000 population, respectively (Cassini et 
al., 2019). Of note, carbapenem-resistant Klebsiella pneumoniae had a high 
burden of disease because of its higher attributable mortality, and the burden 
increased the most (by 6 fold) in terms of number of infections and number of 
deaths between 2007 and 2015. In addition, the burden of infections with CRO 
was focused in the southern and eastern part of Europe: Italy, Greece, Croatia, 
Bulgaria and Hungary in particular. The proportion of disability-adjusted life-
years due to all CRO increased from 18% (56,150 of 311,715) in 2007 to 28% 
(185,421 of 678,845) in 2015 (Cassini et al., 2019), indicating the emergence 
and rapid increase of CRO in Europe during this period. In terms of 
carbapenem usage in Europe, carbapenems ranked second among the most 
commonly antimicrobial prescriptions used for the treatment of HCAI (9.9%) 
(Plachourasi et al., 2018). 
1.2.1.3 Asia-Pacific 
In South and Southeast Asia, where the rates of carbapenem resistance are 
some of the highest in the world, estimated prevalence of carbapenem-
resistant Acinetobacter baumannii ranged from 1% to >90% and that of 
carbapenem-resistant Pseudomonas aeruginosa ranged from 23.3% to 46.7% 
(Kiratisin et al., 2012; Sheng et al., 2013). Carbapenem resistance rates in 
Enterobacteriaceae have been lower (0.4%-25.0%) than those in 
carbapenem-resistant Acinetobacter baumannii/Pseudomonas aeruginosa, 
but longitudinal studies have shown dramatic increases in resistance rates 
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over time (Kiratisin et al., 2012; Sheng et al., 2013). Regional resistance 
surveillance programme results for 12 Asia-Pacific nations in 2011 indicated 
that carbapenem resistance rates for Klebsiella spp. ranged from 0% to 25% 
and carbapenem-resistant Pseudomonas aeruginosa from 0% to 50%, highest 
in Philippines (50%) (Mendes et al., 2013). Metallo-beta-lactamases (mainly 
NDM, IMP and VIM) and OXA-48 predominated in this region. In East Asia, 
the 2018 report from Japan Nosocomial Infections Surveillance which include 
1,947 facilities reported that the non-susceptible rates to imipenem and 
meropenem were 0.2% and 0.1% for E. coli, 0.7% and 0.6% for Klebsiella 
pneumonia, 0.0-5.3% and 0.2-1.4% for other Enterobacteriaceae species, 
19.8% and 15.9% for Pseudomonas aeruginosa, and 2.1% and 1.6% for 
Acinetobacter baumannii, respectively (Japan Nosocomial Infections 
Surveillance, 2018). The report from China CRE network covering 25 tertiary 
hospitals in 14 provinces found that the incidence of CRE infection in China 
was 4.0 per 10,000 discharges and the overall hospital mortality rate was 
33.5% (Zhang et al., 2018). A five-year study from the same network showed 
that the overall in-hospital and 14-day mortality rates of bacteremia caused by 
CRE were 32.9% and 31.1%, respectively (Wang et al., 2019). KPC- and 
metallo-beta-lactamases-type carbapenemases were widespread in China. 
Compared with the above regions, disease burden of CRO in New Zealand 
and Australia is relatively low currently. However, the rate of CPE colonisation 
and infection has increased sharply in recent years, and nearly all CPE have 
been imported from overseas (Australian Commission on Safety and Quality 
in Health Care, 2017; Blakiston et al., 2017). In New Zealand, the incidence of 
CPE has increased from three isolates in 2012 to 45 in 2016. The most 
common carbapenemases were NDM and OXA-48, accounting for 59% and 
31% respectively of all carbapenemases identified in Enterobacteriaceae in 
New Zealand (Ministry of Health New Zealand Goverment, 2018). 
Carbapenemases commonly identified in clinical isolates in Australia include 
IMP, NDM, VIM, KPC and OXA48-like (Australian Commission on Safety and 
Quality in Health Care, 2017). The mortality rate associated with the first 
documented outbreak of CPE in Australia, involving 10 cases identified in the 
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seven months to December 2012, was 40% (Australian Commission on Safety 
and Quality in Health Care, 2017). Given this rapid growing public health 
threat, both governments issued relevant guides for screening and infection 
control and prevention management for CPE (Australian Commission on 
Safety and Quality in Health Care, 2017; Ministry of Health New Zealand 
Goverment, 2018). 
1.2.1.4 Latin America 
Recent surveillance in Latin America reveals that rates of carbapenem 
resistance range up to 66% for Pseudomonas aeruginosa and as high as 90% 
for Acinetobacter baumannii isolates across the different countries of Latin 
America, with the resistance rate among Acinetobacter baumannii isolates 
greater than 50% in many countries (Vincent et al., 2009; Gales et al., 2011). 
The percentages of Pseudomonas aeruginosa isolates non-susceptible to 
meropenem and imipenem were 43% and 48%, respectively, which compares 
unfavourably with Pseudomonas aeruginosa isolates collected in Europe (24% 
and 30%, respectively) and North America (11% and 15%, respectively) during 
the same period (Unal and Garcia-Rodriguez, 2005). In Latin America, the 
mortality rate among patients with nosocomial infections caused by metallo-
beta-lactamases carrying Pseudomonas aeruginosa has been reported as 
greater than 50% (Zavascki et al., 2006b). 
Even though information about the prevalence of carbapenemases in Latin 
America is scarce, a review of the literature on different classes and types of 
carbapenemases (Maya et al., 2013), including their current dissemination 
through the Latin American region concluded that carbapenemases belonging 
to all of the three classic classes (A, B and D) have been identified all over the 
Latin American region. New enzymes belonging to this group, as well as the 
ones that have been described in other regions around the world, are 
continuously being reported in Latin American countries (Maya et al., 2013). 
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1.2.1.5 Africa 
Whilst the epidemiology of CRO has been widely described and reported in 
detail in the above regions since their emergence, sparse data are available 
and relatively little is known about the spread and distribution of CRO in Africa 
(World Health Organization, 2018). To inform the gaps, several studies have 
retrospectively reviewed the published work conducted in this region. 
Most studies were conducted in North Africa (74%, 61/83), followed by 
Southern Africa (12%, 10/83). CPO were isolated from humans, the hospital 
environment and community environmental water samples. The prevalence of 
CPO in hospital settings ranged from 2.3% to 67.7% in North Africa and from 
9% to 60% in sub-Saharan Africa. The carbapenemases detected comprised 
KPC, metallo-beta-lactamases, and OXA-48/58/163/181 (Manenzhe et al., 
2015).  
In East Africa, Tanzania exhibited the highest level of carbapenem resistance 
at 35% while Democratic Republic of Congo had the lowest level at 1%. 
Uganda was the only country with studies documenting carbapenem 
resistance obtained amongst hospital environment with incidence ranging from 
21% in Pseudomonas aeruginosa to 55% in Acinetobacter baumannii. 
Carbapenem resistance was more common in Acinetobacter baumannii (23%), 
followed by Pseudomonas aeruginosa (17%), Klebsiella pneumoniae (15%), 
Proteus mirabilis (14%) and E. coli (12%) mainly isolated from respiratory tract, 
blood, urine and wound/pus. The regional carbapenemases detected were 
IMP, VIM-1, SPM-1, NDM-1, OXA-23/24/58 and KPC (Ssekatawa et al., 2018). 
A review of carbapenem-resistant E. coli/Klebsiella spp. including data from 22 
African countries highlighted data gaps in sub-Saharan Africa (Mitgang et al., 
2018). Estimated crude median national carbapenem resistance proportions 
(>1%) for E. coli/Klebsiella spp. were reported from Uganda, Mauritania, 
Nigeria, Ethiopia, Madagascar, Kenya and Cameroon. The carbapenemases 
(or mechanism) accounted for carbapenem resistance included OXA, NDM, 
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VIM, IMP, KPC, DIM, GES and Porin-related mechanisms (Mitgang et al., 
2018). 
1.2.2 Detection 
Antimicrobial susceptibility testing is the initial step for detection of 
carbapenem resistance, including disk diffusion, broth microdilution, E-test and 
automated systems. The results are interpreted according to the 
recommendations from Clinical and Laboratory Standards Institute (CLSI) 
(Clinical and Laboratory Standards Institute, 2019) or European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) (The European Committee on 
Antimicrobial Susceptibility Testing, 2019) guidelines (Table 1-3). Although the 
guidelines have lowered the breakpoints values to permit better detection of 
carbapenemases, using these breakpoints could still miss some 
carbapenemase producers like OXA-48/OXA-181 or KPC (Potron et al., 2011; 
Gagetti et al., 2016). There is no consensus on the cut-off breakpoint values 
of carbapenems that should be applied for carbapenemase activity. When a 
strain shows non-susceptibility (i.e., intermediate or resistant) to carbapenems 
in antimicrobial susceptibility testing, the mechanisms of resistance still 
remains unknown. Therefore, detection of carbapenemase production and/or 
presence of other resistance mechanisms are required. In practice, detection 
of carbapenemase comprise phenotypic and genotypic approaches. 
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1.2.2.1 Phenotypic methods 
A series of phenotypic tests has been developed for detection of 
carbapenemases, however, none of them has 100% sensitivity or 100% 
specificity. The advantages and disadvantages are summarised in Table 1-4. 
The modified Hodge test is a phenotypic method recommended by CLSI which 
is based on whether the growth of indicator strain is affected by the test strain 
with an inactivation effect on carbapenems via carbapenemase production. 
The indicator strain is streaked to an agar plate first and then a 10 µg 
meropenem or ertapenem susceptibility disk is placed in the centre of the plate. 
The test strain is streaked from the edge of the disk to the edge of the plate in 
a straight line. After 16-24 hours of incubation, examine the plate for a clover 
leaf-type indentation at the intersection of the test strain and the indicator strain, 
within the zone of inhibition of the carbapenem susceptibility disk. This method 
usually works well for the detection of KPC and OXA-48 production but lacks 
sensitivity and specificity in detecting metallo-beta-lactamases. Moreover, this 
method is time-consuming as it requires at least 24-48 h. Additionally, 
carbapenemase-inhibition tests using molecules that inhibit the activity of 
carbapenemases is also an approach. Inhibition 
by ethylenediaminetetraacetic acid or dipicolinic acid are used for metallo-
beta-lactamases detection while boronic acid is applied for KPC detection. 
However, these tests are not suitable for detection of carbapenemase 
producers among AmpC-positive species such as Enterobacter spp. or OXA-
48/OXA-181 producers (Giske et al., 2011). 
Another technique recommended by CLSI is the modified carbapenem 
inactivation method. This method detects the carbapenemase production of 
the test strain by measuring the growth of an indicator strain with a 
carbapenem which is inactivated by the test strain. Despite good sensitivity 
and specificity, this method is time-consuming as it requires at least 24-32 h 
(van der Zwaluw et al., 2015). 
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Colorimetric assay is a faster test with lower false-positive rate than modified 
Hodge test. The change of color corresponds to the change in pH of the 
reaction system caused by carbapenemase hydrolysis of carbapenems 
(Nordmann et al., 2012c). A variety of commercial colorimetric products are 
available like Carba NP test, Rapid Carb Blue Kit and Rosco Rapid Carb 
Screen. However, this technique is insufficiently sensitive for the detection of 
OXA-48 production (Tamma et al., 2017b). 
Spectrophotometric assay is reported as an accurate method to detect 
carbapenemases which measure the hydrolysis of carbapenems at a specific 
wavelength (Takeuchi et al., 2018). This approach can differentiate 
carbapenemase-mediated carbapenem resistance and non-carbapenemase-
mediated carbapenem resistance with high sensitivity and specificity. But it 
cannot discriminate different carbapenemase types and the extraction of 
carbapenemase is time-consuming, taking 12-18 h. 
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry is 
an increasing widely used method to detect carbapenemases by analysing the 
degradation spectrum of carbapenem hydrolysis (Burckhardt and 
Zimmermann, 2011). However, the technique requires expensive equipment. 
1.2.2.2 Genotypic methods 
Genotypic methods based on molecular techniques are reference or gold 
standards for detection of both enzymatic and non-enzymatic carbapenem 
resistance mechanisms and identification of specific carbapenemase types. 
Polymerase chain reaction is the most widely used traditional genotyping 
method, with more efficient methods, such as multiplex polymerase chain 
reaction and real-time polymerase chain reaction also available. Various 
commercial assays or systems based on polymerase chain reaction are 
available (Ledeboer et al., 2015; Cunningham et al., 2016), including 
GeneXpert platform, Check-Points system and Verigene. Whole genome 
sequencing is more widely used in recent years as it allows detection of both 
carbapenemase encoding genes and other associated resistance 
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mechanisms. However, these advanced approaches requires expertise, well-
trained technicians and financial support. The advantages and disadvantages 
are summarised in Table 1-4. 
Overall, using the genotypic methods as gold standards, sensitivity and 
specificity of these phenotypic methods ranged from 70% to >90% (Lutgring 
and Limbago, 2016; Cui et al., 2019; Nordmann and Poirel, 2019).
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1.2.3 Risk factors for acquiring carbapenem resistance 
From both clinical and epidemiological perspectives, a comprehensive 
understanding of risk factors for acquiring CRO (i.e. infection or colonisation) 
is fundamental to designing infection prevention and control policies and 
helping healthcare staff make more effective judgements and select rational 
prophylactic/therapeutic options. Additionally, a thorough understanding of the 
risk factors will help to predict an individual’s risk of CRO acquisition, through 
early identification of high risk populations and thus to prevent spread of CRO. 
Many risk factors contribute to CRO acquisition and they can be generally 
classified into two groups: (1) patient-specific factors and (2) healthcare-
associated factors. Patient-specific factors include demographic 
characteristics such as age, gender, ethnicity and comorbidities. Healthcare-
associated factors comprise exposure to healthcare environment, invasive 
medical procedures undergone and previous antimicrobial treatments before 
CRO acquisition. Such factors include history of hospitalisation, length of 
intensive care unit (ICU) stay, history of surgical procedures, placement of an 
indwell catheter or colonization by other resistant bacteria. Nevertheless, risk 
factors for CRO acquisition have not been completely characterized and 
conflicting results have been reported in various studies conducted in different 
countries or healthcare facilities. The conflicting results usually result from 
great heterogeneity across these studies. Various factors might account for 
the huge heterogeneity, including study setting (such as acute healthcare 
facilities, long-term healthcare facilities and ICU), study design (retrospective 
or prospective study, case-control or cohort or cross-sectional study, active 
surveillance or screening), study population (such as neonates, children, 
adults and immunocompromised patients), definition of carbapenem 
resistance (such as CLSI guideline, EUCAST criteria and automatic systems), 
mechanism of carbapenem resistance (enzymatic and non-enzymatic), 
selection of cases and controls. Additionally, there are different definitions of 
CRO presence including acquisition (both infection and colonisation), 
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colonisation, infection, and the progression from colonisation to infection, 
amplifying the heterogeneity across studies. 
To date, only one study has systematically reviewed the risk factors for CRE 
acquisition among hospitalized patients and quantified the effects of such risk 
factors by meta-analyses (van Loon et al., 2018). Moreover, the researchers 
also summarized the environmental sources/reservoirs and the most 
successful infection prevention strategies related to CRE. They found that the 
use of medical devices generated the highest pooled estimate for acquiring 
CRE (odds ratio, OR: 5.09; 95% confidence interval, 95%CI: 3.38-7.67), 
followed by carbapenem use (OR: 4.71; 95%CI: 3.54-6.26). To control hospital 
outbreaks, bundled interventions, including barrier/contact precautions used 
for patients colonised or infected with CRE, are needed (van Loon et al., 2018). 
Additionally, it is necessary to optimise the therapeutic approach, which is an 
important message to infectious disease specialists, who need to be actively 
involved in a timely manner in the treatment of patients with known CRE 
infections or suspected carriers of CRE (van Loon et al., 2018). Similarly, an 
earlier systematic review and meta-analyses investigating risk factors 
associated with carbapenem-resistant Pseudomonas aeruginosa and sources 
and reservoirs for the pathogen showed that carbapenem use (OR: 7.09; 
95%CI: 5.43-9.25) and medical devices (OR: 5.11; 95%CI: 3.55-7.37) 
generated the highest pooled estimates (in 't Holt et al., 2014). Furthermore, 
cumulative meta-analyses indicated that the pooled estimate of carbapenem 
use was stable and the pooled estimate of medical devices increased with 
time. In multivariate analyses, use of carbapenem, use of fluoroquinolones, 
use of vancomycin, use of other antibiotics, having medical devices, ICU 
admission, having underlying diseases and length of hospital stay were 
significant risk factors (in 't Holt et al., 2014). Both studies highlighted the 
importance of prudent antibiotic stewardship and appropriate use of medical 
devices in curbing spread and outbreaks of CRO. 
Despite the heterogeneity, a systematic review and meta-analysis based on 
all available evidences focusing on risk factors for different CRO acquisition 
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status (i.e. infection or colonisation) is still necessary to identify risk factors 
which are helpful for containment of CRO spread and clarifying current 
knowledge gaps warranting further study in the future. 
1.2.4 Infection prevention and control measures 
Infection prevention and control is universally acknowledged as a key 
component to combat the spread and outbreak of antimicrobial resistant 
microorganisms in healthcare systems. There is a global consensus that 
urgent infection prevention and control actions are needed and should be 
given to CRO which poses a significant public health threat worldwide (World 
Health Organization, 2017c). After highlighting carbapenem-resistant 
Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa 
(CRE-CRAB-CRPsA) as the top critical priority pathogens in the WHO 
publication in 2017 (World Health Organization, 2017b), WHO developed 
infection prevention and control guidelines for the prevention and control of 
CRE-CRAB-CRPsA in healthcare facilities accordingly later in the same year 
(World Health Organization, 2017c). The guidelines identified eight key 
recommendations listed below (Table 1-5) that could be applied to healthcare 
facility level, and these recommendations could also be used to improve the 
development of national policies on the infection prevention and control of 
CRE-CRAB-CRPsA transmission and infection within health sectors. 
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The European Centre for Disease Prevention and Control conducted a 
systematic review of the infection prevention and control of spread of CRE in 
2014 (European Centre for Disease Prevention and Control, 2014). A group of 
experts attending meetings hosted by the European Centre for Disease 
Prevention and Control created a list of epidemiological risk factors placing 
patients “at-risk” of carriage (both colonisation and clinical infection) with CRE 
and constructed a list of core and supplemental infection prevention and 
control measures to be implemented for “at-risk” patients upon admission to 
healthcare settings (Magiorakos et al., 2017). According to the European 
Centre for Disease Prevention and Control guidance, individuals “at-risk” for 
carriage (both colonisation and clinical infection) of CRE included: (1) a history 
of an overnight stay in a healthcare setting in the last 12 months; (2) dialysis-
dependent or cancer chemotherapy in the last 12 months; (3) known previous 
carriage (both colonisation and clinical infection) of CRE in the last 12 months; 
(4) epidemiological linkage to a known carrier of a CRE. Core infection 
prevention and control measures included antimicrobial stewardship, 
environmental cleaning, equipment reprocessing, faecal and medical waste 
management, guidelines and processes, hand hygiene, infrastructure and 
capacity for patient accommodation, microbiological capacity, staff education, 
staffing and surveillance (Magiorakos et al., 2017). Preliminary supplemental 
measures comprised pre-emptive isolation of patients on admission, active 
screening on admission and contact precautions (Magiorakos et al., 2017). 
Both guidelines specified that they were putting forward recommendations and 
suggestions, and are in no way prescriptive for all countries and different 
healthcare settings. Therefore, such recommendations or suggestions could 
be adapted or tailored to local needs to establish local infection prevention and 
control measures and policies. Due to the alarming global increase in CRO 
and inspired by such guidelines, more and more countries have set up their 
own surveillance systems or programmes for antimicrobial resistance including 
CRO (European Centre for Disease Prevention and Control, 2019a; Ministry 
of Health New Zealand Goverment, 2018) or work together to build up regional 
Epidemiology of CPO in Scotland 
28  Introduction 
 
or global surveillance systems or programmes as described in the above 
Section 1.2.1.  
1.3 Carbapenem resistance in the UK and Scotland 
1.3.1 Disease burden 
The disease burden of infections caused by carbapenem resistant E.coli, 
Klebsiella pneumonia, Acinetobacter spp. and Pseudomonas aeruginosa in 
disability-adjusted life-years in the UK in 2015 were lower than most countries 
of the European Union and European Economic Area (Cassini et al., 2019). 
The disability-adjusted life-years per 100,000 population, incidence per 
100,000 population, mortality per 100,000 population caused by infections with 
these CRO were 0.10-2.43, 0.04-1.41 and 0.00-0.08, respectively (Cassini et 
al., 2019). A national study of CPE including 21 sentinel UK laboratories in 
2013-2014 showed that 36% of CRE isolates produced carbapenemases, 
resulting in a national prevalence of CPE 0.02% (95%CI: 0.01%-0.03%) and 
incidence of CPE 0.007 per 1,000 patient-days (95%CI: 0.005-0.010) 
(Trepanier et al., 2017). The UK prevalence and incidence of clinically 
significant CPE is currently low, however, recommended infection prevention 
and control measures such as strict standard precautions and single en-suite 
room are not universally followed, notably screening high-risk patients on 
admission (applied by 86%), using a CPE ‘flag’ on patients’ records (70%) and 
alerting neighbouring hospitals when transferring affected patients (only 30%) 
(Trepanier et al., 2017). Furthermore, the national percentages of carbapenem 
resistance increased significantly between 2015 and 2018 among Klebsiella 
pneumonia (from 0.4% to 0.7%) and Pseudomonas aeruginosa (from 2.4% to 
6.0%) isolates (European Centre for Disease Prevention and Control, 2019c). 
The reported incidence of CPE per 1,000 patient-days in Scotland (0.001) was 
lower than that in England (up to 0.033) and Northern Ireland (0.006) 
(Trepanier et al., 2017). In addition, the proportion of carbapenems among all 
antibacterials for systemic use was lower than that in England and Northern 
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Ireland according to a point prevalence survey conducted in 1,209 European 
acute care hospitals in 28 of 31 European Union and European Economic Area 
countries in 2016-2017 (Plachourasi et al., 2018). Nevertheless, the Scottish 
One Health Antimicrobial Use and Antimicrobial Resistance annual report 
showed that there has been a 39% year on year increase in the incidence of 
reported CPO isolates since 2013 while the secondary care use of 
carbapenems between 2014 and 2018 decreased by 3.9% (Health Protection 
Scotland, 2019b; Health Protection Scotland, 2018d). To date, up to 16 types 
of carbapenemases including both single carbapenemase type and 
carbapenemases combinations have been reported in Scotland (Health 
Protection Scotland, 2019b). Given the high incidence of carbapenem 
resistance in the surrounding countries, frequent and increasing travels 
between them and high transferability of carbapenemases between individuals 
and species, it is urgently recognised that further characterisation of CPO 
cases in Scotland is essential. This improved epidemic intelligence will inform 
interventions to reduce transmission of CPO including the further development 
of the national CPE admission screening policy (Health Protection Scotland, 
2019b). 
1.3.2 Healthcare system in Scotland 
The National Health Service (NHS) Scotland consists of 14 regional NHS 
Boards which are responsible for the protection and the improvement of 
their population’s health and the delivery of frontline healthcare services 
(Scotland's Health on the Web, 2019). The 14 regional NHS Boards are 
shown in Figure 1-2. The number of hospitals in each NHS Board and the 
midyear population estimates are listed in   
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Table 1-6. In addition, there are two national hospitals (Golden Jubilee 
National Hospital and The State Hospital). Golden Jubilee National Hospital 
provides quaternary cardiology, respiratory and orthopaedic services, and The 
State Hospital provides high security beds for detained patients, respectively. 
These two national hospitals are managed by a Special Health Board and 
provide services for the whole of Scotland.
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Figure 1-2. Map of National Health Service (NHS) Boards in Scotland (as 
of December 2019)  
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1.3.3 Steps to identify CPO in Scotland 
The steps to identify a CPO isolate (according to Health Protection Scotland 
staff Julie Wilson, personal communication by email, December 8, 2017) are 
illustrated in Figure 1-3. A specimen from clinical indications or surveillance 
programme is submitted to a diagnostic laboratory and cultured onto an agar 
plate. The strains that grow on the agar plate are identified by VITEK® 
microbial identification system. If VITEK reports the isolate as being non-
susceptible to a carbapenem, the results including both the identifier and strain 
identification information are transmitted to the Electronic Communication of 
Surveillance in Scotland SQL server at Health Protection Scotland (HPS). The 
diagnostic laboratory then refers the carbapenem resistant isolate to the 
antimicrobial resistance and healthcare associated infections reference unit at 
Public Health England for detection of carbapenemase production. If the 
reference laboratory confirms the production of carbapenemase, it will email 
the result to HPS which is then manually entered into the Electronic 
Communication of Surveillance in Scotland database. Public Health England 
do not currently transfer any result electronically into Electronic 
Communication of Surveillance in Scotland. Antimicrobial susceptibility testing 
is only performed if the diagnostic laboratory has requested it. 
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Figure 1-3. Steps to identify a carbapenemase-producing organism 
(CPO) isolate 
Source: Health Protection Scotland staff Julie Wilson, personal communication 
by email, December 8, 2017 
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1.3.4 Policies and screening programme in the UK, including 
Scotland 
In 2010, the Scottish Chief Medical Officer issued a letter on antimicrobial 
resistance to clinicians highlighting the need for awareness of 
carbapenemases and other emerging resistance (The Scottish Government, 
2010). Emergence of CPE was flagged as a concern for the UK in the same 
year. The actions recommended were that clinicians should seek early advice 
from their local microbiologist if infection with a CPO is a possibility (The 
Scottish Government, 2010). 
In 2013, a joint Chief Medical Officer/Chief Nursing Officer/Chief 
Pharmaceutical Officer letter described the emerging threat from CPE and the 
requirements for an acute hospital admission screening programme for CPE 
(The Scottish Government, 2013). Given that some European countries have 
moved to an endemic situation of CRO and that the number of CPE isolates in 
the UK and Scotland is rising, it is recommended that each Scottish NHS Board 
has a CPE action plan in place by December 2013. Additionally, hospitals 
should have systems in place to rapidly identify: (1) patients who have been 
transferred from a hospital abroad; (2) patients who have been hospitalised 
abroad within the last 12 months; (3) patients who have previously been 
positive for CPE at any body site. These patients should be immediately 
isolated and advice taken from the Infection Prevention and Control Team (The 
Scottish Government, 2013). 
In 2015, the Scottish Government issued the mandatory healthcare associated 
infection and antimicrobial resistance policy requirements (The Scottish 
Government, 2015), stating that HPS were currently supporting NHS Boards 
to implement CPE screening. It is the expectation that NHS Boards will inform 
HPS of confirmed CPE cases as per the current guidance. 
In May 2016, HPS published “Toolkit for the early detection, management and 
control of carbapenemase-producing Enterobacteriaceae in Scottish acute 
settings” which has been updated in May 2019 (Health Protection Scotland, 
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2016b). This toolkit has been adapted from Public Health England ‘Acute trust 
toolkit for the early detection, management and control of carbapenemase-
producing Enterobacteriaceae’ and takes account of published UK guidance 
multidrug-resistant organisms from the Healthcare Infection Society. It 
contains a set of recommendations based on scientific evidence and 
consensus of expert opinion to prevent cross transmission of CPE within acute 
healthcare settings in NHS Scotland. Shortly afterwards, Healthcare 
Improvement Scotland conducted a study and concluded that the current 
literature on identifying CPE in hospital screening samples is inadequate to 
inform selection of the most effective screening test and/or method to identify 
patients colonised by CPE (Healthcare Improvement Scotland, 2016). Also, 
the Scottish Microbiology and Virology Network Antimicrobial Susceptibility 
Testing Group endorsed use of the UK Standards for Microbiology 
Investigations (Public Health England, 2016) to test CPE. 
Again, the Chief Nursing Officer letter issued in March 2017 reinforced the 
mandatory policy requirement for CPE screening in NHS Boards across 
Scotland (The Scottish Government, 2017). 
In September 2017, HPS published “Toolkit for managing carbapenemase-
producing Enterobacteriaceae (CPE) in Scottish non-acute care settings” 
(Health Protection Scotland, 2017). The guidance was adapted from Public 
Health England ‘Carbapenemase-producing Enterobacteriaceae: non-acute 
and community toolkit’ (Public Health England, 2015) and contains a set of 
recommendations and practical advice to reduce the spread of CPE in non-
acute and community settings in Scotland, including management of 
individuals positive for CPE, communications within healthcare settings and 
household, and risk assessment on managing individuals positive for CPE. 
Also, CPE-related advice leaflets are also available, including ‘Advice leaflet 
for individuals receiving care at home or in the community who have an 
infection with, or are colonised by carbapenemase-producing 
Enterobacteriaceae (CPE)’, ‘Advice leaflet for the family of a person who is a 
carrier of carbapenemase-producing Enterobacteriaceae (CPE)’, ‘Advice 
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leaflet for contacts of a carbapenemase-producing Enterobacteriaceae (CPE) 
carrier’ (Health Protection Scotland, 2018b; Health Protection Scotland, 2018c; 
Health Protection Scotland, 2018a). These leaflets introduce knowledge 
regarding definition, clinical significance and spread of CPE and guidance on 
getting advices from healthcare providers to individuals with CPE and their 
families or contacts.  
In summary, the Scottish government and HPS started to pay attention to CRO 
and set up a series of policies to screen for and control spread of CPE from 
2010 onwards. By the end of 2017, guidance for the detection and 
management of CPE in both acute and non-acute care settings had been 
issued. Nevertheless, the level of compliance with these guidance remains 
unclear. 
 
1.4 Aims of this thesis 
I conducted a systematic review and meta-analysis on risk factors for CRO 
infection and colonisation in healthcare facilities worldwide, aiming to provide 
a critical appraisal of the existing evidence in the association between patient- 
and healthcare-associated factors and CRO acquisition (infection and 
colonisation) and to examine whether and to what extent certain study-design 
characteristics can account for heterogeneity across these published studies. 
Such an analysis will identify knowledge gaps and inform future work. 
To date, unpublished sources suggest that the number of reported CPO in 
Scotland is increasing (Health Protection Scotland, 2019b). However, there 
has not been any rigorous temporal or spatial analysis of the data. Therefore, 
I conducted a retrospective epidemiology study of CPO in Scotland over the 
time period 2003 (when the first case was observed) to 2016. The aims are to 
calculate the incidence of CPO and examine the temporal trends and spatial 
distribution for the time frame of the study, to summarise the microbiological 
characteristics of CPO isolates, including species (e.g. Escherichia coli, 
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Pseudomonas aeruginosa), carbapenemases and antimicrobial susceptibility, 
and to determine mortality rate, survival and risk factors for all-cause 30-day 
mortality from CPO. 
Finally, a subgroup of hospitalised patients infected with or colonised by CPO 
in Scortland were enrolled as cases in a matched case-control study, this study 
aims to determine risk factors for CPO infection and colonisation among 
hospitalised patients, to evaluate the impact of CPO on patient prognosis 
(mortality rates and survival), and to compare antimicrobial susceptibility 
between isolates from CPO cases and controls. 
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Chapter 2 Risk factors for the presence of 
carbapenem-resistant organisms 
(CRO) among patients in healthcare 
facilities: a systematic review and 
meta-analysis 
2.1 Background 
Carbapenems were introduced in 1985 to provide enhanced coverage as 
compared with other β-lactams and stability against extended-spectrum β-
lactamases (ESBL) capable of hydrolysing almost all other β-lactam antibiotics 
(Pitout and Laupland, 2008). Accordingly, carbapenems are often used as last 
resort antibiotics for treatment of invasive multidrug-resistant infections. In the 
past two decades, there has been an increased usage of carbapenems 
because of the global spread of ESBL-producing isolates (European Centre 
for Disease Prevention and Control, 2017; World Health Organization, 2014; 
Centers for Disease Control and Prevention, 2013). As a result, there is an 
emerging global public health threat of carbapenem-resistance, leaving few 
effective therapeutic options available for multidrug-resistant infections and 
ultimately causing high mortality and increased care costs (Tischendorf et al., 
2016; Daroukh et al., 2014). Carbapenem resistance occurs mainly in Gram-
negative bacilli comprising Enterobacteriaceae such as Escherichia coli (E. 
coli) and Klebsiella pneumonia and non-fermenters such as Pseudomonas 
aeruginosa and Acinetobacter baumannii. In 2017, the World Health 
Organization (WHO) published a list of antibiotic-resistant bacteria that are of 
global priority which included carbapenem-resistant Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacteriaceae (World Health 
Organization, 2017b).  
Effective and easily operationalized prevention and infection control strategies 
against carbapenem-resistant organisms (CRO) are imperative. From clinical 
and epidemiological perspectives, a comprehensive understanding of risk 
factors for the presence of CRO is fundamental to designing and tailoring such 
Epidemiology of CPO in Scotland 
40  Risk factors for CRO: a systematic review and meta-analysis 
 
infection prevention and control policies. Additionally, this will help to identify 
high risk individuals and populations. Though risk factors for CRO infections 
and colonisations are identified in published studies, the results are often 
inconsistent. This may reflect, at least in part, different study characteristics, 
such as study setting, design, population of interest, organisms, definition of 
resistance and selection of controls, generating great heterogeneity across 
studies. Conclusions obtained by combining studies without regard to this 
heterogeneity may be unreliable and potentially misleading (Choi and Lam, 
2017). In addition, understanding the sources of heterogeneity could provide 
guide for better study design of risk factor studies. This chapter aims to provide 
an in-depth analysis of risk factors for CRO presence among patients in 
healthcare facilities worldwide and thus provide up-to-date information on this 
topic from both clinical and epidemiological perspective. 
The specific aims of this chapter are: 
1) to evaluate an estimation method of standard deviation from the sample 
size, median, range and/or interquartile range; 
2) to investigate the risk factors for the presence, infection and 
colonisation of CRO in healthcare settings; 
3) to compare risk factors for CRO infection and colonisation; 
4) to investigate risk factors associated with hospital-acquired infection 
caused by CRO; 




A protocol was developed according to the items in the checklist detailed in 
the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines (Appendix 2-1) (Liberati et al., 2009) and registered on 
PROSPERO (International prospective register of systematic reviews) 
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(registration number: CRD42018081433). The review focuses on primary 
peer-reviewed papers of risk factor studies for the presence of CRO among 
patients in healthcare facilities worldwide published from Jan 1, 1986 to Dec 
31, 2016. 
2.2.2 Search strategy 
Electronic literature searches using the pre-piloted search terms and subject 
headings and tailored search strategies with corresponding search terms were 
applied to four umbrella databases, Embase, MEDLINE, Global Health and 
Web of Science, as well as the top three Chinese databases, i.e., China 
National Knowledge Infrastructure (http://www.cnki.net/), Chongqing VIP 
databases (http://lib.cqvip.com/) and Wanfang Data 
(http://www.wanfangdata.com.cn/). 
Literature searching was performed using Science Citation Index Expanded, 
Social Sciences Citation Index, Conference Proceedings Citation Index-
Science, Conference Proceedings Citation Index-Social Science & 
Humanities, Book Citation Index-Science, Book Citation Index-Social 
Sciences & Humanities, Emerging Sources Citation Index, Current Chemical 
Reactions and Index Chemicus provided through Web of Science 
(https://apps.webofknowledge.com). Simultaneously, Embase, MEDLINE and 
Global Health were searched through OvidSP (http://ovidsp.tx.ovid.com), 
search strategy for Embase was appropriately tailored for searching the other 
databases. For Chinese databases, similar strategies and related search 
terms were used. The detailed search strategy with search terms for each 
database are listed in Appendix 2-2. The reference lists of review papers were 
hand searched for eligible papers included in the review. 
2.2.3 Eligibility criteria 
Any published primary peer-reviewed paper was included if it reported risk 
factors associated with the presence of CRO (infection, colonisation, 
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acquisition, i.e., infection, colonisation or both of them) in a defined population 
admitted to a healthcare facility (hospitals or long-term care facilities). 
Inclusion criteria (studies fulfilled all of the following criteria): 
 Primary peer-reviewed study published between 1st January 1986 and 
31st December 2016 (1st January 1989-31st December 2016 for 
Chongqing VIP databases) 
 Any language 
 Study type: observational studies (case-control study, cohort study, or 
cross-sectional study) 
 Study population: patients or residents in a healthcare facility, i.e., 
hospitals and long-term care facilities 
 Any sample size 
 Reporting risk factors associated with the presence (infection and/or 
colonisation) of CRO 
Exclusion criteria (studies fulfilled any of the following criteria): 
 Animal studies 
 Environmental studies 
 Reporting risk factors for multidrug resistance including carbapenem 
resistance 
 Reporting risk factors for resistance to both carbapenem and other 
antibiotics 
 Publication type: reviews, case reports, case series, comments, 
conference abstracts, conference posters, editorials, errata, weekly 
reports and letters to the editor 
 No reply from or no means of contacting authors when further details 
were required on the candidate risk factors investigated and/or the 
numbers of cases and controls 
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2.2.4 Literature selection and data extraction 
Titles, authors, journals, published year and abstracts from the databases 
were downloaded into an Endnote file. After deleting duplicate papers, titles 
were screened in conjunction with available abstracts against the inclusion and 
exclusion criteria to identify studies which merit further consideration, i.e. 
checking full text. Following perusal of the full text of these studies, a decision 
as to whether to include the study was made. 
All the included studies were perused to extract variables of interest and were 
entered into a Microsoft Excel 2013 spread sheet for further analysis. Data was 
extracted under the following headings (defined in Appendix 2-3): 
 Reference characteristics: author, year of publication, study period, 
study country and corresponding WHO region (World Health 
Organization, 2017a) and World Bank Income group (The World Bank, 
2017). 
 Study design characteristics: status, study type, study setting, 
healthcare type, specialty, study population, organism, resistance 
mechanism, definition of carbapenem resistance, definitions of cases 
and controls. 
 Risk factor analysis characteristics: numbers of cases and controls, 
candidate risk factors, univariate or multivariate analysis and 
corresponding cut-off p value, numbers of cases and controls with 
exposure to candidate risk factors, odds ratio (OR), 95% confidence 
interval (95% CI) and corresponding P value of univariate/multivariate 
analysis. 
After the literature search and excluding duplicate papers, I selected papers 
identified by literature search based on titles and abstracts, and then 
conducted the literature selection and data extraction by reading full text. 
Another investigator (Melissa Taylor, MSc student at Liverpool school of 
tropical medicine) performed literature selection based on titles and abstracts 
for 10% of the papers identified by literature search and found no new eligible 
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papers. Then we conducted the literature selection and data extraction 
independently by reading full text. Any uncertainties or discordance regarding 
literature selection and data extraction were arbitrated by my supervisor 
(Professor Mark Woolhouse). 
2.2.5 Quality assessment 
For all included studies, a quality assessment was performed by two 
investigators independently (Ruby Tabor, undergraduate student at Deanery 
of Biomedical Sciences and myself) using a modified system based on the 
Newcastle-Ottawa quality assessment scale for case-control and cohort 
studies (Appendix 2-4) (Wells et al., 2011). For case-control studies, the 
included studies were judged on three broad aspects: the selection of study 
groups, the comparability of the groups and assessment of exposure. Scores 
of 4, 2 and 2 were assigned for the three aspects, respectively. For cohort 
studies, the included studies were judged on three broad aspects: the selection 
of study groups, the comparability of the groups and assessment of outcome. 
Scores of 4, 2 and 1 were assigned for the three aspects, respectively. For 
cross-sectional studies, an eleven-item system based on Agency for 
Healthcare Research and Quality guidelines were used (Appendix 2-4) (Zeng 
et al., 2012). Because there has been controversy about how many stars 
should be used as a cut-off for a study to be of high quality, the percentage of 
each score that included studies achieved was listed instead of defining which 
studies were of high quality and which ones were not. Studies with the lowest 
scores in each scales for each study type (case-control, cohort and cross-
sectional) were considered to have low quality. Study quality was not 
considered an exclusion criterion. 
2.2.6 Definition of outcome and risk factors 
The outcome of interest is the presence of CRO, including infection, 
colonisation and acquisition from any site of the body. CRO infection was 
defined as hospital-acquired if it fulfilled any of the following criteria: 1) the 
authors specified they investigated risk factors for hospital-acquired or 
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nosocomial infections caused by CRO; 2) Samples with CRO were collected 
at 48 hours or more after hospital admission (Cardoso et al., 2014; Horan et 
al., 1992). 
The risk factors investigated were placed in one of five categories: group 1, 
demography including age and gender; group 2, prior healthcare exposure 
including prior hospitalisation, hospital transfer, intensive care unit (ICU) stay 
and presence of drug resistant organisms; group 3, comorbidities and severity 
of comorbidity index such as Charlson Comorbidity index scores (CCI), Acute 
Physiology And Chronic Health Evaluation II scores (APACHE II) and 
Sequential Organ Failure Assessment scores (SOFA); group 4, prior exposure 
to invasive medical procedure and/or devices; group 5, prior antibiotic 
exposure. Definitions of some risk factors varied substantially across the 
included papers which may resulted in different strengths of evidence for 
association between these risk factors and the outcome, so risk factors were 
defined as precisely as possible based on the original definitions in the 
included papers (Appendix 2-5). 
2.2.7 Statistical analysis 
All the reported risk factors including in these studies could be classified as 
either categorical or continuous.  
For each categorical risk factor in each study, the OR and 95%CI were re-
calculated using the raw data in the original study. A meta-analysis was 
performed accordingly to obtain pooled estimates of ORs using a random-
effects model based on the method of DerSimonian-Laird (DerSimonian and 
Laird, 2015). This was done only if ≥5 studies reported the same risk factor. 
To summarise the evidence, four aggregate parameters were calculated for 
each risk factor: (i) frequency of being a candidate risk factor, defined as the 
number of studies that included the factor; (ii) frequency of being a statistically 
significant risk factor, from the re-analysis of the raw data; (iii) likelihood of 
statistical significance, defined as (ii)/(i); (iv) pooled OR estimates, from the re-
analysis of the raw data. For each risk factor investigated in ≥5 studies, the 
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four parameters were calculated respectively for the three types of CRO status 
(presence, colonisation and infection including hospital-acquired infection as 
defined in Appendix 2-3) where appropriate. The I2 statistic was used to 
quantify statistical heterogeneity (Higgins et al., 2003). For the risk factors 
investigated in more than ten studies with highest pooled OR estimates and/or 
most likely significant, potential sources of heterogeneity were explored with 
meta-regression and subgroup analyses if I2 ≥75% (Choi and Lam, 2017). In 
addition, for risk factors investigated in no less than five studies after excluding 
studies of low quality, a sensitivity analysis was performed in comparison to 
pooled ORs calculated regardless of study quality to examine whether the 
results would differ substantially when the studies of low quality were excluded. 
Factors considered included World Bank Income group, study type, study 
setting, healthcare type, specialty, study population, organisms, resistance 
mechanism, CRO status, selection of cases and controls and sample size 
(Appendix 2-3). Publication bias was examined using Egger’s test for factors 
investigated in more than ten studies (Egger et al., 1997). 
For each continuous risk factor in each study, if the raw data were reported as 
median with range or interquartile range (IQR), mean was estimated from 
Wan’s method [16]. Standard deviation (SD) were estimated from Wan’s and 
Walter’s methods separately (Wan et al., 2014; Walter and Yao, 2007), and 
standardised mean difference (SMD) and 95%CI were calculated accordingly. 
The results were compared. The summary statistics were defined as: m=the 
median, n=the sample size, a=the minimum value of the range, b=the 
maximum value of the range, q1=the first quartile, q3=the third quartile. The 
raw data was reported in three scenarios: C1=(m, n, a, b), C2=(m, n, q1, q3), 
C3=(n, a, b). Wan et al (Wan et al., 2014) provided formulas of mean and SD 
estimation for C1 and C2 while Walter et al (Walter and Yao, 2007) provided 
formulas of SD estimation for C3:  
𝐶1:  𝑚𝑒𝑎𝑛 ≈
a + 2m + b
4
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𝐶2:  𝑚𝑒𝑎𝑛 ≈
q1 + m + q3
3







𝐶3:  𝑆𝐷 ≈ 𝑓 × (𝑏 − 𝑎) 
For C1 and C2 formula, ∅−1(𝑧) is the upper 𝑧th percentile of the standard 
normal distribution. For C3 formula, f is a tabulated conversion factor derived 
from linear interpolation according to corresponding tabulated values of 
sample sizes (Walter and Yao, 2007). If the raw data was reported as mean 
and SD, SMD and 95%CI were calculated with raw data in the original study. 
Publication bias was examined using Egger’s test for factors investigated in 
more than ten studies (Egger et al., 1997). 
All the analyses were performed using R version 3.3.3. Maps were drawn using 




2.3.1 Studies identified 
The literature search identified 49,980 papers including 18,836 duplicates. Due 
to some short search terms involved in search strategies, many papers not 
relevant to the topic of interest were identified and they could be excluded by 
scanning the title and abstract. After applying inclusion and exclusion criteria 
at the title and abstract levels, 30326 papers not relevant to the topic and 21 
non-primary peer-reviewed papers were excluded and the remaining 797 
papers were retained for full text assessment (Figure 2-1). Finally, 227 papers 
were identified for data extraction and further review including 191 (84.1%) 
papers from English databases and 36 (15.9%) papers from Chinese 
databases (Figure 2-1). Because some papers reported more than one study 
due to different study characteristics, data from 254 distinct studies were 
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extracted from the 227 papers (Appendix 2-6). Twenty-three papers generated 
2 studies and 2 papers generated 3 studies, details are listed in Appendix 2-6. 
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Figure 2-1. Flowchart of literature selection 
 
2.3.2 Study characteristics 
Understanding characteristics of included studies would provide a general idea 
of the variety of these studies regarding study design and research interest. 
Characteristics of studies included in the review are listed in Table 2-1. All the 
227 papers included in the review performed univariate analysis and 202 of 
them performed multivariate analysis as well. Univariate P value of variables 
as cut-off for inclusion in multivariate analysis varied from P≤0.05 to P≤0.5 
while all multivariate analyses set statistical significance at P≤0.05. The 
detailed information are shown below. 
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Figure 2-2. Number of papers published by year 
 
2.3.2.2 Geographic distribution 
According to the venue where the studies were conducted reported by the 
authors, the 227 papers involved in this review were from 37 countries/regions 
(Appendix 2-6), including 18 (48.6%) high income countries/regions, 16 
(43.2%) upper-middle income countries/regions and 3 (8.1%) lower-middle 
income countries/regions by World Bank Income groups (Version 2017). None 
of these studies were conducted in low income countries. In terms of the 
number of papers, 125 (55.1%) were conducted in high income 
countries/regions, 97 (42.7%) in upper-middle income countries/regions and 
only 5 (2.2%) in lower-middle income countries/regions (Table 2-1). By WHO 
regions, most papers were from Europe (77/227, 33.9%), the Western Pacific 
(77/227, 33.9%) and the Americas (56/227, 24.7%). Over half of the studies 
were from China (60/227, 26.4%), America (33/227, 14.5%), Brazil (16/227, 
7.0%) and Israel (16/227, 7.0%). Figure 2-3 shows the geographic distribution 
of papers regarding to administrative units, i.e., states and provinces where 
these studies were conducted. 
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Figure 2-3. Geographic distribution of included papers 
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2.3.2.3 Study setting and study population 
Thirty-two (14.1%) of all the 227 papers were multi-centre studies. Twenty-one 
of the 32 multi-centre studies were conducted in healthcare facilities located in 
the same city while 10 were conducted in different cities of the same country 
and 1 in seven Latin American countries. 
Regarding type of healthcare facilities, the majority of these studies were 
conducted in tertiary care hospitals (190/227, 83.7%). Five studies were 
conducted in post-acute care settings, comprising 2 in post-acute care 
hospitals, 1 in long-term care facility, 1 in nursing homes and 1 in a 
rehabilitation hospital. Three were in secondary care hospitals while 2 studies 
were conducted in paediatric hospitals and 2 in long-term acute care hospitals. 
Additionally, the remaining 25 (11.0%) studies conducted in hospitals did not 
specify the type. It is noteworthy that 62 of 227 (27.3%) papers were conducted 
among inpatients in ICU. 
In terms of study population, 55 (24.2%) papers focused on adults and the cut-
off age for adult definition differed between studies though. Thirteen (5.7%) 
focused on paediatric patients, including 7 in neonates. Additionally, 9 papers 
were conducted specifically among solid organ or hematopoietic stem cell 
transplantation recipients while 3 were among burn inpatients. 
2.3.2.4 Definition of carbapenem resistance 
According to the updated definition of carbapenem resistance (Centers for 
Disease Control and Prevention, 2015), carbapenem resistance was defined 
following either of: 1) Phenotypic resistance. Resistant to any carbapenem 
antimicrobial including doripenem, meropenem, imipenem or ertapenem; 2) 
Genotypic resistance. Documented to produce carbapenemase. Definition of 
carbapenem resistance varied substantially across these studies. One 
hundred and one (44.5%) of the 227 papers interpreted carbapenem 
resistance according to Clinical and Laboratory Standards Institute (CLSI) 
guidelines issued in different years which differed from each other slightly. 
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However, most of these papers did not specify the method of antimicrobial 
susceptibility testing. On the contrary, 49 (21.6%) papers clarified the methods 
and corresponding standards they used, and they were various though. 
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¶ score (number of studies with the score/total number of studies of the study 
type, percentage); 
 
2.3.4 Evaluation of two standard deviation estimation methods 
Both Walter’s and Wan’s methods provided SD estimation from sample size 
and range. I performed both methods to estimate SD of 101 continuous 
variables which just provided sample size and range, and then calculated SMD 
using these SD values accordingly (Appendix 2-8). The 101 variables 
generated 202 SD values estimated for both cases and controls and 
accordingly 101 SMD values. One hundred and fifty-two of the 202 SD values 
differed from each other by 0.05 (75.2%), 29 (14.4%) by 0.05-0.10 and 21 
(10.4%) by 0.10-0.98, respectively. Consequently, 90 (89.1%) of the 101 
continuous variables showed identical results of SMD while 10 (9.9%) differed 
from each other by 0.01 and 1 (1.0%) by 0.05. However, all the differences did 
not affect the interpretation of the results (Appendix 2-8). Wan’s method 
provides both SD and mean estimation from both range and IQR while 
Walter’s method just provide SD estimation from range. For simplicity of 
calculation and scope of application, I chose Wan’s method. 
2.3.5 Risk factors associated with the presence of CRO 
In total, 77 categorical and 11 continuous risk factors were included in the 
meta-analyses. The pooled OR estimates and SMD for each risk factor are 
listed in Appendix 2-7 The factors most likely to be significant and/or with the 
highest pooled ORs are labelled in Figure 2-4 A. Prior presence of CRO 
generated the highest OR estimate (pooled ORs 7.14, 95%CI 3.68-13.85, 
I2=41%), followed by presence of vancomycin-resistant Enterococci (VRE) 
(pooled ORs 6.93, 95%CI 3.90-12.32, I2=0%), prior imipenem usage (pooled 
ORs 6.60, 95%CI 4.67-9.33, I2=74%) and prior any carbapenem usage 
(pooled ORs 4.79, 95%CI 4.17-5.51, I2=76%). Prior combination therapy, 
oxazolidinone and vancomycin usage had high likelihoods of being statistically 
significant (72.73%, 64.71% and 63.04% respectively). Mechanical ventilation 
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(64.29%, pooled ORs 3.42, 95%CI 2.87-4.09, I2=80%) and a nasogastric tube 
(61.11%, pooled ORs 3.33, 95%CI 2.50-4.44, I2=86%) both had high 
likelihoods of being significant and a high pooled OR estimate. Although 
demography and comorbidities were commonly investigated, these factors 
generally had lower pooled OR estimates and likelihoods of being significant. 
An exception was decubitus ulcer (pooled ORs 3.08, 95%CI 1.90-4.99, 
I2=63%) (Figure 2-4 A). In terms of continuous factors, increased length of ICU 
stay, hospital stay, mechanical ventilation, urinary catheter and carbapenem 
therapy were risk factors for CRO (Appendix 2-7). It is noteworthy that 75.0% 
of the 16 studies investigating whether duration of mechanical ventilation was 
a risk factor found that longer mechanical ventilation in days increased risk of 
CRO presence (SMD 0.70, 95%CI 0.47-0.93, I2=76%). In addition, higher CCI 
and APACHE II scores were associated with CRO presence. 
Sensitivity analyses were performed for 74 categorical risk factors (Appendix 
2-9). Whether a risk factor is significant or not based on the pooled OR 
estimates and 95%CI was different for three factors when studies of low quality 
were included and excluded (Appendix 2-9), but none of them were leading 
risk factors. 
2.3.6 Comparison of risk factors for CRO infection and 
colonisation 
CRO infections usually result in higher mortality and require timely treatments 
while individuals with CRO colonisation tend to be asymptomatic but facilitates 
potential transmission of carbapenem resistance as the reservoir of CRO. 
Clinical staff and public health staff/policy makers might have different 
preferences for risk factors for infection and colonisation of CRO given that 
clinical staff would like to identify and treat infections as soon as possible while 
public health staff/policy makers would like to take infection prevention and 
control measures for people with CRO colonisation to prevent them from 
developing to infections. Different risk factors were expected, therefore it is 
important to look at them respectively. The pooled OR estimates and SMD for 
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each risk factor are listed in Appendix 2-7. The risk factors most likely to be 
significant and/or with the highest pooled ORs are labelled in Figure 2-4 B and 
C. Leading risk factors for both CRO infection and colonisation were prior 
carbapenem usage, prior oxazolidinone usage, ICU stay, and use of 
mechanical ventilation and nasogastric tube. For CRO infection, prior CRO 
carriage ranked first for both the likelihood of being significant (5/6, 83.3%) and 
pooled OR estimate (pooled ORs 5.82, 95%CI 3.03-11.20, I2=31%) while no 
CRO colonisation study investigated this factor; decubitus ulcer ranked second 
for both likelihood of being significant (4/5, 80.0%) and pooled OR estimate 
(pooled ORs 5.08, 95%CI 1.98-13.05, I2=82%). Prior combination therapy and 
amikacin usage had high likelihoods of being statistically significant (80.0%). 
Increased length of ICU stay, hospital stay, mechanical ventilation, CCI and 
APACHE II scores were associated with CRO infection (Appendix 2-7). In 
contrast, prior polymycin usage (pooled ORs 5.75, 95%CI 2.88-11.48, 
I2=33%), insertion of a gastrostomy tube (pooled ORs 4.66, 95%CI 1.82-11.98, 
I2=31%) and parenteral nutrition (pooled ORs 3.41, 95%CI 2.22-5.25, I2=0%) 
were risk factors achieving higher pooled OR for CRO colonisation only. CRO 
infection and colonisation shared some same leading risk factors, however, 
there were different risk factors for infection and colonisation. CRO infections 
tend to be specifically associated with (severity of) comorbidities while 
colonisation with antibiotic and medical devices exposure. 
Sensitivity analyses after removing studies of low quality for CRO infection and 
colonisation are summarized in Appendix 2-9. Whether a risk factor is 
significant or not based on the pooled OR estimates and 95%CI was different 
for two factors for CRO infection and three factors for CRO colonisation 
(Appendix 2-9) when studies of low quality were included and excluded, but 
none of them were leading risk factors. 
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2.3.7 Risk factors associated with hospital-acquired CRO 
infection 
The pooled OR estimates and SMD for each risk factor are listed in Appendix 
2-7. The risk factors most likely to be significant and/or with the highest pooled 
ORs are labelled in Figure 2-4 D. For hospital-acquired infection, prior 
carbapenem usage ranked first for both the likelihood of being significant 
(41/54, 75.9%) and pooled OR estimate (pooled ORs 4.28, 95%CI 3.27-5.59, 
I2=80%). Similar to CRO infection, prior combination therapy, ICU stay and use 
of mechanical ventilation and nasogastric tube were also leading risk factors 
for hospital-acquired infection according to likelihood of being significant 
and/or pooled ORs (Figure 2-4 D). In particular, use of mechanical ventilator 
(likelihood of being significant 67.65%, pooled ORs 3.88, 95%CI 2.76-5.45, 
I2=87%) and prolonged usage (likelihood of being significant 81.82%, SMD 
0.80, 95%CI 0.49-1.11, I2=77%) were significantly associated hospital-
acquired infection. Additionally, prior polymyxin usage, prior cefepime usage 
and steroid treatment were risk factors achieving higher likelihoods of being 
significant and/or higher pooled OR estimates (Figure 2-4 D). 
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Figure 2-4. Panel (A) Risk factors for the presence of CRO 
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Figure 2-4. Panel (B) Risk factors for CRO infection 
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Figure 2-4. Panel (C) Risk factors for CRO colonisation 
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Figure 2-4. Panel (D) Risk factors for CRO hospital-acquired infection 
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Figure 2-4. Risk factors for carbapenem-resistant organisms (CRO) status showing pooled odds ratio (OR) against 
percentage of studies where risk factor was statistically significant for (A) Presence of CRO. (B) CRO infection. (C) CRO 
colonization. (D) CRO hospital-acquired infection. Size of dot denoting the number of risk studies in which the factor was 
included. Colour of point indicating one of five categories of risk factor: green, demography including age and gender; blue, 
healthcare-associated exposure; yellow, comorbidities; purple, exposure to invasive medical procedure and/or devices; red, 
prior antibiotic exposure. Risk factor Key: 1. Age (>65yrs); 2. Gender-male; 3. Prior hospitalisation; 4. Hospital transfer; 5. ICU 
stay; 6. Prior presence of CRO; 7. Presence of ESBL producers; 8. Presence of methicillin-resistant Staphylococcus aureus 
(MRSA); 9. Presence of vancomycin-resistant Enterococci (VRE); 10. Chemotherapy; 11. Steroid usage; 12. Decubitus ulcer; 
13. Diabetes mellitus; 14. human immunodeficiency virus (HIV); 15. Liver diseases; 16. chronic obstructive pulmonary disease 
(COPD); 17. Malignancy; 18. Hematologic malignancy; 19. Neurological disease; 20. Neutropenia; 21. Renal failure; 22. Trauma; 
23. Hypertension; 24. Heart failure; 25. Coronary artery disease; 26. Stroke; 27. Blood transfusion; 28. Intravenous catheter; 29. 
central venous catheter (CVC); 30. Arterial catheter; 31. Dialysis; 32. Hemodialysis; 33. Drainage; 34. Enteral nutrition; 35. 
Parenteral nutrition; 36. Endoscopy; 37. Endotracheal tube; 38. Gastrostomy; 39. Mechanical ventilation; 40. Nasogastric tube; 
41. Tracheostomy; 42. Transplantation; 43. Urinary catheter; 44. Prior aminoglycoside use; 45. Prior amikacin use; 46. Prior 
antifungal use; 47. Prior β-lactam/β-lactamase inhibitor use; 48. Prior amoxicillin-clavulanate (AMC) use; 49. Prior ampicillin-
sulbactam (AMS) use; 50. Prior cefoperazone-sulbactam (SCF) use; 51. Prior piperacillin-tazobactam (TZP) use; 52. Prior 
carbapenem use; 53. Prior ertapenem use; 54. Prior imipenem use; 55. Prior meropenem use; 56. Prior cephalosporin use; 57. 
Prior first generation cephalosporins use; 58. Prior second generation cephalosporins use; 59. Prior third generation 
cephalosporins use; 60. Prior fourth generation cephalosporins use; 61. Prior cefepime use; 62. Prior first/second generation 
cephalosporins use; 63. Prior third/fourth generation cephalosporins use; 64. Prior combination antimicrobial therapy; 65. Prior 
glycopeptide use; 66. Prior vancomycin use; 67. Prior clindamycin use; 68. Prior macrolide use; 69. Prior metronidazole use; 
70. Prior oxazolidinone use; 71. Prior penicillin use; 72. Prior extended spectrum penicillin use; 73. Prior polymyxin use; 74. Prior 
fluoroquinolone use; 75. Prior ciprofloxacin use; 76. Prior tigecycline use; 77. Prior trimethoprim-sulfamethoxazole (TMP-SMX) 
use. 
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2.3.8 Study characteristics accounting for heterogeneity 
Leading risk factors (from Figure 2-4) with high heterogeneity (I2>75%) and 
consistent definitions were investigated for sources of heterogeneity. Study 
organism (5.5-44.1%), case-control selection (2.0-35.8%), study population 
(3.6-16.0%), sample size (6.6-15.2%), study setting (1.2-10.5%) and specialty 
(ICU or non-ICU) (3.1-10.2%) were the characteristics accounting for most 
heterogeneity (Appendix 2-10). However, generally the heterogeneity could 
not be reduced substantially through sub-group analyses based on these 
variables (noting that sample sizes were often small).  
 
2.4 Discussion 
From 2005 onward global carbapenem usage increased due to the 
appearance of multidrug-resistant organisms worldwide (Kwint et al., 2012; 
Liew et al., 2011; Meyer et al., 2010) and the number of studies on risk factors 
for CRO has shown an upward trend since then (Figure 2-2). The majority of 
these studies were conducted in European, the Americas and Western Pacific 
regions where CRO are endemic or epidemic. Also, the geographical 
distribution of published work mirrors the geographical distribution of Gross 
Domestic Product (The World Bank, 2017) with no studies from low income 
countries. The lack of financial support and a formal framework for 
collaboration among surveillance programmes across the regions providing 
accurate and reliable data may account for this gap. Some high income 
countries (e.g. Canada, New Zealand) have CRO surveillance programmes 
but have low incidence of CRO and have not published any risk factor studies. 
2.4.1 Prior antibiotic exposure related risk factors 
For both CRO presence and infection, prior CRO carriage had both the highest 
likelihood of being significant and the highest pooled OR estimate. Notably, 
most of these studies (6/7, 85.7%) showed that preoperative CRO colonisation 
increased the risk of postoperative CRO infection. The rate of postoperative 
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infection among colonised patients was consistently close to 40%, this whilst 
the patients were given targeted antibiotic prophylaxis (Freire et al., 2016c; 
Giannella et al., 2015; Salsano et al., 2016). Moreover, exposure to 
carbapenems and cumulative carbapenem exposure in days were widely 
reported as risk factors for CRO presence. It was reported that antimicrobial 
susceptible organisms in body flora of inpatients could be replaced with 
antimicrobial resistant strains over time (Ozkurt et al., 2005; Altoparlak et al., 
2004; Erol et al., 2004) and for each additional day of antibiotic therapy, the 
risk of carbapenem resistant Enterobacteriaceae (CRE) isolation increased by 
47% compared to general hospitalised controls (Lee et al., 2013a). This study 
found that combination therapy was among the leading risk factors for CRO 
infection including hospital-acquired infections. One reasonable explanation is 
that, empirical combination therapy consisting of cephalosporins or 
carbapenems combined with a glycopeptide or oxazolidinone for both Gram 
negative and positive coverage is initiated when an infection with multidrug-
resistant organisms is suspected but before diagnostic test results (which may 
take 48 hours) are available (van Loon et al., 2018). Correspondingly, 
exposure to carbapenems or cephalosporins have been demonstrated as risk 
factors for VRE infections (Weinstein and Hayden, 2000; Morris et al., 1995; 
Beezhold et al., 1997; Tornieporth et al., 1996). Although some studies 
suggested that two or more antimicrobials could increase protection 
(Papadimitriou-Olivgeris et al., 2014; Tumbarello et al., 2012; Zarkotou et al., 
2011; Tzouvelekis et al., 2012), a residual impairment of normal flora resulting 
from antimicrobial toxicity of combination therapy might increase the risk of 
acquiring CRO (Onguru et al., 2008; Salsano et al., 2016). It is generally 
accepted that selective pressure caused by antibiotic use could disrupt the 
commensal flora and thus predispose individuals to multidrug-resistant 
organisms colonisation and infection. A mouse model demonstrated that CRE 
intestinal colonisation was promoted by antibiotics that lacked significant 
activity against CRE but disrupted anaerobic flora (Perez et al., 2011). 
In addition, prior polymyxin E (also known as colistin) usage was a leading risk 
factor for hospital-acquired CRO infection specifically. Some studies reported 
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that the commonly used antibiotics for nosocomial infections, such as 
antipseudomonal penicillins, carbapenems, glycopeptides, and colistin were 
determined as risk factors for the development of CRO infection due to 
selective pressure or cross-resistance (Akgul et al., 2016; Wu et al., 2011; 
Cardoso et al., 2012). Moreover, duration of colistin administration prior to 
carbapenem-resistant Klebsiella pneumonia isolation was independently 
associated with increased frequency of hospital-acquired carbapenem-
resistant Klebsiella pneumonia infection (Mantzarlis et al., 2013). This may be 
explained by the fact that, patients with hospital-acquired CRO infection were 
extensively treated with colistin during ICU stay. This study found that 
prolonged ICU stay was a risk factor for hospital-acquired CRO infection. 
Papadimitriou-Olivgeris et al. demonstrated that patients in ICU were more 
likely to received colistin (31.6%) than patients in medical or surgical wards 
(0.8%) in addition to a longer length of ICU stay (Papadimitriou-Olivgeris et al., 
2012). Similarly, patients with CRO nosocomial infection have more often 
received broad-spectrum antimicrobial therapy, such as cefepime which 
ranked third in terms of pooled OR estimate, and are associated with severe 
illness before infection onset (Zheng et al., 2013). 
2.4.2 Prior healthcare exposure related risk factors 
Among healthcare facility exposure, VRE carriage was a leading risk factor 
associated with CRO presence (as indicated by the magnitude of pooled OR 
estimates and the likelihood of being statistical significant). Interestingly, 
exposure to vancomycin and oxazolidinone (which is a recommended 
treatment of VRE infections) were also among the leading risk factors (Figure 
2-4) (Bleumin et al., 2012; Dirajlal-Fargo et al., 2014; Ling et al., 2015; 
Tumbarello et al., 2014; Gomez Rueda and Zuleta Tobon, 2014; Sanchez-
Romero et al., 2012; Daikos et al., 2010; Orsi et al., 2013; Papadimitriou-
Olivgeris et al., 2012; Satlin et al., 2016; Swaminathan et al., 2013; Torres-
Gonzalez et al., 2015). Again, these findings could be explained by the 
combination empirical or prophylactic therapy for both Gram negative and 
positive coverage. 
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2.4.3 Prior invasive medical procedure/devices exposure 
related risk factors 
Invasive indwelling devices or procedures have been widely investigated as 
risk factors for multidrug-resistant organisms acquisition as bypass the innate 
host mechanical defences and provide a niche for microorganisms and/or 
facilitate the entry to the host (Papadimitriou-Olivgeris et al., 2014; Cunha et 
al., 2016; Borer et al., 2012). Mechanical ventilation and nasogastric tube were 
leading risk factors associated with different CRO status. More specifically, 
longer duration of mechanical ventilation was also a leading risk factor for CRO 
infection including hospital-acquired infection (Figure 2-4 C and D, Appendix 
2-7). Mechanical ventilation is a treatment option that is often necessary in 
critical ill patients (ICU patients in particular) and it is related with the burden 
of the disease (Mantzarlis et al., 2013). Its duration might be considered as a 
marker of disease severity (Polito et al., 2011). Moreover, the application of 
mechanical ventilation usually requires sedation and thus favours the 
development of nosocomial infections (Nseir et al., 2010). Gastrostomy, 
parenteral nutrition and urinary catheter were leading risk factors for CRO 
colonisation specifically (Figure 2-4 C). However, it is usually difficult to confirm 
if these factors reflect the result of inter-patient/personnel cross transmission 
(Cunha et al., 2016; Hong et al., 2012; Anderton et al., 1993). Nevertheless, 
the exist of CRO in the natural or manmade environment is a prerequisite for 
the entry to occur, so implementation and good compliance of aseptic 
technique during invasive procedures and infection control measures during 
daily medical work. 
All the above factors should be interpreted with caution as they may present 
surrogate markers of critical illness and extensive healthcare exposure rather 
than reflecting a direct association. The same risk factors are associated with 
multidrug-resistant organisms other than CRO (Lynch, 2001; Merrer et al., 
2000; Nseir et al., 2011). Consistent with this interpretation, multiple other 
studies have reported that longer duration of ICU stay and of hospitalisation 
are known risk factors (Gregory et al., 2010; Routsi et al., 2013; Ben-David et 
al., 2014; Harris et al., 2011; Lautenbach et al., 2010). This study also identified 
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that ICU stay, longer ICU and hospital stay before CRO isolation were 
consistently leading risk factors for different CRO status (Figure 2-4, Appendix 
2-7). Longer hospital stay could predispose to greater risk for colonization with 
CRO strains through patient-to-patient transmission (Kwak et al., 2005; Borer 
et al., 2012). Moreover, higher scores of the severity of comorbidity index CCI 
and APACHE II which is an ICU scoring system were risk factors for CRO 
presence and infection (Appendix 2-7). 
2.4.4 Demography and comorbidities related risk factors 
Demography and comorbidities were the most common candidate risk factors 
investigated by the majority of studies due to accessibility from medical 
records. Comparing with other groups of risk factors, demography and 
comorbidities are less likely modifiable in the respect of interventions to 
prevent emergence and transmission of CRO. However, almost all of them 
were risk factors with lower percentage of being a risk factor and pooled OR 
estimates for different CRO status with the exception of decubitus ulcers for 
CRO infection and steroid administration for CRO hospital-acquired infection 
(Figure 2-4). Patients with decubitus ulcer are more likely to have a history of 
hospitalisation and are more debilitated and prone to subsequent infections as 
decubitus ulcers are favourable sites for bacterial colonisation until they are 
closed (Ny et al., 2015; Patel et al., 2011). Steroid administration is well 
recognised as the marker of immunocompromised status (Coutinho and 
Chapman, 2011). They are usually to treat immunocompromised patients with 
malignancy or undergone transplantation who are vulnerable to infections 
(Barshes et al., 2004; Furtado et al., 2010). 
2.4.5 Study characteristics contributing to the heterogeneity 
across studies 
This study did not identify any protective factors in terms of pooled OR 
estimates/SMD and 95% confidence interval. Variation in a range of study 
characteristics potentially contributed to heterogeneity between studies. 
Although 44.5% of these studies defined carbapenem resistance according to 
CLSI guidelines (Table 2-2), the interpretation criteria of carbapenem 
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resistance issued in different years differed from each other slightly. Moreover, 
a previous study demonstrated that minimum inhibitory concentration testing 
revealed discordant results comparing with disk diffusion testing when the 
same guideline was adopted and susceptibility to one carbapenem did not 
necessarily correlate with susceptibility or resistance to the other carbapenems 
tested (Barron et al., 2016). The majority of these studies did not clarify the 
specific mechanisms of carbapenem resistance (215/254, 84.6%). However, 
the mechanisms of carbapenem resistance may be associated with different 
sets of risk factors, outcomes and transmission of resistance, given that 
carbapenemases are encoded by genes frequently carried on mobile genetic 
elements responsible for horizontal transmission among species and rapid 
worldwide spread of carbapenem resistance while the non-enzymatic 
mechanism is frequently associated with a loss in fitness to the organism and 
reduced transmissibility. In this respect, discrimination of mechanisms of 
carbapenem resistance is important for risk factor studies, especially detection 
of the presence of carbapenemases. This study showed that genotypic and 
phynotypic resistance could account for 1.2-7.8% of total heterogeneity 
(Appendix 2-10). van Loon et al. stated that all risk factors showed a decreased 
(or equal) pooled OR when only studies in which carbapenemase production 
was shown were included (van Loon et al., 2018). However, this study showed 
that higher pooled ORs but also greater heterogeneity were obtained when 
only studies investigating carbapenemase-producing organisms (CPO) were 
included. Some studies have found that healthcare associated exposure was 
more strictly related to non-CPO strains than CPO strains (Armand-Lefevre et 
al., 2013; Orsi et al., 2013) as carbapenemase production does not always 
confer high-level carbapenem resistance (Anderson et al., 2007). 
It is not surprising that studies those focus on non-fermenters have less 
heterogeneity than those focus on Enterobacteriaceae as the former only 
involve Pseudomonas spp. and Acinetobacter spp. while the latter comprise 
multiple genera and species. Similarly, studies those focus on paediatric 
patients have less heterogeneity than those on adults and generated higher 
risk estimates due to better consistency of age definitions and immaturity of 
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immune system. Choices of controls accounted for substantial amount of 
heterogeneity (up to 35.8%). There has been considerable debate regarding 
the choice of controls in risk factor studies of antimicrobial resistance (Orsi et 
al., 2013; Satlin et al., 2016; Bleumin et al., 2012). More than half (144/254, 
56.7%) of these studies chose CRO as cases and CSO as controls. Some 
studies argued that selecting patients harbouring CSO as controls might raise 
concerns as patients with CSO do not necessarily represent the source of 
studied population, thus overestimating the association between antimicrobial 
exposure and CRO cases (Ahn et al., 2014; Lee et al., 2013a). As discussed 
above, many risk factors may be surrogate markers of severe, prolonged 
illness that is not controlled for by selecting controls with similar severity of 
illness and length of stay. Choice of controls should reflect the question to be 
answered. Meta-regression analyses also indicated that risk factors showed 
more consistency and lower risk estimates when studies were conducted in 
ICU specifically, especially for risk factors associated with invasive indwelling 
devices (Appendix 2-10). This might be due to common use of such life support 
devices in ICU. 
2.4.6 Estimation of standard deviation from sample size and 
range 
For continuous factors, sample mean and SD are often used to perform meta-
analysis. However, some studies only reported sample size, median, range 
and/or IQR. Thereby, sample mean and SD should be estimated from them. 
Two studies provided such estimation methods with different equations (Walter 
and Yao, 2007; Wan et al., 2014). The current study demonstrated the 
consistency of the two methods reached 89.1% with 101 factors being tested 
and all the different estimations generated from the two methods did not affect 
the interpretation of the risk factor. Considering that Walter and Yao’s (Walter 
and Yao, 2007) method only provided equations estimating SD from sample 
size and range while Wan et al. (Wan et al., 2014) provided mean and SD 
estimation methods from both range and IQR, the latter estimation method was 
preferred and adopted. Of note, both methods are based on the assumption 
that data are normally distributed, the true underlying distribution is unlikely to 
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be known in practice and medians, ranges and IQRs are often reported when 
data do not follow a normal distribution. But it is difficult to get the raw data and 
if a distribution (more likely to be misspecified) is arbitrarily chosen, the 
estimates from the wrong model can be even worse than that from the normal 
distribution assumption (Wan et al., 2014). From such respects, the current 
method seems like a reasonable compromise. 
2.4.7 Strengths and limitations 
To the best of my knowledge, this is the first study to systematically review risk 
factors for the presence of CRO (including both Enterobacteriaceae and non-
fermenters) in healthcare facilities worldwide, although there was a systematic 
review just focused on risk factors for CRE (van Loon et al., 2018). A strength 
of this study is that the overall risk estimates of multiple risk factors were 
evaluated by using raw data extracted from individual studies and summarised 
with four aggregate parameters. Some studies simply count up the number of 
significant and non-significant results in individual studies which is known as 
vote-counting (Gurevitch et al., 2018), neglecting the magnitude and statistical 
significance of effects. The metric of the likelihood of being a statistically 
significant risk factor measures the consistency of the risk factors while the 
frequency of being a candidate risk factor reflects what risk factors 
investigators are interested in and the accessibility of getting such information 
from medical records. However, for some risk factors, this metric should be 
interpreted with caution as only a small number of studies investigated them. 
Another strength is the exploration of potential study design-associated 
sources of heterogeneity for different CRO status which provide evidence and 
directions for future studies aiming to explore the risk factors for antimicrobial 
resistance. The sensitivity analysis showed that the pooled estimates were 
robust after removing studies of low quality. 
There are also some limitations. First, only univariate analysis could be 
conducted without individual data from each study. In individual studies, some 
factors were significant in univariate analysis but were not independent risk 
factors in multivariate analysis adjusting for other factors. Therefore, I am not 
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able to evaluate to what extent one factor are confounded or biased by other 
factors. Second, although some possible causes of heterogeneity were 
explored, other methodological characteristics might accounting for 
heterogeneity such as study quality, time distribution of risk factors before 
CRO diagnosis and definition of carbapenem resistance were not considered. 
Hence, a random-effects model for meta-analyses were adopted. 
 
2.5 Conclusion 
The two estimation methods of standard deviation had good consistency. This 
study highlights that prior carriage of multidrug-resistant organisms, prior 
carbapenem or oxazolidinone use, presence of mechanical ventilation or 
nasogastric tube, ICU stay, longer ICU stay, longer hospital stay and longer 
duration of mechanical ventilation were most consistently found to be leading 
risk factors for CRO. Screening and pre-emptive managements should 
prioritise patients with these risk factors to limit the emergence and spread of 
CRO in healthcare settings. Given that most infections occur in early post 
procedure period and colonisation precedes infection, screening should be 
performed both before and after invasive procedures, mechanical ventilation 
and nasogastric tube in particular. Empirical combination therapy including 
carbapenem, oxazolidinone, vancomycin, colistin or cefepime should be 
initiated with caution. More efforts should be made to evaluate risk factors 
associated with CRO in low income countries and high income countries with 
low CRO incidence. In the future researchers should take study organism, 
case-control selection, study population, sample size and study setting into 
account when designing risk factor studies for carbapenem resistance.  
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Chapter 3 Clinical characteristics and 
outcomes of CPO 
3.1 Background 
In the past two decades, emergence of carbapenem-resistant organisms 
(CRO) has become a global public health crisis, leaving few effective 
therapeutic options available to treat multidrug-resistant infections (Kim et al., 
2014c; Kim et al., 2012b). Resistance to carbapenems arises from two general 
mechanisms: carbapenemase production or non-enzymatic. CRO strains that 
do not produce carbapenemases (non-enzymatic) are usually less resistant to 
other antibiotics (Nordmann et al., 2012a) and their carbapenem resistance 
trait is not transferable. Carbapenemases, by contrast, are encoded by genes 
frequently carried on mobile genetic elements such as plasmids and 
transposons which could be transferred between different species and 
individuals. Therefore, carbapenemase-producing organisms (CPO) have 
largely been responsible for the rapid and extensive worldwide spread of CRO 
and considered of more clinical concern than non-enzymatic CRO. 
In Scotland, an increasing number of CPO were reported since its first 
observation in 2003 (Palepou et al., 2005). Although the incidence of CPO 
isolates reported remains low, it shows an upward trend (Information Services 
Division Scotland, 2016). There has been an increase in carbapenems use in 
acute hospitals and incidence of CPO isolates over the past five years 
(Information Services Division Scotland, 2016; Health Protection Scotland, 
2018d). The epidemiology of Scottish CPO isolates, however, remains 
unclear. Given that CPO are of more clinical concern as discussed in Section 
1.1.2 and there are no comprehensive data of CRO in Scotland, this thesis 
specifically focuses on CPO reported in Scotland. The aim of this chapter is to 
conduct a detailed analysis of epidemiological characteristics of CPO in 
Scotland. Insights based on these findings will further the development of 
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effective and appropriate prevention and infection control strategies, thus 
curbing future emergence and spread of CPO in Scotland. 
The specific aims of this chapter are: 
1) to examine CPO incidence and temporal trend at national level; 
2) to investigate the spatial distribution of CPO at National Health Service 
(NHS) Board level; 
3) to investigate the microbiological characteristics of CPO isolates, 
including specimen (e.g. urine, blood and sputum), organism (e.g. 
Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa), 
carbapenemase (e.g. KPC, VIM and NDM) and antimicrobial resistance 
profile; 
4) to determine mortality rate of CPO cases and compare survival of CPO 
cases by gender, status (infection or colonisation), source (healthcare- 
or community-associated), organism and carbapenemase; 
5) to determine risk factors for all-cause 30-day mortality among 
hospitalised patients with CPO. 
 
3.2 Methods 
3.2.1 Study design 
This is a retrospective study of epidemiology of CPO isolated in Scotland 
between 2003 and 2016. This study was reviewed and approved by the Public 
Benefit and Privacy Panel for Health and Social Care (Reference number: 
1617-0328) (Appendix 3-1). The study population were individuals from whom 
CPO isolates were isolated in Scotland. 
  Epidemiology of CPO in Scotland 
 
Clinical characteristics and outcomes of CPO  81 
 
3.2.2 Data 
3.2.2.1 Data sources 
All the data included in this study were extracted from the datasets listed below 
(Table 3-1). The additional data was acquired for 2017 including only the 
number of distinct individuals with CPO isolation.
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3.2.2.2 Data extraction, linkage, provision and storage 
In Scotland, specimens with suspected CPO from clinical indications or 
surveillance programme were submitted to a Scottish diagnostic laboratory. 
Identification of isolates and antimicrobial susceptibility testing were performed 
by VITEK®2 (bioMérieux, Marcy-I’Étoile, France) (Trepanier et al., 2017). If 
the isolate was non-susceptible to ≥1 carbapenem, the diagnostic laboratory 
would refer the isolate to the antimicrobial resistance and healthcare 
associated infections reference unit at Public Health England for confirmation 
of carbapenemase production by in-house polymerase chain reaction 
(Trepanier et al., 2017). 
Construction of the database required extraction and linkage of datasets held 
at Health Protection Scotland (HPS) and Information Services Division for all 
hospitalised patients testing positive for CPO. Linkages were performed by 
HPS and Information Services Division via electronic Data Research and 
Innovation Service. The Community Health Index number was replaced with 
an anonymised patient identifier in the file made available for analysis. The 
anonymised file was transferred to electronic Data Research and Innovation 
Service team which bases at the FARR Institute to enable preparation, 
provision and storage of data via the National Services Scotland National Safe 
Haven. The National Services Scotland National Safe Haven is a secure 
environment in which data are linked, accessed and analysed. This 
environment provides a high powered computing service, secure analytic 
platform, secure file transfer protocol for receipt of data, and provision of a 
range of analytic software (SPSS, STATA, SAS and R). Access is provided via 
a secure access point, a physically secure area containing a computer with no 
external devices e.g. disc, CD, USB drives or printer access, or remotely via 
an accredited organisation’s personal computer or laptop. This allows trusted 
and authorised researchers to analyse linked individual level data while 
maintaining the utmost confidentiality. To remotely access the safe haven, 
there is a two factor authentication process, the first part of which will be receipt 
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of an access code via the researchers’ mobile phone followed by entering the 
user name and periodically updated password. 
3.2.2.3 Ethics 
Patients have been informed of the use of their data via two main routes. The 
first involves the publication of generic leaflets explaining how National 
Services Scotland uses patient data and these are available in a wide range 
of healthcare premises. The second method is the National Services Scotland 
privacy notice which is published on the National Services Scotland website 
(https://nhsnss.org/how-nss-works/data-protection/). This notice provides 
information to persons on how National Services Scotland stores and uses 
NHS Scotland data. All data for analyses in this study were anonymised. 
Clinical Research Governance of College of Medicine & Veterinary Medicine 
of University of Edinburgh and NHS Lothian Research & Development team, 
West of Scotland Research Ethics Service and Usher Institute of University of 
Edinburgh were consulted for ethical approval. No Research & Development, 
NHS and formal departmental ethical review or approval were required. The 
study is covered by National Safe Haven generic ethics approval (Reference 
number: 1617-0328) (Appendix 3-1). 
3.2.3 Definition 
3.2.3.1 CPO and microbiological characteristics 
CPO were defined as carbapenemase-producing Gram-negative bacilli 
isolated from both clinical and surveillance samples in Scotland confirmed by 
antimicrobial resistance and healthcare associated infections reference unit 
Public Health England. CPO were categorised as either carbapenemase-
producing Enterobacteriaceae (CPE) or carbapenemase-producing non-
fermenters and each CPO was described at family, genus and species levels 
(Table 3-2). All the samples where CPO were isolated in were aggregated into 
7 specimen groups (Table 3-3). Carbapenemases included GES, KPC, IMI, 
IMP, NDM, VIM and OXA-48. According to Ambler’s structural classification 
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One CPO isolation was defined on the basis of organism (species level), 
carbapenemase, isolation date and specific specimen. Isolations different in 
any of these characteristics represented different isolations. 
One CPO isolate was defined on the basis of organism at species level and 
carbapenemase. A difference in either organism or carbapenemase 
represented different isolates. 
3.2.3.3 Source: healthcare-associated and community-associated 
Regarding source, all cases were classified as either healthcare-associated or 
community-associated following the criteria: 1) healthcare-associated, 
specimen with a positive culture was collected at least 48 hours after hospital 
admission or specimen with a positive culture was collected within 48 hours of 
hospital admission in patients that had previous hospital admission within one 
year before the index hospitalisation admission or specimen with a positive 
culture was collected in community but the individual had previous hospital 
admission within one year before the index specimen collection; 2) community-
associated, specimen with a positive culture was collected within 48 hours of 
hospital admission in patients that had no hospital admission within one year 
before the index hospitalisation admission or specimen with a positive culture 
was collected in community and the individual had no previous hospital 
admission within one year before the index specimen collection. If one case 
had more than one CPO isolations, the classification was based on the first 
isolation. 
3.2.3.4 Status: infection and colonisation 
As discussed in Section 2.3.6, infection and colonsiation have different 
implications for healthcare of antimicrobial resisatnce from clinical and public 
health perspectives, therefore the status of each CPO case was categorised 
as an infection, a colonisation or an unclassifiable subject. The definitions of 
status are listed in Table 3-5. CPO presence represented a positive test of 
CPO, regardless of the status. 
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For CPO infection cases, they were classified as hospital-acquired infection 
(HAI), healthcare-associated infection (HCAI) or community-acquired infection 
(CAI) following the definitions (Cardoso et al., 2014; Horan et al., 1992): 1) 
HAI, specimen with a positive culture was collected at least 48 hours after 
hospital admission; 2) HCAI, specimen with a positive culture was collected 
within 48 hours of hospital admission in patients that had previous hospital 
admission within one year before the index hospitalisation admission or 
specimen with a positive culture was collected in community but the individual 
had previous hospital admission within one year before the index specimen 
collection; 3) CAI, specimen with a positive culture was collected within 48 
hours of hospital admission in patients that had no hospital admission within 
one year before the index hospitalisation admission or specimen with a 
positive culture was collected in community and the individual had no previous 
hospital admission within one year before the index specimen collection. 
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3.2.3.5 Mortality 
CPO attributed death fulfilled any of the following criteria: 1) infection was 
primary cause of death, no specimen restrictions and time lapse between CPO 
isolation and death ≤ 30 days; 2) chronic disease was primary cause of death, 
acute infection was secondary cause of death, specimen matched infection 
and time lapse between CPO isolation and death ≤ 30 days; 3) sepsis was 
secondary cause of death, no specimen restrictions and time lapse between 
CPO isolation and death ≤ 30 days; 4) specimen was from normally sterile 
sites, infection was either primary or secondary cause of death and time lapse 
between CPO isolation and death ≤ 30 days. 
3.2.3.6 Rates 
CPO incidence was calculated with midyear population estimates per year, 
using the formula: 
incidence =
number of CPO cases per year
midyear population estimates per year
∗ 100,000 
The percentage of infection, colonisation and unclassifiable cases per year 
was examined using the formula: 
Percentage of CPO cases of different status
=
number of CPO infection, colonisation or unclassifiable cases per year
total number of CPO cases per year
∗ 100 
The percentage of healthcare- and community-associated cases per year was 
examined using the formula: 
Percentage of CPO cases of different sources
=
number of CPO healthcare −  or community − associated cases per year
total number of CPO cases per year
∗ 100 
The percentage of each genus in each family and percentage of each 
carbapenemase per year was examined using the formula: 
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Percentage of genus =
number of CPO isolates of the genus per year
total number of CPO isolates per year
∗ 100 
Percentage of carbapenemase =
number of CPO isolates producing the carbapenemase per year
total number of CPO isolates per year
∗ 100      
Antimicrobial resistance rate was defined using the formula: 
Resistance rate
=
number of CPO isolates resistant or intermediate to the tested agent
number of CPO isolates tested for this agent
∗ 100 
Case fatality rate was defined as the number of CPO attributed deaths per 100 
CPO cases using the formula: 
case fatality rate =
number of CPO attributed deaths
number of CPO cases
∗ 100 
Hospital mortality rate was defined using the formula: 
Hospital mortality rate =
number of CPO cases died in hospital
total number of CPO cases
∗ 100 
All cause 30-day or 1-year mortality rate was defined using the formula: 
All cause 30 − day or 1 − year mortality rate =
number of CPO cases died within 30 days or 1 year after CPO isolation
total number of CPO cases
∗ 100  
 
3.2.4 Statistical analysis 
All statistical analyses were carried out using R (version 3.5.1) on the secure 
analytical platform within the National Services Scotland National Safe Haven 
provided and supported by electronic Data Research and Innovation Service 
team. Maps were drawn using ArcGIS (version 10.5.1). A P value <0.05 was 
considered significant. 
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3.2.4.1 Temporal trends 
The temporal trend of CPO incidence at national level was explored using an 
exponential model; temporal trends of Enterobacteriaceae and non-fermenters 
at national level (change in the number of cases with Enterobacteriaceae and 
non-fermenters over time offset by the corresponding midyear population 
estimates) were explored using a generalised linear model (Poisson 
regression or a quasi-Poisson regression for over-dispersed data, with a log 
link function). Differences in temporal incidence trends between 
Enterobacteriaceae and non-fermenters were examined by testing for an 
interaction between bacterial family and isolation year. 
Temporal trends of CPO infection, colonisation and unclassifiable incidence at 
national level (change in the number of CPO infection, colonisation and 
unclassifiable cases over time offset by the corresponding number of CPO 
cases in each year) were explored using a generalised linear model (Poisson 
regression or a quasi-Poisson regression for over-dispersed data, with a log 
link function). Differences in temporal incidence trends between infection and 
colonisation were examined by testing for an interaction between status and 
isolation year. 
Temporal trends of healthcare-associated and community-associated CPO 
incidence at national level (change in the number of healthcare-associated and 
community-associated cases over time offset by the corresponding number of 
CPO cases in each year) were explored using a generalised linear model 
(Poisson regression or a quasi-Poisson regression for over-dispersed data, 
with a log link function). Temporal trends of percentage by source (as defined 
in Section 3.2.3.6) among CPO cases (change in the number of CPO cases of 
each source over time offset by the corresponding number of CPO cases in 
each year) were explored using a generalised linear model (Poisson 
regression or a quasi-Poisson regression for over-dispersed data, with a log 
link function). 
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For HAI cases, NHS board of treatment was used; for the other cases, NHS 
board of residence was used. Given the possibility of patients being identifiable 
and personal information disclosure due to small numbers of CPO cases (less 
than 5 cases) and geographical proximity, NHS Highland/NHS Western 
Isles/NHS Orkney/NHS Shetland, and NHS Ayrshire & Arran/NHS Borders 
were respectively combined together. CPO incidence in each NHS Board was 
calculated following the formula defined in Section 3.2.3.6.  
Temporal trends of percentage by genus and carbapenemase (as defined in 
Section 3.2.3.6) among CPO isolates (change in the number of CPO isolates 
of each genus/with each carbapenemase over time offset by the 
corresponding number of CPO isolates in each year) were explored using a 
generalised linear model (Poisson regression or a quasi-Poisson regression 
for over-dispersed data, with a log link function). 
3.2.4.2 Microbiological characteristics 
For one CPO case, if there were multiple isolations of the same isolate from 
the same specimen on different dates then only the first isolation was included 
in the study. This method was used in order to more uniformly assess diversity 
of carbapenemases and independent specimen sources for statistical 
analysis. 
Antimicrobial resistance rates of each antimicrobial agent for 
Enterobacteriaceae and non-fermenters isolates were evaluated respectively. 
The resistance rates were compared between the two families and between 
infection and colonisation using Pearson’s Chi-squared test or Fisher’s exact 
test as appropriate. 
3.2.4.3 Survival and mortality 
The Kaplan-Meier method was used to plot 1-year survival curves. Differences 
between survival curves at 30-day and 1-year by gender, status (infection and 
colonisation), source (healthcare-associated and community-associated) and 
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bacterial family were evaluated by the log-rank test (Mantel, 1966; Peto and 
Peto, 1972). 
For risk factors for 30-day mortality of hospitalised CPO cases, all the 
hospitalised CPO cases were divided into two groups: dead (non-survivor) or 
alive (survivor) within 30 days after CPO isolation. Independent variables 
included demographics, microbiological characteristics, comorbidities, 
healthcare exposure in the prior 90 days before CPO isolation (i.e. specimen 
date), invasive procedures in the prior 90 days before CPO isolation. The 
definition of each independent variable is listed in Appendix 3-2. A generalised 
linear mixed model with hospital where CPO was isolated as a random effect 
was used. Univariate analysis was performed first with each variable entered 
the model on its own and all variables with P<0.10 were carried forward for 
multivariate analysis. Correlations between variables with P<0.10 in univariate 
analysis were checked by calculating correlation coefficients (Spearman’s rank 
correlation coefficient between continuous variables, Cramér’s V between 
dichotomous variables or point-biserial correlation coefficient between 
continuous variables and dichotomous variables) and variance inflation factor 
(VIF). Also, possible interactions between variables were checked. For 
variables with high-level correlation (correlation coefficient≥0.70) and 
multicollinearity (VIF>4), variables with greater corrected Akaike Information 
Criterion (AICc) value were removed from the model, the remaining variables 
were considered to be included in the multivariate analysis. Models with all 
possible independent variable combinations were considered for the final 
multivariate model. These models were ranked based on AICc values (from 
low to high) and Akaike weights (from high to low). Candidate models were 
selected using ΔAICc<2 and Akaike weights>0.05, with the best approximating 
candidate model having the highest Akaike weights (Anderson and Burnham, 
2002). Model averaging was used to construct the final multivariate model 
using the Akaike weights of the candidate models (Anderson et al., 2000). For 
statistical purpose, variables with zero values in either group were removed 
from multivariate analyses, i.e. no patients in either group had exposure to the 
potential risk factor of interest. Odds ratio (OR) and 95% confidence interval 
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(95%CI) were calculated to determine the strengths of these associations. A P 




This section provides a comprehensive description of CPO including numbers 
of CPO cases/isolations/isolates, demographic and clinical characteristics of 
CPO cases, and status (infection/colonisation/unclassifiable) and source 
(healthcare-associated/community-associated) of CPO cases. A total of 290 
persons were diagnosed with CPO isolation in Scotland between 2003 and 
2017. Unfortunately, the metadata was not available for 2003 (n=1) and 2017 
(n=75), so only 214 distinct CPO cases identified between 2004 and 2016 were 
included in subsequent analyses, other than incidence analysis at national 
level. Among the 214 CPO cases, 170 (79.4%) had a single isolation while 44 
(20.6%) had multiple isolations, resulting in 285 CPO isolations. There was a 
total of 243 distinct CPO isolates obtained from the 214 CPO cases. One-
hundred and seventy-three (71.2%) of the 243 isolates were isolated from 
hospitalised patients in 29 hospitals, including 12 tertiary care hospitals 
(107/173, 61.8%), 14 secondary care hospitals (63/173, 36.4%) and 3 
community/rehabilitation hospitals (3/173, 1.7%), and the remaining 70 
isolates were isolated in the community. 
Metadata were not complete for 3 cases, all of which were female. Medical 
records were available for the remaining 211 cases and analysis of CPO status 
and source was performed on these. One hundred and fifty (71.1%) of the 211 
cases were hospitalised patients. Clinical characteristics of CPO cases are 
listed in Table 3-6 and the definitions of these characteristics are listed in 
Appendix 3-2. Healthcare exposure characteristics of index hospitalisation 
were available only for 150 hospitalised CPO cases.  
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Figure 3-1. Gender distribution of 211 carbapenemase-producing 
organisms (CPO) cases within 20-year age groups. Bar chart shows 
number of cases per 20-year age group; scatter plot and line chart 
illustrate gender distribution of 211 CPO cases per 20-year age group. 
 
The 211 cases comprised 78 (37.0%) infection cases, 85 (40.3%) colonisation 
cases and 48 (22.7%) unclassifiable cases. Due to the small numbers of cases 
in 2007-2008 (less than 5), they were combined together. The temporal 
distribution of CPO cases by status is shown in Figure 3-2. Among the 78 
infection cases, there were 46 (59.0%) HAI cases, 18 (23.1%) HCAI cases and 
14 (17.9%) CAI cases. Seventy-two of the 78 infection cases were hospitalised 
patients and nearly half (35/72, 48.6%) of them were hospitalised in surgical 
specialties while 25.0% (18/72) were in ICU/HDU. Urinary tract infection (UTI) 
(23/78, 29.5%) was the most common, followed by bloodstream infection 
(21/78, 26.9%), respiratory tract infection (12/78, 15.4%), wound infection 
(9/78, 11.5%), gastrointestinal infection (7/78, 9.0%), bacterial meningitis 
(3/78, 3.8%) and skin and soft tissue infection (3/78, 3.8%). Due to the small 
numbers of bacterial meningitis and skin and soft tissue infection cases (less 
than 5), they were combined together. Numbers of infection cases by infection 
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type and bacterial family and genus are shown in Figure 3-3. There were 
significant differences in the number of infection types associated with 
bacterial family (P<0.001, Fisher’s exact test). All UTI and gastrointestinal 
infections were caused by Enterobacteriaceae isolates, majority of which were 
Enterobacter spp., Escherichia coli (E. coli) and Klebsiella spp. isolates. Half 
(6/12, 50.0%) of respiratory tract infections were caused by Pseudomonas 
spp. isolates. For the other infection types, more infections were caused by 
Enterobacteriaceae isolates than non-fermenters. 
Incidence of infection increased significantly over time (P<0.001, based on a 
Poisson regression model) while proportion of infection cases tended to stay 
stably since 2013 (Figure 3-2). Among the 85 colonisation cases, more than 
half of the isolates were isolated from urine (47/85, 55.3%), followed by 
alimentary (9/85, 10.6%), wound (9/85, 10.6%), respiratory (4/85, 4.7%) and 
superficial (3/85, 3.5%) samples. Incidence of colonisation increased 
significantly over time (P<0.001, based on a Poisson regression model). There 
was no difference in temporal incidence trends between infection and 
colonisation (P=0.467, by testing the interaction between status and isolation 
year). Out of the 48 unclassifiable cases, 89.3% (43/48) were isolated between 
2013 and 2016 while 33 (76.7%) of them were isolated from alimentary and 
urine samples. Incidence of unclassifiable cases increased significantly over 
time (P<0.001, based on a Poisson regression model).  
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Figure 3-2. Temporal distribution of number and percentage of 211 
carbapenemase-producing organisms (CPO) cases by status (infection, 
colonisation and unclassifiable). A, temporal distribution of number of 
211 CPO cases by status. B, temporal distribution of percentage of 211 
CPO cases by status. 
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Figure 3-3. Infection types of carbapenemase-producing organisms 
(CPO) infection cases (n=78) by bacterial family (A) and genus (B).
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Among the 211 cases, 149 (70.6%) were healthcare-associated cases. Due to 
the small numbers of cases in 2007-2008 (less than 5), they were combined 
together. The temporal distribution of CPO cases by source is shown in Figure 
3-4. Incidences of both healthcare-associated and community-associated 
increased significantly over time (P<0.001, based on a Poisson regression 
model), but there was no difference in temporal incidence trends between 
them (P=0.310, by testing the interaction between source and isolation year). 
Community-associated cases were reported since 2009 and the number of 
community-associated cases increased dramatically after 2013 but the 
percentage of community-associated cases among all the cases reported in 
each year did not change significantly (P=0.374, based on a Poisson 
regression model). The source of CPO cases was differently distributed in 
different status (P<0.001, Pearson’s Chi-squared test), i.e. community-
associated cases were more likely to be colonisations (39/62, 62.9%) while 
healthcare-associated cases were more likely to be infections (64/149, 43.0%). 
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Figure 3-4. Temporal distribution of number and percentage of 211 
carbapenemase-producing organisms (CPO) cases by source 
(healthcare-associated or community-associated). A, temporal 
distribution of number of 211 CPO cases by source. B, temporal 
distribution of percentage of 211 CPO cases by source. 
 
Overall, there were slightly more colonisation cases than infection cases and 
most of CPO cases were healthcare-associated. Incidences of both CPO 
status (infection and colonisation) and source (healthcare-associated and 
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community-associated) increased significantly over time but there were no 
differences between different status and source. 
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3.3.2 Incidence and trends 
Examination of CPO incidence and its temporal trends and spacial distribution 
would help to evaluate the resistance situation and current national acute 
hospital admission screening programme of CPE, thus enabling comparison 
of CPO incidences across NHS Boards, between Scotland and other 
nations/countries and informing local public health bodies to take further 
actions to combat CPO. 
3.3.2.1 Incidence and temporal trends of incidence at national level 
There were no CPO isolations in 2005 and 2006. Exponential models were 
used to fit the incidence data (Incidence~a*b^Year). The overall incidence of 
CPO cases increased between 2003 and 2017 (Incidence~0.025*1.332^Year, 
P<0.001), from 0.02 to 1.38 per 100,000 population (Figure 3-5). To evaluate 
the impact of active surveillance for CPE introduced in August 2013, an 
exponential model was used to fit the data before (2003-2013) its introduction. 
Before surveillance, the model was Incidence~0.021*1.330^Year (95%CI for 
b: 1.161-1.499). To compare incidences of the two bacterial families, Poisson 
regression models were used. Incidences of both Enterobacteriaceae and 
non-fermenters increased significantly over time (P<0.001), but incidence of 
Enterobacteriaceae (yearly increase of 42.5%) increased faster than that of 
non-fermenters (yearly increase of 21.5%) (P=0.001, by testing the interaction 
between bacterial family and isolation year) (Figure 3-6). 
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Figure 3-5. Carbapenemase-producing organisms (CPO) incidence in 
Scotland 2003-2017. Black circles show CPO incidence (number of CPO 
cases per 100,000 population) and black lines illustrate temporal trend of 
CPO incidence between 2003 and 2017, fitting based on exponential 
distribution. Green lines illustrate temporal trend of CPO incidence 
before conduction of Scottish CPE active surveillance (i.e. between 2003 
and 2013) fitting based on exponential distribution and green open 
circles indicate the predicted CPO incidence between 2014 and 2017 
from the before surveillance model (2003-2013). The black square dot 
dashes show the difference between the actual incidence and predicted 
incidence from before surveillance model between 2014 and 2017. For 
statistical purpose, ‘Year’ was replaced in the model by 0 (2003), 1 (2004), 
2 (2005), etc. 
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Figure 3-6. Carbapenemase-producing organisms (CPO) incidence in 
Scotland 2003-2017 by bacterial family (Enterobacteriaceae and non-
fermenters). Circles show CPO incidence (number of CPO cases per 
100,000 population) in each year for Enterobacteriaceae (green) and non-
fermenters (red). Lines illustrate temporal trend of CPO incidence, fitting 
based on Poisson distribution. 
 
3.3.2.2 Spatial distribution of incidence at NHS Board level 
The 214 CPO cases were reported from 13 out of 14 NHS Boards in Scotland. 
NHS Dumfries & Galloway and NHS Forth Valley had the highest CPO 
incidence, followed by NHS Lothian and NHS Fife (Figure 3-7). Furthermore, 
the CPO cases from these four NHS Boards accounted for 71.5% (153/214) 
of all cases reported in Scotland between 2003 and 2016. The distribution of 
CPO cases by NHS Board over time is shown in Figure 3-8 A and more NHS 
boards had CPO cases reported over time (Figure 3-8 B). Source (healthcare-
associated and community-associated) distribution of CPO cases varied 
among these NHS Boards (P=0.010, Fisher’s exact test). Healthcare-
associated cases were more than community-associated cases for all the NHS 
Boards except NHS Ayrshire & Arran/NHS Borders (Figure 3-9). Infection and 
colonisation distribution of CPO cases were similar among these NHS Boards 
(P=0.551, Fisher’s exact test). Number of CPO infection cases were more than 
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that of CPO colonisation cases in NHS Lothian, NHS Greater Glasgow & Clyde 
and NHS Lanarkshire (Figure 3-10).
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Figure 3-7. Spatial distribution of carbapenemase-producing organisms 
(CPO) incidence by National Health Service (NHS) Board. AA/BR, NHS 
Ayrshire & Arran/NHS Borders; DG, NHS Dumfries & Galloway; FF, NHS 
Fife; FV, NHS Forth Valley; GGC, NHS Greater Glasgow & Clyde; GN, NHS 
Grampian; LN, NHS Lanarkshire; LO, NHS Lothian; TY, NHS Tayside; 
HG/OR/SH/WI, NHS Highland/NHS Orkney/NHS Shetland/NHS Western 
Isles.
Epidemiology of CPO in Scotland 






Figure 3-8. (A) Temporal distribution of 214 carbapenemase-producing 
organisms (CPO) cases by National Health Service (NHS) and (B) 
accumulated number of NHS Board with CPO cases reported over time.
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Figure 3-9. Spatial distribution of number and percentage of 211 
carbapenemase-producing organisms (CPO) cases by National Health 
Service (NHS) Board and source (healthcare-associated and community-
associated). (A) Number of 211 CPO cases by NHS Board and source 
(healthcare-associated and community-associated); (B) Percentage of 
211 CPO cases by NHS Board and source. AA/BR, NHS Ayrshire & 
Arran/NHS Borders; DG, NHS Dumfries & Galloway; FF, NHS Fife; FV, 
NHS Forth Valley; GGC, NHS Greater Glasgow & Clyde; GN, NHS 
Grampian; LN, NHS Lanarkshire; LO, NHS Lothian; TY, NHS Tayside; 
HG/OR/SH/WI, NHS Highland/NHS Orkney/NHS Shetland/NHS Western 
Isles.
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Figure 3-10. Spatial distribution of number and percentage of 211 
carbapenemase-producing organisms (CPO) cases by National Health 
Service (NHS) Board and status (infection and colonisation). (A) Number 
of CPO cases (78 infection cases and 85 colonisation cases) by NHS 
Board and status; (B) Percentage of CPO cases (78 infection cases and 
85 colonisation cases) by NHS Board and status. AA/BR, NHS Ayrshire 
& Arran/NHS Borders; DG, NHS Dumfries & Galloway; FF, NHS Fife; FV, 
NHS Forth Valley; GGC, NHS Greater Glasgow & Clyde; GN, NHS 
Grampian; LN, NHS Lanarkshire; LO, NHS Lothian; TY, NHS Tayside; 
HG/OR/SH/WI, NHS Highland/NHS Orkney/NHS Shetland/NHS Western 
Isles. 
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Overall, CPO incidence increased significantly and more NHS Boards reported 
CPO over time. The current national screening programme of CPE had an 
impact on the increasing incidence. CPO incidences and source (healthcare-
associated/community-associated) varied across NHS Boards. More efforts 
should be made to explore factors accounting for these differences in the 
future. 
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3.3.3 Microbiological characteristics 
3.3.3.1 Specimen type of CPO isolations 
Specimen type of CPO isolations indicates where CPO isolates were isolated 
from and may provide reference for selection of samples used for active 
surveillance of CPO. There were 269 unique CPO isolations. Urine (103, 
38.3%), alimentary (55, 20.4%) and wound (42, 16.0%) predominated at 
aggregate level with urine (99, 36.8%), rectal swab (45, 16.7%) and wound 
swab (32, 11.9%) being the most common specimens (Figure 3-11). In 
general, the number of CPO isolations from wound, urine and alimentary 
samples increased gradually. The majority of CPO isolations were from urine 
and alimentary samples from 2013 onward (Figure 3-12). 
 
 
Figure 3-11. Specimen types of 269 carbapenemase-producing 
organisms (CPO) isolations according to aggregate specimen (inner 
circle) and specific specimen (outer circle) 
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Figure 3-12. Temporal distribution of aggregate specimen types of 269 
carbapenemase-producing organisms (CPO) isolations 
 
3.3.3.2 Bacterial organisms and carbapenemases of CPO isolates 
The 243 CPO isolates were represented by 8 genera and 14 species, the 
majority of them being in the bacterial family Enterobacteriaceae (206/243, 
84.8%). Klebsiella pneumoniae (65/206, 31.6%), Enterobacter cloacae 
(52/206, 25.2%) and E.coli (50/206, 24.3%) were the most common species. 
Pseudomonas aeruginosa (29/37, 78.4%) predominated among non-
fermenters (Figure 3-13). 
VIM (75/243, 30.9%), NDM (56/243, 23.0%), KPC (43/243, 17.7%) and OXA-
48 (43/243, 17.7%) were the most common carbapenemases (Figure 3-14). 
VIM-producing Enterobacter spp. (29/243, 11.9%), NDM-producing E.coli 
(25/243, 10.3%) and KPC-producing Klebsiella spp. (24/243, 9.9%) were the 
most common CPO isolates (Figure 3-15). Ambler class B enzymes (IMP, 
NDM and VIM) were commonly isolated from both Enterobacteriaceae and 
non-fermenters while class A and D enzymes were isolated from either 
Enterobacteriaceae or non-fermenters exclusively (Figure 3-15). The temporal 
distribution of these isolates producing Ambler class B enzymes in both 
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families showed that the percentage of Enterobacteriaceae producers 
increased over time while non-fermenters producers dropped (Figure 3-16). 
Enterobacter spp. and Klebsiella spp. were the species with the greatest 
enzyme variety. NDM was present in all genera. It is noteworthy that CPO 
isolates producing more than one carbapenemase emerged in 2015 and the 
two NDM/IMP-producing isolates were isolated from both Enterobacteriaceae 
and non-fermenters (Figure 3-15). 
 
 
Figure 3-13. Family (inner circle), genera (middle circle) and species 
(outer circle) of 243 carbapenemase-producing organisms (CPO) isolates
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Figure 3-14. Carbapenemases of 243 carbapenemase-producing 
organisms (CPO) isolates. Stacked bar chart shows annual number of 
CPO isolates producing different carbapenemases between 2004 and 
2016. Pie chart shows total number of CPO isolates producing different 
carbapenemases between 2004 and 2016.
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Figure 3-15. Distribution of species and carbapenemases of 243 
carbapenemase-producing organisms (CPO) isolates. A, Ambler class A 
carbapenemases; B, Ambler class B carbapenemases; D, Ambler class 




Figure 3-16. Temporal distribution of carbapenemase-producing 
organisms (CPO) isolates producing Ambler class B carbapenemases by 
bacterial family (Enterobacteriaceae and non-fermenters)
  Epidemiology of CPO in Scotland 
 
Clinical characteristics and outcomes of CPO  119 
 
3.3.3.3 Carbapenemases of CPO cases by source and status 
Examination of the association between carbapenemases and source/status 
will help to answer if the source or status has impact on survival of CPO cases 
with different carbapenemases. The percentages of healthcare-associated 
were higher than those of community-associated cases among four of the ‘big 
5’ carbapenemases (VIM, NDM, KPC and IMP) (Figure 3-17). The 
percentages of source were different among either the ‘big 5’ carbapenemases 
or all carbapenemases (P<0.001, Fisher’s exact test). More than half of CPO 
cases (21/36, 58.3%) producing OXA-48 were community-associated, 
followed by cases producing NDM (22/46, 47.8%). In contrast, all the cases 
with IMP were healthcare-associated. VIM and IMP producers were 
significantly associated with healthcare-associated source while NDM and 
OXA-48 producers were more likely to be community-associated (Table 3-7). 
In terms of status (infection and colonisation), the percentages of status were 
different among either the ‘big 5’ carbapenemases (P=0.002, Pearson’s Chi-
squared test) or all carbapenemases (P=0.007, Fisher’s exact test). 
Percentage of infection was higher than that of colonisation for cases with IMP 
(Figure 3-18, Table 3-8). VIM producers were more likely to cause infection 
(Figure 3-18, Table 3-8). In contrast, NDM and OXA-48 production were 
significantly associated with CPO colonisation (Figure 3-18, Table 3-8). 
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3.3.3.4 Temporal trends of organisms and carbapenemases of CPO 
isolates 
Understanding temporal trends of organisms and carbapenemases of CPO 
isolates will inform future efforts for surveillance and infection prevention and 
control measures for some specific CPO isolates with upward trends. 
3.3.3.4.1 Temporal trend of organisms 
In terms of both number and percentage of CPO isolates, Klebsiella spp., 
Enterobacter spp., Escherichia spp. and Pseudomonas spp. isolates 
predominated over time. Isolates reported in 2004 and 2007 were not included 
in the temporal trend analysis due to the quite small numbers (less than 5 
isolates). The percentage of both Enterobacter spp. and Pseudomonas spp. 
isolates decreased significantly over time (Figure 3-19 A and B, Table 3-9). It 
is noteworthy that other species producing carbapenemases were reported 
since 2014, including Providencia spp., Acinetobacter spp. and Proteus spp. 
(Figure 3-19 A and B). Citrobacter spp. isolates were first reported in 2009 and 
then in 2012, and persisted since 2014 (Figure 3-19 C). Among the 206 
Enterobacteriaceae isolates, the percentage of Enterobacter spp. isolates 
decreased significantly over time (Figure 3-19 C and D, Table 3-9). The 
percentage of Klebsiella spp. and Escherichia spp. increased but they were 
not significant (Figure 3-19 C and D, Table 3-9). A temporal trend test of 
percentage of species among non-fermenters isolates was not performed due 
to small numbers of isolates (Figure 3-19 E). 
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Figure 3-19. Temporal distribution of number and percentage of 243 
carbapenemase-producing organisms (CPO) isolates by bacterial family 
and species. A, temporal distribution of number of 243 CPO isolates by 
bacterial species. B, temporal distribution of percentage of 243 CPO 
isolates by bacterial species. C, temporal distribution of number of CPO 
isolates by bacterial species among 206 Enterobacteriaceae isolates. D, 
temporal distribution of percentage of CPO isolates by bacterial species 
among 206 Enterobacteriaceae isolates. E, temporal distribution of 
number of CPO isolates by bacterial species among 37 non-fermenters 
isolates. 
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3.3.3.4.2 Temporal trend of carbapenemases 
KPC was the first reported carbapenemase and persisted throughout but the 
percentage among all the CPO isolates dropped significantly (Figure 3-20 A 
and B, Table 3-10). Likewise, IMP persisted through all the years since its first 
report in 2010, though the percentage decreased significantly in 2010-2016 
and the number increased in 2015-2016 (Figure 3-20 A and B, Table 3-10). In 
contrast, the percentage of NDM producers increased significantly over time 
(Figure 3-20 A and B, Table 3-10). The percentage of VIM producers 
decreased while the percentage of OXA-48 producers rose, but both trends 
were not statistically significant (Figure 3-20 A and B, Table 3-10). Notably, IMI 
producers were first reported in 2010 and presented again since 2015, and all 
of them were Enterobacter spp. isolates. Multiple-carbapenemase and GES-5 
producers were first reported in 2015 and the number of such isolates 
increased in 2016 (Figure 3-20 A). 
Among the 206 Enterobacteriaceae isolates, temporal trends of different 
carbapenemases were similar to all CPO isolates except IMP (Figure 3-20 C 
and D, Table 3-10). The decrease in percentage of IMP producers was not 
significant (Figure 3-20 C and D, Table 3-10) as half (9/18) of IMP producers 
were Pseudomonas spp. isolates which dropped significantly over time (Table 
3-9). A temporal trend test of percentage of carbapenemases among non-
fermenters isolates was not performed due to few numbers of isolates (Figure 
3-20 E and F).
Epidemiology of CPO in Scotland 
126  Clinical characteristics and outcomes of CPO 
 
     
(A)                                                          (B)
      
(C)                                                          (D) 
     
(E)                                                          (F) 
Figure 3-20. Temporal distribution of number and percentage of 243 
carbapenemase-producing organisms (CPO) isolates by bacterial family 
and carbepenemase. A, temporal distribution of number of 243 CPO isolates 
by carbepenemase. B, temporal distribution of percentage of 243 CPO isolates 
by carbepenemase. C, temporal distribution of number of CPO isolates by 
carbepenemase among 206 Enterobacteriaceae isolates. D, temporal 
distribution of percentage of CPO isolates by carbepenemase among 206 
Enterobacteriaceae isolates. E, temporal distribution of number of CPO isolates 
by carbepenemase among 37 non-fermenters isolates. F, temporal distribution 
of percentage of CPO isolates by carbepenemase among 37 non-fermenters 
isolates. 
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3.3.3.5 Spatial distribution of carbapenemases of CPO isolates 
Understanding spatial distribution of carbapenemases by NHS Boards would 
indicate whether there was potential clonal spread of some carbapenemases 
within NHS Boards. Nearly half of CPO isolates were isolated in NHS Lothian 
(66/243, 27.2%) and NHS Greater Glasgow & Clyde (53/243, 21.8%) (Figure 
3-21 A). NHS Greater Glasgow & Clyde had the greatest carbapenemase 
variety while NHS Forth Valley had the least only with VIM and OXA-48 (Figure 
3-21 A). 
Majority of VIM producers (65/75, 86.7%) were reported in NHS Forth Valley, 
NHS Lothian and NHS Greater Glasgow & Clyde (Figure 3-21 A). NDM 
producers were reported from most NHS Boards except NHS Forth Valley and 
the North West region (Figure 3-21 A). KPC producers were reported from 
most NHS Boards except NHS Forth Valley (Figure 3-21 A). OXA-48 
producers were isolated from each NHS Board (Figure 3-21 A). The majority 
of IMP producers (13/18, 72.2%) were isolated in NHS Lothian and NHS 
Lanarkshire (Figure 3-21 A). IMI producers were only isolated in NHS Lothian 
and NHS Greater Glasgow & Clyde (Figure 3-21 A). Isolates producing 
NDM+IMP and GES-5 were only reported in NHS Greater Glasgow & Clyde 
(Figure 3-21 A). 
In NHS Lothian, the percentage of VIM producers decreased significantly over 
time (P=0.015, based on a Poisson regression model) (Figure 3-21 C and D). 
All the 25 VIM-producing isolates were isolated from 23 cases and 22 (95.7%) 
of them were healthcare-associated cases. Eighteen of the 23 cases (78.3%) 
were hospitalised in Hospital A or had been hospitalised in the hospital in the 
prior 9 days before CPO isolation. Moreover, 16 of the 18 cases were from 
Haematology or Neurosurgery Specialties and 17 of them had been admitted 
to a HDU in the prior 90 days before CPO isolation. NDM-producing isolates 
were isolated from either urine or rectal swabs in 9 cases and 5 of them were 
community-associated cases. Thirteen OXA-48 cases were reported since 
2013 and 7 (53.8%) of them were isolated in community or community-
associated cases. In 2014, five of 6 cases carrying OXA-48 producers were 
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identified in surgical Specialties in the same hospital (Hospital B). IMP 
producers accounted half of the total IMP producers reported from Scotland 
(9/18, 50.0%). Interestingly, all of them were isolated in the Hospital A 
(healthcare-associated cases as well) and 8 of them were hospitalised in 
Haematology or Neurosurgery Specialties and 8 of them had been admitted to 
HDU in the prior 14 days before CPO isolation. In addition, IMP producers 
isolated between 2010 and 2012 were all Pseudomonas spp., but all the all 
the isolates were Enterobacteriaceae afterwards. 
In NHS Greater Glasgow & Clyde, the percentage of VIM producers decreased 
significantly over time (P=0.012, based on a Poisson regression model) 
(Figure 3-21 E and F). Ten (83.3%) of the 12 cases carrying VIM were 
healthcare-associated cases and 11 (91.7%) were Pseudomonas spp. 
carriers. The number of NDM producers increased continuously since the first 
report in 2013 which were isolated from 12 cases (Figure 3-21 E and F). Eight 
of the 12 were either community-associated cases or isolated from community. 
The number of OXA-48 producers rose continuously since the first report in 
2014 which were isolated from 8 cases (Figure 3-21 E and F). Seven (63.6%) 
of the 11 isolates were from rectal swab/faeces/urine samples. 
In NHS Forth Valley, the majority of CPO isolates were VIM producers (28/32, 
87.5%) (Figure 3-21 A, B, G and H) and they were identified from 25 cases, of 
which all were healthcare-associated cases and 23 (92.0%) were isolated from 
urine/rectal swab samples. All of them were Enterobacteriaceae isolates. 
Notably, all of the 25 cases were hospitalised or had been hospitalised in prior 
two months in the same hospital (Hospital C), and 13 (52.0%) of the 25 cases 
were from Geriatric Medicine Specialty and 9 (36.0%) were from General 
Medicine Specialty. 
In NHS Dumfries & Galloway, there was a sudden increase of CPO isolates in 
2016 and most (9/13, 69.2%) of the isolates were NDM-producers (Figure 3-21 
I and J). All the 12 NDM-producing isolates (11 Enterobacteriaceae and 1 non-
fermenters isolates) were isolated in urine and rectal swab samples from 9 
cases and 7 of them were isolated in community or community-associated 
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cases. Seven of the 9 cases (77.8%) were reported in community or 
community-associated cases. The single OXA-48-producing case was a 
community-associated case and the isolates were from urine and rectal swab. 
In NHS Fife, all the 8 cases with KPC were healthcare-associated cases. NDM- 
and OXA-48-producing isolates accounted for more than half of the isolates 
reported in 2015 and 2016 (8/12, 66.7%) (Figure 3-21 K and L). Six of the 8 
isolates were isolated in community or from community-associated cases and 
7 were isolated from urine/rectal swab samples. 
For the other NHS Boards, due to small numbers of isolates (less than 20) they 
were not investigated in detail. However, NDM- and OXA-48-producing 
isolates in NHS Tayside and NHS Grampian had been reported since 2014. 
The two cases carrying IMP-producing isolates from NHS Lanarkshire in 2015-
2016 and one case carrying IMP-producing isolate from NHS Dumfries & 
Galloway in 2015 had been hospitalised in the Cardiac Surgery Specialty in 
the same hospital (Hospital D). 
There might be clonal persistence and spread of some CPO isolates in some 
hospitals, however, more phylogeny analyses are required to confirm this. 
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Figure 3-21. Number and percentage of 243 carbapenemase-producing 
organisms (CPO) isolates by carbapenemase and National Health 
Service (NHS) Board over time. A, number of CPO isolates by 
carbapenemase and NHS Board. B, percentage of CPO isolates by 
carbapenemase and NHS Board. Number (C) and percentage (D) of CPO 
isolates by carbapenemase in NHS Lothian. Number (E) and percentage 
(F) of CPO isolates by carbapenemase in NHS Greater Glasgow & Clyde. 
Number (G) and percentage (H) of CPO isolates by carbapenemase in 
NHS Forth Valley. Number (I) and percentage (J) of CPO isolates by 
carbapenemase in NHS Dumfries & Galloway. Number (K) and 
percentage (L) of CPO isolates by carbapenemase in NHS Fife. AA/BR, 
NHS Ayrshire & Arran/NHS Borders; DG, NHS Dumfries & Galloway; FF, 
NHS Fife; FV, NHS Forth Valley; GGC, NHS Greater Glasgow & Clyde; GN, 
NHS Grampian; LN, NHS Lanarkshire; LO, NHS Lothian; TY, NHS 
Tayside; HG/OR/SH/WI, NHS Highland/NHS Orkney/NHS Shetland/NHS 
Western Isles.
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3.3.3.6 Antimicrobial resistance profiles of CPO isolates 
Antimicrobial susceptibility analyses may provide alternative therapeutic 
options for CPO if they were susceptible to some antimicrobial agents. 
Antimicrobial susceptibility testing results of 54 CPO isolates from 47 CPO 
cases were available, including 42 Enterobacteriaceae isolates and 12 non-
fermenters isolates. The 54 isolates involved in the analyses were from 14 
hospitals located in 10 NHS Boards between 2008 and 2016. These isolates 
were highly resistant to majority of the antimicrobial agents except for 
aminoglycosides (Table 3-11, Figure 3-22). Enterobacteriaceae isolates were 
resistant to most of the antimicrobial agents, especially to the third generation 
penicillins (100%), imipenem (100%), β-Lactam/β-lactamase inhibitor 
combinations (94.4-96.7%) and the third generation cephalosporins (93.6-
100%). By contrast, resistance rates were relatively low to aminoglycosides 
(26.2-28.0%) (Table 3-11, Figure 3-22). Also, non-fermenters isolates were 
highly resistant to most agents except for aztreonam (37.5%). It is notable that 
resistance rate to aztreonam of Enterobacteriaceae isolates was significantly 
higher than that of non-fermenters isolates while resistance rate to gentamicin 
of Enterobacteriaceae isolates was significantly lower than that of non-
fermenters isolates (Table 3-11, Figure 3-22). For all the antimicrobial agents 
tested, there were no differences between isolates causing CPO infection and 
colonisation (Table 3-12). Aminoglycosides could be alternative therapeutic 
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Figure 3-22. Radar plot of antimicrobial resistance rates of carbapenemase-producing organisms (CPO) isolates by 
bacterial family (Enterobacteriaceae and non-fermenters)
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3.3.4 Outcomes of CPO cases 
As metadata of CPO cases available were from 2003 to 2016 while the death 
data available were from 2003 to 2017, numbers of deaths within one year are 
accurate and complete. Three cases with incomplete medical records were 
excluded. All cause 30-day and one-year mortality rates were 11.8% (25/211) 
and 28.9% (61/211) respectively. Hospital mortality rate was 15.6% (33/211). 
Thirteen (52.0%) of the 25 cases that died within 30 days after CPO isolation 
were infection cases. Thirty-one (50.8%) of the 61 cases died within one year 
after CPO isolation were infection cases. The presence of CPO was a 
contributory cause of 12 deaths, therefore case fatality rate was 5.7% (12/211) 
and all of them were infection cases. 
Among the 150 hospitalised cases, the median duration between CPO 
isolation and discharge from hospital was 17.5 days (IQR 8-39.25 days) with 
16 (10.7%) patients discharged to healthcare facilities. For 72 hospitalised 
cases with CPO infection, the median duration between CPO isolation and 
discharge from hospital was 20 days (IQR 8.75-33.75 days) with 8 (11.1%) 
patients discharged to healthcare facilities. For 45 hospitalised cases with 
CPO colonisation, the median duration between CPO isolation and discharge 
from hospital was 17 days (IQR 6-45 days) and 6 (13.3%) patients were 
discharged to healthcare facilities. There were no differences of duration 
between CPO isolation and discharge from hospitals and the proportion of 
discharge to healthcare facilities between infection and colonisation (P=0.527 
tested by Wilcoxon rank-sum test and P=0.946 tested by Pearson’s Chi-
squared test, respectively). 
Comparison of survival of CPO cases by different factors in the subsections 
below could help to evaluate the impact of these factors on survival. 
3.3.4.1 Survival by gender, status and source 
There was no difference of 30-day or one-year survival between female and 
male cases (P=0.600/0.100, log-rank test) (Figure 3-23). There was no 
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difference of 30-day survival between infection and colonisation cases 
(P=0.100, log-rank test); however, one-year survival of infection cases was 
significantly lower than that of colonisation cases (P=0.003, log-rank test) 
(Figure 3-24). Among all the 211 cases, both 30-day and one-year survival of 
community-associated CPO cases were significantly higher than those of 
healthcare-associated CPO cases (P=0.010/0.001, log-rank test) (Figure 
3-25). Regarding CPO infection, there was no difference of 30-day or one-year 
survival among different CPO source (P=0.700/0.400, log-rank test) (Figure 
3-26). 
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Figure 3-23. Survival (in days) of 211 carbapenemase-producing 
organisms (CPO) cases and comparison by gender 
 
 
Figure 3-24. Survival (in days) of 211 carbapenemase-producing 
organisms (CPO) cases and comparison by status (infection, 
colonisation and unclassifiable) 
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Figure 3-25. Survival (in days) of 211 carbapenemase-producing 
organisms (CPO) cases and comparison by source (healthcare-
associated and community-associated) 
 
 
Figure 3-26. Survival (in days) of 78 carbapenemase-producing 
organisms (CPO) infection cases. CAI, community-acquired infection; 
HAI, healthcare-acquired infection; HCAI-healthcare-associated 
infection. 
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3.3.4.2 Survival by organism and carbapenemase 
In terms of bacterial family, the 211 CPO cases comprise 177 (83.9%) cases 
only with Enterobacteriaceae, 29 (13.7%) cases only with non-fermenters and 
5 (2.4%) cases with both Enterobacteriaceae and non-fermenters isolates. 
Four of the 5 cases with both Enterobacteriaceae and non-fermenters isolates 
were infection cases. Both 30-day and one-year survival of cases only with 
non-fermenters were significantly lower than those of cases only with 
Enterobacteriaceae (P<0.001/P=0.010, log-rank test) (Figure 3-27). 
Distribution of bacterial family (Enterobacteriaceae and non-fermenters) did 
not vary with CPO status (infection/colonisation/unclassifiable) (P=0.314, 
Pearson’s Chi-squared test). Regarding carbapenemase, seven cases with 
CPO isolates produced more than one carbapenemases. IMI and GES-5 were 
combined together with KPC due to small numbers as all of them belong to 
Ambler class A. 30-day and one-year survival were significantly different 
among CPO cases with different carbapenemases (P<0.001/P<0.001, log-
rank test) (Figure 3-28). It is noteworthy that OXA-48 producers had better 
survival as only two cases died within one year after CPO isolation (Figure 
3-28). The distribution of carbapenemases varied among different CPO status 
(infection/colonisation/unclassifiable) (P=0.007, Fisher’s exact test). Survival 
of cases with different carbapenemases were not compared further by status 
due to small numbers. Looking further by combining organism and 
carbapenemase, 17 cases with more than one carbapenemase-producing 
organism or produced more than one carbapenemase, and the groups with 
less than 5 cases were excluded from the analysis. There were significant 
differences among different groups of 30-day/one-year survival 
(P<0.001/P=0.003, log-rank test) (Figure 3-29). Cases with KPC producing 
Enterobacter spp. and cases with IMP producing Pseudomonas spp. had 
worse survival than cases with other CPO isolates (Figure 3-29). Survival of 
cases with different organisms and carbapenemases were not compared 
further by status due to small numbers. 
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Figure 3-27. Survival (in days) of 211 carbapenemase-producing 
organisms (CPO) cases and comparison by bacterial family 
(Enterobacteriaceae and non-fermenters) 
 
 
Figure 3-28. Survival (in days) of 211 carbapenemase-producing 
organisms (CPO) cases and comparison by carbapenemase 
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Figure 3-29. Survival (in days) of carbapenemase-producing organisms 
(CPO) cases and comparison by both organism and carbapenemase. 
Klebsiella_KPC, KPC producing Klebsiella spp.; Enterobacter_KPC, KPC 
producing Enterobacter spp.; Klebsiella_OXA48, OXA-48 producing 
Klebsiella spp.; Ecoli_OXA48, OXA-48 producing E. coli; 
Klebsiella_NDM, NDM producing Klebsiella spp.; Ecoli_NDM, NDM 
producing E. coli; Enterobacter_IMP, IMP producing Enterobacter spp.; 
Pseudomonas_IMP, IMP producing Pseudomonas spp.; Klebsiella_VIM, 
VIM producing Klebsiella spp.; Enterobacter_VIM, VIM producing 
Enterobacter spp.; Pseudomonas_VIM, VIM producing Pseudomonas 
spp. 
 
Cases with non-fermenters, infections and being healthcare-associated had 
worse survival. Survival were significantly different among CPO cases with 
different carbapenemases. 
3.3.4.3 Risk factors for 30-day all-cause mortality of hospitalised CPO 
cases 
There were 150 hospitalised cases including cases infected or colonised by 
CPO and 23 of them (15.3%) died within 30 days after CPO isolation. Among 
all the potential risk factors with P value less than 0.1 in univariate analysis, 
respiratory tract infection was highly correlated with diseases of the respiratory 
system (correlation coefficient=0.74). Diseases of respiratory system had a 
higher AICc value and was accordingly removed from the multivariate model. 
Although sepsis was not highly correlated with systemic infection or organ 
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failure (correlation coefficient=0.60), given that sepsis is part of systemic 
infection or organ failure and had a higher AICc value, sepsis was removed 
from the multivariate model. Univariate analysis indicated that all-cause 30-
day mortality was associated with advanced age, presence of carbapenemase 
producing non-fermenters, sepsis, malignancy, respiratory tract infection and 
systemic infection or organ failure (Appendix 3-3). Multivariate analysis 
showed that older than 60 years old (adjusted odds ratio, aOR 3.36, 95%CI 
1.06-10.63, P=0.033), carbapenemase producing non-fermenters presence 
(aOR 4.88, 95%CI 1.64-14.47, P=0.005) and diseases of systemic infection or 
organ failure (aOR 4.21, 95%CI 1.38-12.81, P=0.032) were independent risk 
factors for 30-day mortality (Appendix 3-3). More aggressive healthcare should 
be considered for these patients to improve prognosis, 
 
3.4 Discussion 
The incidence of CPO in the UK was relatively low compared to other countries 
(Weiner et al., 2016; European Centre for Disease Prevention and Control, 
2019b) and detection of CPO in Scotland (incidence rate 0.1 per 100,000 
patient-days) was lower than that in England and Northern Ireland (incidence 
rate 0.85 per 100,000 patient-days) in healthcare settings (Grundmann et al., 
2017). However, the number of CPO isolates isolated in Scotland has been 
increasing over recent years (Figure 3-14). Moreover, CPO had been reported 
from 13 of 14 NHS Boards and in more NHS Boards over time (Figure 3-7 and 
Figure 3-8). According to guidance from European Centre for Disease 
Prevention and Control, understanding and monitoring the local 
epidemiological situation is necessary to implement and refine CRO 
prevention and control strategies timely (Magiorakos et al., 2017). To date, no 
comprehensive epidemiology study of CPO at both national and individual 
level has been conducted in Scotland. To my knowledge, this is the first 
epidemiological study of CPO in Scotland. 
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There is currently no acknowledged episode definition and de-duplication 
criterion for a patient for CPO, and the work is underway to provide an 
appropriate definition at a UK level (Health Protection Scotland, 2016a). The 
longest interval between isolations with the same organism and 
carbapenemase from the same individual was 740 days in this study, 
indicating possible long-term persistence of CPO. As a result, no definition of 
episodes was attempted here and analysis was based on patients, i.e., CPO 
cases, using the first isolation for patients with multiple CPO isolations, unless 
stated otherwise. 
3.4.1 CPO incidence: temporal trend and geographical 
distribution 
In 2013, Scotland launched an acute hospital admission screening programme 
for CPE (Scottish Government, 2013). Therefore, the increase of CPO cases 
reported afterwards, CPE in particular, may reflect increased awareness and 
testing due to the introduction of CPE screening programme noting that 1) the 
true incidence was higher than the extrapolations from the model in 2003-2013 
(Figure 3-5); 2) incidence of Enterobacteriaceae increased significantly faster 
than that of non-fermenters (Figure 3-6); 3) most of the isolates were from 
alimentary and urine samples which were usually used for screening and the 
number of isolates from these specimens increased since 2013 (Figure 3-11 
and Figure 3-12). However, a real increase in CPO may also contribute to the 
observed increase as incidence of both CPO infection and colonisation cases 
also increased. Actually, CPO incidence might be underestimated as 
approximately only three quarters of patients audited had undergone CPE 
screening in line with national policy (76.1%) (Health Protection Scotland, 
2019a). 
More than half of CPO cases (58.8%) were older than 60 years old. The gender 
distribution of CPO cases by age groups was not the same as that of 
Scotland’s population, but female cases were more frequent than male cases 
among cases older than 80 years old (Figure 3-1) which is similar to Scottish 
gender distribution (The Scottish Public Health Observatory, 2017). In addition, 
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survival of male cases was lower than that of female cases within one year 
after CPO isolation (Figure 3-23). Longer life expectancy/health life 
expectancy of Scottish females might account for these findings (Cristina et 
al., 2018). 
In terms of geographical distribution, NHS Forth Valley and NHS Dumfries & 
Galloway had higher incidence than other NHS Boards. Some factors might 
contribute to the differences of CPO incidence across NHS Boards. First, the 
population size. CPO incidence was calculated based on population estimates 
(defined in Section 3.2.3.6) and the incidence might be high due to small 
population size even though the absolute number of CPO cases was small, 
rural areas in particular, say NHS Dumfries & Galloway. Second, healthcare 
capacity and compliance with the national screening programme. Large NHS 
Boards (such as NHS Lothian and NHS Great Glasgow & Clyde) have better 
healthcare capacity and uaually provide healthcare support for NHS Boards 
which are small and in rural areas. Third, environment and animal associated 
factors. Antimicrobial resistance is a threat involving humans, environment and 
animals. Whether antimicrobial resistance in the environment and animals 
contributes to carbapenem resisatnce in humans remains unknown in 
Scotland. Fourth, frequent travel and medical exchange between England and 
Scotland probably has an effect. The higher incidence in NHS Dumfries & 
Galloway which is the southernmost NHS Board might be an example.To 
better understand these potential underlying factors, the “One Health” 
approach (Thakur and Gray, 2019) and phylogeny analyses using both 
metadata and molecular data and collaboration across nations and NHS 
Boards are required. Also, the compliance with the national acute hospital 
admission screening programme of CPE in different NHS Boards should be 
evaluated to check if this contributed to the different geographical distribution 
of CPO. 
In NHS Lothian, VIM and IMP which were associated with healthcare-
associated and infection and had adverse impacts on survival accounted for 
more than half (34/65, 52.3%) of isolates reported from this Board. More 
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importantly, 84.4% (27/32) of all the cases with VIM/IMP had been hospitalised 
in the same hospital and 25 (78.1%) had been stayed in 
Haematology/Neurosurgery Specialties or HDU in the prior 90 days before 
CPO isolation. In NHS Forth Valley, all the cases with VIM had been admitted 
to the same hospital and more than half of them (13/25, 52.0%) had stayed in 
the General Medicine Specialty in the prior 90 days before CPO isolation. All 
the cases with IMP isolated in NHS Lanarkshire and Dumfries & Galloway in 
2015-2016 had been admitted to Cardiac Surgery Specialty in the same 
hospital. These epidemiological data shows the possibility of clonal 
persistence and spread in some Specialties of some hospitals, however, the 
evidence was restricted by no access to whole genome sequence data of 
these isolates. NDM and OXA-48 producers were reported from most NHS 
Boards and they persisted in these Boards in recent years (2013-2016). 
Additionally, many of these isolates were isolated in the community or from 
community-associated cases from urine or alimentary samples, indicating the 
influence of active surveillance programme and the threat of CPO in the 
community. 
3.4.2 Microbiological characteristics of CPO isolates 
Similar to English data (Public Health England, 2018), the ‘big 5’ 
carbapenemases (VIM, NDM, KPC, OXA-48 and IMP) accounted for 96.7% of 
all the 243 CPO isolates. In contrast to a London study that reported 34% 
carbapenem resistant non-fermenters (Freeman et al., 2015), only 15.2% of 
all the CPO isolates in Scotland were non-fermenters. Carbapenemases were 
more diverse since 2015 as CPO isolates with combination enzymes 
NDM/IMP and NDM/OXA-48, and GES-5 emerged. All the 3 IMI-producing 
isolates were Enterobacter cloacae as has been described previously 
(Queenan and Bush, 2007) and all OXA-48-producing isolates were 
Enterobacteriaceae, mostly among E. coli and Klebsiella spp. which is 
consistent with the global distribution (Poirel et al., 2012). However, 
Pseudomonas spp. harbouring OXA-48 like families have been identified in 
England (Meunier et al., 2016). Metallo-carbapenemase enzymes, including 
VIM, NDM and IMP, are widely distributed in both Enterobacteriaceae and 
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non-fermenters. Indeed, such enzymes have historically been most common 
in Pseudomonas aeruginosa and Acinetobacter spp., although they have 
recently moved to Enterobacteriaceae (Walsh, 2010; Daikos et al., 2009). This 
study also demonstrated the same overall trend (Figure 3-16). It is noteworthy 
that VIM producers have been reported from all species and they were more 
common in Enterobacteriaceae than in non-fermenters in Scotland, but has 
been found more common in non-fermenters than in Enterobacteriaceae in 
other countries (Cornaglia et al., 2011; Luzzaro et al., 2004). 
The percentage of NDM and OXA-48 producers increased significantly over 
time while that of KPC and IMP producers dropped significantly over time. 
However, cases with NDM and OXA-48 producers had better survival than 
those with KPC and IMP producers (Figure 3-28). This study highlights another 
urgent public health threat, the presence and transmission of CPO in the 
community. The overall community-associated rate was 29.4% (62/211) and 
the number of community-associated cases increased after 2013 (Figure 3-4). 
A scoping review found that the percentage of either community-associated or 
community-onset Carbapenemase-resistant Enterobacteriaceae (CRE) 
ranged from 0.04% to 29.5% (Kelly et al., 2017) while a study reported the rate 
of community-onset infections caused by CPE as 22.9% (Pano-Pardo et al., 
2016). Moreover, 69.4% (43) of the 62 community-associated cases in this 
study were NDM/OXA-48 producers and NDM/OXA-48 were associated with 
community-associated source and colonisation status (Figure 3-17 and Figure 
3-18, Table 3-7 and Table 3-8). In contrast, KPC, VIM and IMP were more 
likely to be healthcare-associated (81.6%, 90.6% and 100.0%, respectively) 
and VIM/IMP were significantly associated with healthcare-associated source 
(Figure 3-17, Table 3-7). The occurrence of OXA-48 producers in the 
community is often a consequence of importations from endemic countries 
(Poirel et al., 2012). Also, it is well known that Indian subcontinent is the 
progenitor and epicentre of NDM and many of the UK NDM-1 positive patients 
had travelled to India or Pakistan within the past year, or had links with these 
countries (Kumarasamy et al., 2010). Unfortunately, travel information is not 
available in this study. Although enhanced data in the Electronic Reporting 
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System (ERS) submitted to the antimicrobial resistance and healthcare 
associated infections reference unit include foreign travel, such information is 
filled in retrospectively on a voluntary basis following confirmation of 
carbapenemase production and only 26% of records included foreign travel 
information (Public Health England, 2018). As travel is known to be associated 
with an increased risk for CPO it is therefore essential that travel history 
information, foreign travel to endemic countries in particular, should be 
collected routinely in the community and on admission to healthcare facilities. 
Given the increase in both the number and proportion of NDM/OXA-48 
producers (Figure 3-20, Table 3-10), this could help to ensure that effective 
infection control measures are implemented promptly to curb CPO spread. 
It is well known that carbapenemase-encoding plasmids frequently bear 
resistance determinants for aminoglycosides (aminoglycoside-modifying 
enzymes or 16S rRNA methylases) (Nordmann et al., 2012a). However, our 
study showed that Enterobacteriaceae isolates retained susceptibility to 
aminoglycosides which was consistent with the findings of a study conducted 
in two tertiary care hospitals in Scotland (Toner et al., 2019). In contrast to 
other studies (Buehrle et al., 2017; Tam et al., 2007), non-fermenters isolates 
showed high resistance to aminoglycosides, fluoroquinolones and piperacillin-
tazobactam other than aztreonam. Discrepancies between studies may reflect 
different antimicrobial mechanisms and antimicrobial prescribing practices, 
highlighting the importance of understanding local antibiograms against CPO 
to preserve antibiotic utility and rational treatment. One-year survival of 
infection cases was significantly lower than that of colonisation cases, so 
precautions to improve survival for CPO infection individuals are still needed. 
Some studies suggested that higher antimicrobial resistance might contribute 
to unfavourable outcomes (Kohler et al., 2017; Daikos et al., 2009).  
Comparison of antimicrobial resistance between isolates from infection and 
colonisation cases in this study, however, argues against this hypothesis 
(Table 3-12). 
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3.4.3 Outcomes of CPO cases 
3.4.3.1 Survival of CPO cases  
The status (infection and colonisation) had significantly different impact on the 
survival (Figure 3-24), demonstrating the necessity of differentiating them. The 
survival advantage of cases with NDM and OXA-48 producers (Figure 3-29) 
might contribute to the predominance of NDM/OXA-48 producers in 
community due to prolonged urogenital or gastrointestinal colonisation. One 
study found that all OXA-48 producing K. pneumoniae isolates harboured 
genes which favour host colonisation and none of them were highly virulent 
genotypes (Beyrouthy et al., 2014). Other studies showed E.coli and K. 
pneumoniae as predominant species producing OXA-48; these are 
commensal bacteria that could be a reservoir of the blaOXA-48 genes, 
contributing to the wide dissemination and transmission among different 
ecological sources (Potron et al., 2014; Mairi et al., 2019). In addition, all the 8 
OXA-48 producers that underwent antimicrobial susceptibility testing remained 
susceptible to meropenem, indicating effective treatment options for these 
cases. Moreover, a lower proportion of infection among community-associated 
cases (14/62, 22.6%) than that among healthcare-associated cases (64/149, 
43.0%) might contribute to the survival advantage of community-associated 
cases. The analysis did not reveal a significant difference in survival between 
CAI, HAI and HCAI cases (Figure 3-26). 
In contrast, patients with Amber class A (mainly KPC) and IMP producing 
isolates had worse survival, KPC producing Enterobacter spp. and IMP 
producing Pseudomonas spp. in particular (Figure 3-28 and Figure 3-29). 
Some studies reported KPC-producing strains resulted in increased mortality 
due to resistance to immunological responses (Chiang et al., 2016), limited 
number of antimicrobial agents available to treat (Mouloudi et al., 2010; 
Papadimitriou-Olivgeris et al., 2017) and virulence conferring K. pneumoniae 
and Enterobacter cloacae complex which are predominant species producing 
KPC the ability to colonise mucous surface and evade the phagocytosis of 
immune cells (Paauw et al., 2009; Xu et al., 2018). To date, there is no study 
reporting an association between IMP production and increased risk of 
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mortality. But Cho et al. found that the coexistence of pslA which plays an 
important role in biofilm formation by P. aeruginosa and blaIMP contributed to 
the increase in antimicrobial resistance (Cho et al., 2018). Given that non-
fermenters presence was an independent risk factor for 30-day mortality and 
Pseudomonas spp. are predominant species producing IMP, biofilm producing 
Pseudomonas spp. might be associated with worse survival rather than IMP 
production itself. The association between IMP production and mortality 
warrants more research. In contrast to studies reporting that metallo-beta-
lactamases producers had no impact on increased risk of mortality partly due 
to an apparent susceptibility to various beta-lactams including carbapenems 
(Falcone et al., 2009; Kohler et al., 2017; Mouloudi et al., 2010), this study 
showed that only 10.3% (3/29) of metallo-beta-lactamases-producing isolates 
were susceptible to carbapenems and none to extended-spectrum 
cephalosporins. Another interesting finding is that VIM was more likely to be 
healthcare-associated and cause CPO infection (Figure 3-17 and Figure 3-18, 
Table 3-7 and Table 3-8) and patients with VIM producing Klebsiella spp. 
generally had worse one-year survival than patients with other isolates (Figure 
3-29). VIM producing Klebsiella spp. have been reported mainly in southern 
Europe (Nordmann and Poirel, 2002) and several investigators have 
suggested that patients infected with VIM producing Klebsiella pneumoniae 
had four times increased risk to receive inappropriate empirical treatment 
which presumably led to worse outcome (Daikos et al., 2009; Kollef, 2000). 
Another factor that might have impact on the outcome could be an enhanced 
virulence of the resistant organisms (Kohler et al., 2017). 
3.4.3.2 Risk factors for all-cause 30-day mortality 
Both host- and pathogen-related factors were reported as drivers of an 
adverse outcome. This study found that advanced age, carbapenemase 
producing non-fermenters presence, malignancy, respiratory tract infection 
and systemic infection or organ failure were associated with overall 30-day 
mortality. Advanced age has been observed as a risk factor for mortality by 
many researchers as they represent a vulnerable population for drug resistant 
pathogen colonisation and infection (Mouloudi et al., 2010; Daikos et al., 2009; 
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Akgul et al., 2016). Patients with malignancies usually have more frequent 
exposure to healthcare such as immunocompromised therapy (radiotherapy 
and chemotherapy), invasive procedures (biopsies, bone marrow and spinal 
puncture) and longer hospitalisation and antimicrobial treatment. Respiratory 
infection has been described as a risk factor for 30-day mortality by other 
studies (Jiao et al., 2015; Li and Ye, 2017). The mucosal barrier injury of 
respiratory tract and altered lung tissue would decrease the capacity for 
bacterial clearance and increase probabilities of bacterial colonisation and/or 
infection. Moreover, bacteraemia which was an important driver of a fatal 
outcome generally begins with respiratory tract infection (Nabarro et al., 2017; 
Ng et al., 1996; Xiao et al., 2018), although this study showed that only 4 of 
the 21 bacteraemia cases stemmed from respiratory tract infection. 
Multivariate analysis revealed that both carrying non-fermenters and systemic 
infection or organ failure were independently associated with 30-day mortality, 
reinforced by the significant lower survival of carrying non-fermenters than that 
of Enterobacteriaceae. As far as I know, just one study investigated the 
association between organisms and mortality and did not find any particular 
organism to be linked to mortality (Kalam et al., 2014). Both virulence status 
and antimicrobial resistance may account for this. First, some studies have 
demonstrated that virulence determinants of Pseudomonas species such as 
the secretion of toxins and elastase activity could enhance pathogenicity 
against host defence mechanisms, thus having an unfavourable impact on the 
outcome. In addition, biofilm formation on the lumen of the respiratory tract 
could result in a higher risk of mortality by posing greater resistance against 
antibiotics (Jeong et al., 2014; Kipnis et al., 2006; Sadikot et al., 2005; Rossi 
Goncalves et al., 2017). Second, carbapenem resistance in non-fermenters 
usually stems from a combination of beta-lactamases, porin mutations and 
efflux pump overexpression, conferring reduced susceptibility to antibiotics 
and implying less treatment options and more treatment failure (Buehrle et al., 
2017). However, no significant difference of antimicrobial susceptibility 
between Enterobacteriaceae and non-fermenters suggested that non-
fermenters were simply more virulent. Systemic infection or organ failure is a 
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surrogate marker of critical illness. This host-related factor has been widely 
reported as a predictor of poorer outcome (Daikos et al., 2009; Jeong et al., 
2014; Mouloudi et al., 2010; Bar-Yoseph et al., 2019; Xu et al., 2018). 
Aggressive therapy and infection prevention and control measures should be 
initiated timely in this population. 
3.4.4 Limitations 
There are some limitations of the study. First, not each case could be classified 
as either an infection or a colonisation case due to lack of clinical symptoms 
and laboratory testing data. But the definitions of status were assessed by 
consultant microbiologists and judgement were made accordingly. Second, 
antimicrobial susceptibility testing results were not available for each isolate 
and not all the isolates were tested for the same agents. Third, data on 
antimicrobial treatment in hospital at individual level were not available and 
such information has been reported as risk factors for unfavourable outcomes 
(Punpanich et al., 2012; Kim et al., 2012b). Fourth, no genomic data were 
available to identify possible clonal spread and virulence. Further molecular 
study is warranted to better understand of the phylogeny and pathogenicity of 
local CPO isolates. 
 
3.5 Conclusion 
This is the first epidemiological study of CPO in Scotland since the first report 
in 2003. Incidence and mortality rate of CPO in Scotland are relatively low but 
the incidence is increasing rapidly and CPO had been reported in 13 NHS 
Boards. Source and microbiological characteristics varied among NHS 
Boards. Enterobacteriaceae isolates predominated and increased faster than 
non-fermenters. Community-associated CPO were more likely to be 
colonisation while healthcare-associated CPO were more likely to be infection. 
The ‘big 5’ carbapenemases (VIM, NDM, KPC, OXA-48 and IMP) 
predominated. Cases with NDM/OXA-48 producers and Enterobacteriaceae 
had a survival advantage over other cases. Enterobacteriaceae isolates 
Epidemiology of CPO in Scotland 
154  Clinical characteristics and outcomes of CPO 
 
retained susceptibility to aminoglycosides. Awareness is required that 
inpatients older than 60 years, with systemic infection or organ failure or 
presenting non-fermenters are at higher 30-day mortality risk from CPO. The 
findings of this study will inform screening programmes in both healthcare and 
community settings to help control the spread of CPO. Further molecular study 
is warranted for better understand of possible clonal spread and virulence of 
CPO isolates.
  Epidemiology of CPO in Scotland 
Risk factors associated with CPO among hospitalised patients 155 
 
Chapter 4 Risk factors associated with CPO 
among hospitalised patients: a matched case-
control-control study 
4.1 Background 
Carbapenem resistant organisms (CRO) have been gradually increasing 
worldwide since their first identification more than 30 years ago, thus posing a 
major global public health threat (European Centre for Disease Prevention and 
Control, 2019b; Logan and Weinstein, 2017). Infections caused by CRO are 
associated with significant morbidity and mortality as very few effective 
therapeutic options are available to treatment (Righi et al., 2017). Besides this, 
CRO are likely to result in a financial burden for healthcare systems due to 
prolonged hospital stays, restricted activities in the affected units, additional 
healthcare staff working hours and the screening of samples (Daroukh et al., 
2014; Tischendorf et al., 2016). Resistance to carbapenems arises from 
carbapenemases production or non-enzymatic mechanisms. The latter include 
decreased outer membrane permeability or over-expression of efflux pumps 
with or without production of an ESBL and/or AmpC cephalosporinase 
(Bedenic et al., 2014). CRO strains that do not produce carbapenemases are 
usually less resistant to other antibiotics (Nordmann et al., 2012a) and their 
carbapenem resistance trait is not transferable. For this reason, CRO arising 
from non-enzymatic mechanisms are considered of less clinical concern than 
carbapenemase-producing organisms (CPO). 
Many risk factors contribute to CPO acquisition and they could be generally 
classified into two groups: host-related and healthcare-related factors. Host-
related factors include demographic characteristics such as advanced age, 
gender and comorbidities (Giuffre et al., 2013; Poole et al., 2016; 
Papadimitriou-Olivgeris et al., 2012; Tuon et al., 2012b). Healthcare-related 
factors include exposure to healthcare facilities, medical procedures and 
antibiotics (van Loon et al., 2018). Nevertheless, conflicting results are 
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reported in various studies conducted in different centres, most likely owing to 
the great heterogeneity between these studies, such as different study settings, 
study designs, population of interest, definition of resistance and selection of 
controls. 
Incidence of CPO in Scotland is relatively low but increasing (Health Protection 
Scotland, 2019a). To date, most risk factor studies have been conducted in 
regions of high CRO endemicity (Balvinder et al., 2017; Jia et al., 2018; 
Khadem et al., 2017) and no risk factor studies have been conducted in a low 
incidence setting. Understanding local risk factors for CPO acquisition could 
help to make more targeted and effective surveillance programmes and 
infection prevention and control measures. In 2003, Scotland initiated an acute 
hospital admission screening programme for carbapenemase-producing 
Enterobacteriaceae (CPE), however, the focus was on high-risk individuals 
who has been previously confirmed CPE positive at any time, hospitalised or 
received dialysis outside of Scotland or a close contact of a person who has 
been colonised/infected with CPE in the last 12 months (Scottish Government, 
2013; Health Protection Scotland, 2016b). The programme provided guidance 
on recommendations and practical advice to reduce the spread of CPE in non-
acute and community settings in 2017 (Health Protection Scotland, 2017). This 
retrospective matched case-control study aims to provide more in-depth 
understanding of underlying factors associated with CPO among hospitalised 
patients in Scotland. 
The aims of this chapter are: 
1) to compare outcomes between CPO cases and controls; 
2) to compare antimicrobial resistance rates to routine clinical tested 
antimicrobials between CPO cases and controls; 
3) to investigate risk factors for CPO infection and colonisation among 
hospitalised patients. 
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4.2 Methods 
4.2.1 Study design 
This is a retrospective matched case-control study with two control groups 
(culture positive controls and demographic controls) among hospitalised 
patients in Scotland between 2010 and 2016. For risk factors associated with 
CPO, I attempted to answer two specific questions. First, what are the risk 
factors for acquiring CPO infection or colonisation among hospitalised 
patients? Namely what are the risk factors for being infected or colonised by 
the resistant organism CPO? Comparison between CPO cases and 
demographic controls will help to answer this question. Second, what are the 
risk factors for carbapenemase production among hospitalised patients with 
known pathogens? Namely what are the risk factors for the resistance 
(carbapenemase production) for one patient infected or colonised by a known 
bacterial pathogen. Comparison between CPO cases and culture positive 
controls will help to answer this question. Definitions of cases and controls are 
given in Table 4-1. 
The outcomes of interest were CPO infection and CPO colonisation identified 
in surveillance or clinical cultures. Definitions of infection and colonisation for 
cases and culture positive controls are given in Table 4-2. To explore risk 
factors for CPO infection, each infection case was matched to up to 3 infection 
culture positive controls and 3 demographic controls respectively. To explore 
risk factors for CPO colonisation, each colonisation case was matched to up 
to 3 colonisation culture positive controls and 3 demographic controls 
respectively. Where more than 3 controls matched to one case within the 
defined criteria, the controls with closest admission dates to the CPO 
specimen date were chosen. Unless stated otherwise, controls mentioned 
below include both culture positive controls and demographic controls. The 
index hospitalisation was defined as the hospital stay during which the 
specimen with positive culture was collected for cases and culture positive 
controls and the equivalent hospital stay for demographic controls. 
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This study was reviewed and approved by the Public Benefit and Privacy Panel 
for Health and Social Care (Reference number: 1617-0328) (Appendix 3-1).
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4.2.2 Data 
All the data included in this study were extracted from the datasets listed in 
Table 3-1 in Chapter 3. Data extraction and linkage of datasets for all cases 
and controls were performed via HPS/Public Health Intelligence’s HPS 
Statistics Support Team as described in Chapter 3. All the data were 
anonymised and transferred to Public Health Intelligence’s electronic Data 
Research and Innovation Service team which is based at the FARR Institute 
to enable preparation, provision and storage of data via the National Services 
Scotland National Safe Haven as described in Chapter 3. All analyses 
afterwards were performed within the National Services Scotland National 
Safe Haven. The ethics was reviewed and approved as described in Chapter 
3. 
4.2.3 Definition 
Antimicrobial susceptibility testing were performed as described in Chapter 3 
and the antimicrobial agents included are listed in Table 3-4 in Chapter 3. 
Antimicrobial resistance rates are defined as per the formula: 
Resistance rate =
number of isolates resistant/intermediate to the tested agent
number of isolates being tested for this agent
∗ 100  
Hospital mortality rates were defined as per the formula: 
Hospital mortality rate =
number of cases/controls died during the index hospitalisation
number of cases/controls
∗ 100   
All cause 30-day or 1-year mortality rate was defined as per the formula: 
For CPO cases and culture positive controls, 
All cause 30 − day or 1 − year mortality rate =
number of CPOcases/controls died within 30 days or 1 year after pathogen isolation  
total number of CPO cases/controls
∗ 100  
For demographic controls, 
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All cause 30 − day or 1 − year mortality rate =
number of controls died within 30 days or 1 year after admission date of index hospitalisation
total number of controls
∗ 100  
The potential risk factors of interest associated with CPO infection and 
colonisation were placed in one of four categories: 1) Demographics, including 
age and gender; 2) Comorbidities; 3) Healthcare exposure, healthcare 
information in the prior 90 days before specimen date for cases and culture 
positive controls and admission date of index hospitalisation for demographic 
controls; 4) Invasive procedures, exposure to invasive medical procedure or 
devices in the prior 90 days before specimen date for cases and culture 
positive controls and admission date of index hospitalisation for demographic 
controls. The definitions of each potential risk factor of interest are listed in 
Appendix 4-1. 
4.2.4 Statistical analysis 
All statistical analyses were carried out using R (version 3.5.1) on the secure 
analytical platform within the National Services Scotland National Safe Haven 
provided and supported by Public Health Intelligence’s electronic Data 
Research and Innovation Service team. 
4.2.4.1 Control selection 
Controls were randomly selected from hospitalised patients meeting the 
definitions listed in Table 4-1 by using the rv.uniform command in SPSS 
(according to HPS Statistics Support Team staff Sharon Kennedy, personal 
communication by email, October 3, 2019), which randomly allocated a value 
between 0 and 1 (based on continuous distribution) to each potential control 
where each value had the same chance of occurring. These were then 
stratified at the required level (an id variable is created for this purpose) and 
ranked by the id to allow selection of up to 3 controls. For cases with less than 
3 potential controls, all available matched controls were used to maximise 
matches. Patients allocated to the culture positive controls were removed from 
the demographic controls before sampling for demographic control selection. 
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4.2.4.2 Survival analysis 
The Kaplan-Meier method was used to plot 1-year survival curves. Differences 
of survival curves between cases and controls at 30-day and 1-year were 
evaluated by the log-rank test. 
For comparison of outcomes between cases and controls, Pearson’s Chi-
squared test or Fisher’s exact test as appropriate were used to compare 
mortality rates (all-cause 30-day, all-cause 1-year and hospital mortality rates) 
and rates of discharge to healthcare facilities/private residence. Univariate 
conditional logistic regression analyses were performed to compare length 
between bacteria isolation (cases and positive controls)/admission date 
(demographic controls) and hospital discharge. 
4.2.4.3 Antimicrobial susceptibility comparison 
Antimicrobial resistance rates to each antimicrobial agent for cases and culture 
positive controls with Enterobacteriaceae and non-fermenters isolates were 
evaluated respectively and the resistance rates were compared between 
cases and culture positive controls using Pearson’s Chi-squared test or 
Fisher’s exact test as appropriate. 
4.2.4.4 Risk factor analysis for CPO infection and colonisation 
To investigate risk factors for CPO infection, variables of interest listed in 
Appendix 4-1 were compared 1) between infection cases and infection culture 
positive controls, and 2) between infection cases and demographic controls. 
To investigate risk factors for CPO colonisation, variables of interest listed in 
Appendix 4-1 were compared 1) between colonisation cases and colonisation 
culture positive controls, and 2) between colonisation cases and demographic 
controls. 
Conditional logistic regression modelling using LASSO (Least Absolute 
Shrinkage and Selection Operator) penalty as the variable selection method 
was performed (Tibshirani, 1996; Reid and Tibshirani, 2014). LASSO is a 
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powerful method that performs two main tasks: regularization and feature 
selection. It puts a constraint on the sum of the absolute values of the model 
parameters, the sum has to be less than a fixed value (upper bound). In order 
to do so the method applies a shrinking (regularization) process where it 
penalizes the coefficients of the regression variables by shrinking some of 
them to zero. During the features selection process the variables that still have 
a non-zero coefficient after the shrinking process are selected to be part of the 
model. The goal of this process is to minimize the prediction error. The 
regularization parameter lambda is chosen by cross validation. Univariate 
analysis was performed first to determine the unadjusted association between 
each potential risk factor of interest and CPO infection or colonisation. 
Correlation between variables with P<0.10 in univariate analysis were checked 
by calculating correlation coefficients (Spearman’s rank correlation coefficient 
between continuous variables, Cramér’s V between dichotomous variables or 
point-biserial correlation coefficient between continuous variables and 
dichotomous variables) and variance inflation factor (VIF). Also, interactions 
between potential risk factors were checked. For variables with high-level 
correlation (correlation coefficient≥0.70 or VIF>4), variables with greater 
corrected Akaike Information Criterion (AICc) value were removed from the 
model. After removing variables with high-level correlation, the remaining 
variables were considered to be included in the multivariate model and 
selected using LASSO (lambda used to choose variables=lambda.1se, the 
lambda that minimises cross validation error plus one standard error) 
(Friedman et al., 2010). The selected variables were included in the final 
multivariate analysis to determine the independent associations. For statistical 
purpose, variables with zero values in either group were removed from 
multivariate analyses, i.e. no patients in either group had exposure to the 
potential risk factor of interest. Odds ratios (OR) and 95% confidence intervals 
(CI) were calculated to determine the strengths of these associations. A P 
value <0.05 was considered significant. To test the stability of the final 
multivariate model, variables in the model were removed in turn and the 
significance of the remaining variables were checked. 
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Seventy hospitalised patients infected by CPO and 34 hospitalised patients 
colonised by CPO were identified. All infection and colonisation cases were 
matched with 3 demographic controls. Fifty-six (80.0%) of the 70 infection 
cases could be matched with at least one infection culture positive control while 
32 (94.1%) of the 34 colonisation cases could be matched with at least one 
colonisation culture positive control (Figure 4-1). All these cases and controls 
were from 24 hospitals in 13 National Health Service (NHS) Boards. 
 
 
Figure 4-1. Flowchart of case and control selection 
 
4.3.2 Outcome comparison between cases and controls 
Comparison of outcomes (survival, mortality rate, length of post-isolation 
hospital stay and discharge information) between cases and controls would 
help to evaluate (1) whether CPO had an unfavourable impact on outcomes 
by comparing cases and demographic controls; (2) whether carbapenemase 
production of bacterial pathogens had an unfavourable impact on outcomes 
by comparing cases and culture positive controls. Comparisons of all-cause 
30-day and 1-year survival between cases and controls by status (infection 
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and colonisation) and bacterial families (Enterobacteriaceae and non-
fermenters) are shown in Figure 4-2, Figure 4-3 and Figure 4-4. 
For infection, the 30-day and 1-year survival were significantly lower (P<0.001, 
log-rank test) (Figure 4-2) and all the mortality rates (all-cause 30-day and 1-
year and hospital mortality) were significantly higher for CPO cases than for 
demographic controls (P<0.001) (Table 4-3). However, there were no 
significant differences regarding 30-day/1-year survival (P=0.600/0.100, log-
rank test) (Figure 4-2) and all-cause 30-day/1-year mortality rates 
(P=0.667/0.153) (Table 4-3) between patients with CPO infection (i.e. cases) 
and non-CPO infection (i.e. culture positive controls). Notably, hospital 
mortality rate and length of post-isolation hospital stay of patients with CPO 
infection were significantly higher and longer than those of patients with non-
CPO infection (Table 4-3). For in-hospital deaths, the duration between 
pathogen isolation and death for cases (range: 4-53 days, median: 18 days, 
interquartile range: 9.5-32 days) were significantly longer than for culture 
positive controls (range: 0-27 days, median: 4 days, interquartile range: 1.75-
13.5 days) (P=0.010, Wilcoxon rank-sum test). In terms of bacterial families, 
there was no difference of 30-day/1-year survival between CPO patients and 
non-CPO patients (P=0.200/0.500, log-rank test) (Figure 4-3). 
For colonisation, there was no difference of 30-day survival between cases 
and demographic controls (P=0.200, log-rank test), but the 1-year survival of 
cases was significantly lower than that of demographic controls (P=0.040, log-
rank test) (Figure 4-4). No differences of mortality rates were found between 
cases and demographic controls (Table 4-3). Patients with CPO colonisation 
were more likely to discharge to healthcare facilities (P=0.023) while 
demographic controls to private residence (P=0.007) (Table 4-3). Interestingly, 
no differences were noted between patients with CPO colonisation and 
patients with non-CPO colonisation regarding 30-day/1-year survival 
(P=0.900/0.600, log-rank test) (Figure 4-4), mortality rates and length of post-
isolation hospital stay (Table 4-3). Comparisons of survival between cases and 
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culture positive controls were not performed due to small numbers (less than 
5). 
In general, CPO infection resulted in worse survival and longer hospital stay 
among general hospitalised patients. If a patient was infected by a bacterial 
pathogen, carbapenemase production of the pathogen had no significant 
impact on survival but resulted in higher hospital mortality and longer hospital 
stay. CPO colonisation had no significant impact on survival but resulted in 
longer hospital stay among general hospitalised patients. If a patient was 
colonised by a bacterial pathogen, carbapenemase production of the pathogen 
had no significant impact on outcomes. 
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Figure 4-2. Survival (in days) of infection cases and controls 
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Figure 4-3. Survival (in days) of infection cases and infection culture positive controls by bacterial family 
(Enterobacteriaceae and non-fermenters) 
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Figure 4-4. Survival (in days) of colonisation cases and controls 
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4.3.3 Antimicrobial susceptibility comparison between cases 
and culture positive controls 
Thirty-three CPO isolates (27 Enterobacteriaceae isolates and 6 non-
fermenter isolates) from 31 CPO cases and 87 non-CPO isolates (70 
Enterobacteriaceae isolates and 17 non-fermenter isolates) from 87 culture 
positive controls were included in the analyses. These isolates were from 13 
hospitals located in 8 NHS Boards between 2010 and 2016. The antimicrobial 
resistance pattern of cases and culture positive controls are illustrated in Table 
4-4 and Figure 4-5. In vitro resistance to all tested antibiotics was higher in 
CPO isolates than their matched controls, i.e. non-CPO. In terms of 
Enterobacteriaceae, resistance rates to all the test agents of cases were 
significantly higher than those of controls (Table 4-4, Figure 4-5 A). Although 
resistance rates to all the test agents of cases with non-fermenters were higher 
than those of controls with non-fermenters, significant difference in resistance 
was observed for meropenem and gentamicin (Table 4-4, Figure 4-5 B). 
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Figure 4-5. (A) Antimicrobial resistance rates of cases and culture 
positive controls for Enterobacteriaceae; (B) Antimicrobial resistance 
rates of cases and culture positive controls for non-fermenters. 
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4.3.4 Risk factors associated with CPO infection 
When CPO infection cases were compared with demographic controls, the 
univariate analysis showed that a range of variables were associated with CPO 
infections, including all demographic variables, the majority of healthcare 
exposure variables and some comorbidities and invasive procedures (Table 
4-5, Appendix 4-2). After removing highly correlated variables (Figure 4-6), the 
multivariate analysis indicated that hospitalisation, length of hospitalisation, 
length of ICU stay in the prior 90 days and being immunocompromised were 
independently associated with CPO infection (Table 4-7). 
When CPO infection cases were compared with non-CPO infection controls, 
at univariate level, fewer variables were associated with CPO infections than 
for demographic controls, including gender, some healthcare exposure 
variables, hematologic malignancy, ‘injury, poisoning and certain other 
consequences of external causes’ and ectomy procedures (Table 4-5, 
Appendix 4-2). After removing highly correlated variables (Figure 4-7), the 
multivariate analysis showed that length of hospitalisation, length of HDU stay 
in the prior 90 days were independently associated with CPO infection (Table 
4-7). 
CPO infection were associated with extensive healthcare exposure (a history 
of prolonged hospital/ICU/HDU stay in particular) and immunodeficiency, more 
infection prevention and control measures should target patients with these 
risk factors. 
4.3.5 Risk factors associated with CPO colonisation 
The univariate analysis comparing CPO colonisation and demographic 
controls indicated that CPO colonisation were associated with age, ‘endocrine, 
nutritional and metabolic diseases’ including diabetes mellitus, endoscopic 
operation and majority of healthcare exposure variables (Table 4-6, Appendix 
4-3). After removing highly correlated variables (Figure 4-8), the multivariate 
analysis showed that HDU stay in the prior 90 days and ‘endocrine, nutritional 
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and metabolic diseases’ were independent risk factors for CPO colonisation 
(Table 4-7). Compared with non-CPO colonisation controls, CPO cases were 
more likely to have ‘endocrine, nutritional and metabolic diseases’ (Table 4-6). 
However, no independent risk factors were found (Table 4-7). Among general 
hospitalised patients screening efforts warrant more consideration for those 
admitted to HDU in the preceding 90 days or with endocrine, nutritional and 
metabolic diseases. 
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Figure 4-6. Selection of variables included in the multivariate analysis (Infection cases vs. Demographic controls). AICc, 
corrected Akaike Information Criterion; VIF, variance inflation factor. 
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Figure 4-7. Selection of variables included in the multivariate analysis (Infection cases vs. Infection culture positive 
controls). AICc, corrected Akaike Information Criterion; VIF, variance inflation factor. 
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Figure 4-8. Selection of variables included in the multivariate analysis (Colonisation cases vs. Demographic controls). 
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4.4 Discussion 
Carbapenemase encoding genes are usually located on mobile genetic 
elements which can be easily transferred between bacterial species and 
individuals. Therefore, identifying patients colonised or infected with CPO is 
key to limiting potential transmission. Moreover, it has been reported that 
patients colonised with CPO were more likely than those colonised with non-
CPO to develop infections during their hospitalisation (Tamma et al., 2019) 
and CPO infection was associated with 4 times the risk of 14-day mortality 
compared with non-CPO infection (Tamma et al., 2017a). Given low numbers 
of CPO risk factor studies conducted in low incidence settings and that the 
current Scottish recommendations only focus screening efforts on CPE, there 
is a need to identify the patients at highest risk of CPO infection/colonisation 
to guide screening strategies. Although the sample size is small when 
analyses were conducted for infection and colonisaiton respectively, I did not 
combine them together to increase the statistical depth given that (1) there 
were some statistically significant results showing clearly enough statistical 
power for the comparisons; (2) infection and colonisation have biologically 
different implications from clinical and public health perspectives and the 
findings of this study identified some different risk factors for CPO infection and 
colonisation. This is the first risk factor study for CPO among hospitalised 
patients in Scotland. 
4.4.1 Control selection 
In risk factor analyses for antimicrobial resistance, there has been 
considerable debate regarding control group selection (Harris et al., 2001; 
Harris et al., 2002a; Zavascki, 2004; Harris et al., 2004). However, the main 
principles are the same. The appropriate choice of controls should depend on 
the questions being asked and be representative of the same source 
population (Harris et al., 2001; Wacholder et al., 1992a; Wacholder et al., 
1992b). In this study, I attempted to answer two questions. First, what are the 
risk factors for acquiring CPO infection or colonisation among hospitalised 
Epidemiology of CPO in Scotland 
186  Risk factors associated with CPO among hospitalised patients 
 
patients? Namely what are the risk factors for being infected or colonised by 
the resistant organism CPO? Second, what are the risk factors for 
carbapenemase production among hospitalised patients with known 
pathogens? Namely what are the risk factors for the resistance 
(carbapenemase production) for one patient infected or colonised by a known 
bacterial pathogen. Therefore, I selected two control groups those would best 
allow me to answer these two specific questions. For the first question, I 
compared patients colonised or infected by CPO with randomly selected 
hospitalised patients (no patients with CPO and not limited to patients tested 
positive for other pathogens, therefore similar to all admissions, namely 
demographic controls). For the second question, I compared patients 
colonised or infected by CPO with those colonised or infected by non-CPO 
(namely culture positive controls). This was to help to ensure that risk factors 
identified in this comparison were not merely risk factors for the pathogen. To 
minimise selection bias and confounding effects, the cases and controls were 
matched by participating hospital, admission date, specimen site and organism 
classification (Enterobacteriaceae or non-fermenters). Admission to the same 
hospital at a similar time could help to eliminate geographical and temporal 
impact on infection control policies and microbiological methodology. Patients 
with the same category of organism from the same specimen site are more 
likely to have similar disease severity and status (colonisation or infection). 
Some may argue that not controlling for length of hospital stay which might be 
a surrogate marker of comorbidities and extensive healthcare exposure 
between cases and controls may introduce bias and confounding for analyses. 
I did not use length of hospital stay as a matching criterion because: (1). length 
of hospital stay is a potential risk factor of interest in this study and I checked 
the correlation between it and other variables, and the only highly correlated 
factor was removed from the analyses (Figure 4-6, 4-7 and 4-8). (2) the 
number of controls available would be quite small if length of hospital stay is 
used as a matching criterion, which would make the analyses infeasible. 
Additionally, infection and colonisation represent different medical conditions 
with different implications for both clinical therapy and infection control and 
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prevention strategies. Therefore, risk factors analyses were conducted for 
CPO infection and colonisation separately. 
Culture positive controls were colonised or infected by bacterial non-CPO 
pathogens while demographic controls represented the general hospitalised 
patients who are not necessarily infected or colonised by pathogens. 
Therefore, culture positive controls tended to be more debilitated, more likely 
to be treated with antibiotics, intensive care or invasive procedures which were 
similar to cases. Therefore, a weaker association (smaller OR) was expected 
using culture positive controls than using demographic controls for the same 
risk factors of interest. The univariate analyses demonstrated that the ORs 
using culture positive controls were generally smaller than those using 
demographic controls for most potential risk factors of interest (Table 4-5 and 
Table 4-6, Appendix 4-2 and Appendix 4-3). Additionally, more risk factors 
were identified using demographic controls than using culture positive controls, 
implying that some of the risk factors were associated with infections in 
general.  
4.4.2 Risk factors for CPO infection 
Regardless of what the controls were chosen, the majority of healthcare 
exposure variables were associated with CPO infection at a univariate level. 
Time at risk (time interval between index hospital admission and pathogen 
isolation for cases/culture positive controls or discharge from hospitals for 
demographic controls) was highly correlated with length of hospital stay in the 
preceding 90 days as time at risk equalled to length of hospital stay for 53.6% 
of cases, 91.9% of demographic controls and 73.6% of culture positive 
controls, respectively. This indicated that more controls had not been admitted 
to a hospital before the index admission compared with cases, making the prior 
hospitalisation a risk factor for CPO infection. Moreover, the independent risk 
factors for CPO infection among hospitalised patients determined by 
comparing cases and both control groups in a multivariate analysis were 
mainly healthcare exposure variables, including prior hospital stay, length of 
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prior hospital stay, length of HDU stay and length of ICU stay. Prior hospital 
stay was independently related to CPO infection (aOR 4.05, 95%CI 1.52-
10.78, P=0.005) among general hospitalised patients. Risk of infected by CPO 
increased as the patient stayed longer in the hospital for both general 
hospitalised patients (aOR 1.07, 95%CI 1.04-1.10, P<0.001) and patients with 
infections (aOR 1.02, 95%CI 1.00-1.03, P=0.038). These findings are in 
agreement with previous studies (Baran et al., 2008; Furtado et al., 2010; Patel 
et al., 2008). On one hand, prior hospital stay and longer duration of hospital 
stay means more healthcare exposure including contacting with other patients 
and healthcare staff, medical devices and antimicrobial treatment, and thereby 
more opportunities to be colonised or infected subsequently by CPO. On the 
other hand, this may reflect the selection of resistant strains under 
antimicrobial pressure due to the body flora changes over time during a longer 
hospitalisation period.  
Prolonged ICU stay is a well-documented risk factor for multidrug-resistant 
organisms as these patients are usually exposed to the resistant flora, have 
multiple comorbidities and are subject to invasive life support devices or 
procedures, and hence they are at higher risk of acquiring multidrug-resistant 
organisms due to cross transmission mediated by these factors (Mittal et al., 
2016; Zavascki et al., 2006a). In 2000 the UK Department of Health issued the 
report “Comprehensive Critical Care” which defined HDU care as “more 
detailed observations or intervention including support for a single failing organ 
system or postoperative care and those ‘stepping down’ from higher levels of 
care” (UK Government: Department of Health, 2000). Therefore, patients in 
HDU usually require more intensive observation, treatment and nursing care 
than can be provided on a general ward and have one organ failure, while 
patients in ICU usually have multiple organ failure. HDU would not normally 
accept patients requiring mechanical ventilation but could manage those 
receiving invasive monitoring. It is interesting that duration of HDU stay was 
an independent risk factor specifically for CPO among infected patients (Table 
4-7) while duration of ICU stay was not related with CPO even in the univariate 
analysis when cases were compared with culture positive controls (Table 4-5). 
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To exclude the similarity and substitutability between HDU and ICU, duration 
of HDU stay was replaced respectively by duration of ICU stay and ICU stay 
in the multivariate model, the latter (duration of ICU stay and ICU stay) were 
not independently associated with CPO. No previous studies reported 
(prolonged) HDU stay as a risk factor for CPO and there is no obvious 
explanation for such an association but it might be possible that an unknown 
factor could mediate it. Patient and unit characteristics and their association 
with CPO warrants more research. Hospital and ward transfer might 
represented an indirect measure of complex diseases or a greater amount of 
time at risk as described in other studies (Djordjevic et al., 2016; Fortaleza et 
al., 2006; Torres-Gonzalez et al., 2015). 
Compared with demographic controls, CPO infection cases were more likely 
to have some comorbidities, comprising malignancies (hematologic 
malignancies in particular), anaemia, respiratory diseases, genitourinary 
diseases (including renal failure), nervous diseases, injuries and 
immunocompromised status. By contrast, CPO infection cases were just more 
likely to have hematologic malignancies and injuries when compared with non-
CPO infection controls, and neither was found to be an independent risk factor. 
Again, this indicated that culture positive controls had more severe but similar 
illness severity to cases than demographic controls. Hematologic malignancies 
were highly correlated with immunocompromised status (Figure 4-6). Patients 
with hematologic malignancies have been reported to be more likely to acquire 
CRO/CPO, and CRO/CPO were likely to be pathogenic in those patients who 
were more immunocompromised such as hematologic malignancy patients 
(Huang et al., 2012; Torres-Gonzalez et al., 2015; Tumbarello et al., 2014). 
Furthermore, hematologic malignancy patients are subject to multiple 
readmissions to hospital, treatment with broad-spectrum antibiotics and 
chemotherapy agents that may disrupt the gastrointestinal microbiota, thus 
rendering them prone to resistant pathogens (Husni et al., 2002; Wingard et 
al., 1986). Anaemia has been reported as a risk factor for CROs from 
univariate analyses in several studies but they were not independently 
associated with CRO (Li and Ye, 2017; Zilberberg et al., 2017; Zilberberg et 
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al., 2019) a result reproduced by this study. Six of the 10 cases with anaemia 
in this study had acute renal failure as well. Acute renal failure could cause 
various slow poisoning phenomena, such as inhibition of bone marrow function 
resulting in anaemia, haemorrhage and reduced leukocyte production, and 
thus lead to immunocompromised status. Therefore, anaemia is believed to be 
a surrogate marker of an immunocompromised condition. This study also 
identified immunocompromised status as an independent risk factor for CPO 
infection among general hospitalised patients (aOR 3.68, 95%CI 1.16-11.66, 
P=0.027). The comorbidity ‘injury, poisoning and certain other consequences 
of external causes’ is highly correlated with ‘external causes of morbidity’ 
(Figure 4-6 and Figure 4-7) as the former indicates the causes of injury listed 
in the latter, including injuries, burns, corrosions, complications of trauma and 
complications of surgical and medical care. Cutaneous wounds from these 
external causes account for a higher proportion of samples where isolates 
were taken and have been linked with bacterial colonisation and subsequent 
infections (Cheng et al., 2015; Cheng et al., 2016b; Gregory et al., 2010; Kaase 
et al., 2016). Wounds are favourable sites for micro-organism colonisation until 
they are closed and are prone to subsequent infections. In addition, 70.0% 
(14/20) of cases with respiratory diseases were respiratory infections and 
69.7% (23/33) with genitourinary diseases were urinary tract infections while 
the numbers for demographic controls were 60.7% (17/28) and 18.5% (5/27) 
respectively. So respiratory diseases and genitourinary diseases were 
associated with CPO cases more than demographic controls. Again these 
factors might also represented more critical illness of cases as more cases 
than these controls were discharged to healthcare facilities or died in hospital 
(Table 4-3). 
Interestingly, some of invasive procedure related factors were identified as risk 
factors using demographic controls while just one factor was a risk factor using 
culture positive controls (Table 4-5). This finding indicated that there might be 
a possibility of acquiring pathogens due to cross transmission resulting from 
invasive procedures. Nonetheless, no invasive procedure related factors were 
risk factors in multivariate analysis using either of the control groups. 
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In summary, healthcare exposure related factors were most frequently 
associated with CPO infection using both control groups. Demographics, some 
comorbidities and invasive procedure related factors were associated with 
CPO infection when compared with demographic controls while very few of 
these factors were related with CPO infection when compared with non-CPO 
infected controls. Extensive healthcare exposure (prior hospital stay and 
prolonged hospital/ICU/HDU stay) and being immunocompromised were 
independently associated with CPO infection. 
4.4.3 Risk factors for CPO colonisation 
Similar to risk factors for CPO infection, a majority of healthcare exposure 
related factors were associated with CPO colonisation using demographic 
controls while HDU stay was an independent risk factor. However, no such 
factors increased CPO colonisation risk when compared with non-CPO 
colonisation controls (Table 4-6). 
The unique risk factor for CPO colonisation was ‘endocrine, nutritional and 
metabolic diseases’, diabetes mellitus (with complications) in particular. 
Endocrine, nutritional and metabolic diseases including diabetes mellitus with 
complications such as peripheral vascular complications and ketoacidosis as 
an independent risk factor might come from the effects of such disorders on 
the immune system (Lodise et al., 2007; Kim et al., 2014b). A previous study 
has investigated decreased cellular innate immunity such as chemotaxis, 
phagocytosis, and killing in diabetic polymorphonuclear cells and 
monocytes/macrophages (Geerlings and Hoepelman, 1999). Furthermore, 
nutritional and metabolic diseases is linked with heart disease, diabetes, and 
a wide range of other clinical concerns. A previous study reported that 
metabolic disease was an independent risk factor for carbapenem-resistant 
Klebsiella pneumoniae infection in patients colonized with carbapenem-
resistant Klebsiella pneumonia (Akturk et al., 2016). Interestingly, non-CPO 
colonised patients were more likely to have digestive system diseases than 
patients colonised by CPO but this was not independently protective for CPO 
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colonisation (Table 4-7). This finding agrees with some studies reporting that 
digestive system diseases were more common in patients with carbapenem-
susceptible organisms (CSO) but they were not independent protective factors 
for CRO/CPO (Freire et al., 2016b; Freire et al., 2016c; Orsi et al., 2013). 
Endoscopic operation was the only invasive procedure related factor that 
increased the risk of CPO colonisation comparing with demographic controls. 
Some studies reported that exposure to endoscopes was associated with 
apparent acquisition and transmission of CPO due to bacterial contamination 
(Naas et al., 2010; Epstein et al., 2014). However, the 6 cases with endoscopic 
operation in this study came from 5 hospitals in 4 NHS Boards between 2013 
and 2016, indicating no evidence of possible transmission via contaminated 
endoscopes, and awareness of the potential transmission via this route and 
regular reviews of endoscope reprocessing procedures are still required. 
For both CPO infection and colonisation, age was a risk factor when compared 
with demographic controls. Greater age or advanced age is a well-recognised 
risk factor for multidrug-resistant organisms including CPO (Bleumin et al., 
2012; Cezario et al., 2009; Cheng et al., 2015). Some studies argued that 
advanced age was associated with severity of illness and thus a surrogate 
marker of such condition (Bleumin et al., 2012; Tuon et al., 2012b). This study 
is consistent with this as increase of age was a risk factor using demographic 
controls but not a risk factor when compared with culture positive controls 
(Table 4-5 and Table 4-6). 
In summary, comparing with risk factors for CPO infection, fewer risk factors 
were related to CPO colonisation. A history of HDU stay and ‘endocrine, 
nutritional and metabolic diseases’ independently associated with CPO 
colonisation comparing with general hospitalised patients. No risk factors were 
independently associated with an increased risk of CPO colonisation 
comparing with non-CPO controls. 
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4.4.4 Comparison of outcomes between cases and controls 
The prognostic impact of CPO remains controversial and conflicting. An 
interesting finding of this study is that there was no difference of 30-day or 1-
year survival between hospitalised patients infected or colonised by bacterial 
pathogens regardless of carbapenemase production (Figure 4-2 and Figure 
4-4, Table 4-3). However, hospital mortality rate was significantly higher 
among hospitalised patients with CPO infection (cases) than those with non-
CPO infection (culture positive controls) (Table 4-3). This finding agrees with 
a previous study reporting that patients with carbapenem-resistant gram-
negative organisms had higher hospital mortality than patients with 
carbapenem-susceptible gram-negative organisms, but the 30-day mortality 
did not differ between groups (Bal et al., 2018). This could be explained as 
more severe comorbid conditions of cases who might die not because of CPO 
infections but complications developed during hospital stay, such as 
hematologic malignancies which usually accompanied by multiple 
complications, which was associated with CPO infection in this study (Table 
4-5). Also, this could be explained by significant longer duration between 
pathogen isolation and discharge from hospital (including death in hospital) 
(Table 4-3) and higher proportion of ICU/HDU stay (cases vs. culture positive 
controls: 46.4% vs 23.1%) and immunocompromised status (cases vs. culture 
positive controls: 30.4% vs 20.7%). A prospective multicentre study found that 
the difference of 30-day mortality between CRO and CSO bacteremia 
diminished as the number of comorbidities increased (Pena et al., 2012). For 
hospitalised patients with bacterial infections, bacterial family had no impact 
on survival (Figure 4-4). 
Another concern is the longer hospital stay after CPO isolation for infection 
cases and more CPO colonisation cases discharged to healthcare facilities 
(Table 4-3), might result in more medical expense and opportunities for further 
CPO transmission. 
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4.4.5 Comparison of antimicrobial susceptibility between 
cases and controls 
Although complete antimicrobial resistance profiles were not available, the 
isolates involved in these analyses were from 13 hospitals located in 8 NHS 
Boards between 2010 and 2016 including both Enterobacteriaceae and non-
fermenters isolates and these should reflect antimicrobial resistance patterns 
in general. In vitro resistance to all tested antibiotics was higher in CPO 
isolates than their matched controls, i.e. non-CPO (Table 4-4, Figure 4-5). 
Carbapenemases encoding genes are frequently carried on genetic elements 
such as plasmids and transposons that also carry genes encoding for other 
resistance determinants and tend to accumulate resistance genes to different 
antibiotics. In particular, CPE isolates presented a significant higher in vitro 
resistant profile to all tested antibiotics than Enterobacteriaceae without 
carbapenemase production isolates (Table 4-4). Compared with non-
fermenters without carbapenemase production isolates, carbapenemase-
producing non-fermenters isolates presented a significant higher in vitro 
resistant profile to meropenem and gentamicin. An interesting finding was that 
11 (36.7%) of the 30 CPO isolates were susceptible to meropenem and all of 
them were Enterobacteriaceae isolates. The susceptibility rate to 
carbapenems among CPE isolates was 45.8% (11/24) which were similar to 
other studies (16%-55%) (De Laveleye et al., 2017; Mittal et al., 2016). Two 
explanations might accounted for this. Given the identification process of CPO 
in Scotland (if the isolate was non-susceptible to ≥1 carbapenem, the 
diagnostic laboratory would refer the isolate to the reference unit for 
confirmation of carbapenemase prouction) (Trepanier et al., 2017), these 
meropenem susceptible isolates might be non-susceptible to other 
carbapenems but there is paucity of antimicrobial susceptibility data for other 
carbapenems. On the other hand, it had been widely reported that the 
automated systems routinely used in microbiology laboratories might not 
detect 6-87% of the β-lactamases associated with carbapenem resistance in 
known resistant isolates (Tenover et al., 2006; Gasink et al., 2009; Orsi et al., 
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2011), especially for OXA-48 producers as carbapenem resistance is not 
consistently phenotypically expressed and showed lower carbapenem 
minimum inhibitory concentration values than other carbapenemase 
producers (Gupta et al., 2011; Nordmann et al., 2012b; Huang et al., 2014b; 
Dautzenberg et al., 2016; De Laveleye et al., 2017). In line with these studies, 
the 11 imipenem/meropenem susceptible CPO isolates in this study comprised 
7 OXA-48, 3 KPC and 1 NDM producers, illustrating the challenges of 
identification of OXA-48-producing carbapenem-susceptible isolates by 
routine microbiological laboratory methods. By contrast, 5 non-CPO isolates 
showed resistance to imipenem/meropenem including 4 non-fermenters 
isolates and 1 Enterobacteriaceae isolate, indicating that other mechanisms 
rather than dissemination of carbapenemases resulted in carbapenem 
resistance. Previous studies reported that approximately half of CRO tested 
for carbapenemase production appeared to not be carbapenemase producing 
(Chiotos et al., 2017; Mittal et al., 2016). Whether systematic genotypic 
carbapenemase testing should be performed warrants consideration. 
There were some unknown or missing data such as prior antibiotic usage at 
individual level, travel history and complete antimicrobial susceptibility profiles 
which reflected difficulty to obtain or lack of attention on such information. 
Despite this limitation, this study is the first and largest matched case-control-
control study of CPO at national level in Scotland to date, and it identified a 
subgroup of hospitalised patients at higher risk of CPO infection and 
colonisation in whom enhanced infection prevention and control measures 
might be of benefit given that the overall low incidence of CPO in Scotland. 
 
4.5 Conclusion 
Carbapenemase production had no negative impact on survival among 
hospitalised patients with positive cultures, but resulted in worse survival than 
general hospitalised patients. Patients with CPO infection had higher hospital 
mortality and longer hospital stay than both patients with non-CPO infection 
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and general hospitalised patients. CPO isolates had higher resistance rates 
than non-CPO isolates to all the tested antibiotics. A history of (prolonged) 
hospitalisation, prolonged ICU/HDU stay and being immunocompromised 
independently increased risk for CPO infection. A history of HDU stay and 
‘endocrine, nutritional and metabolic diseases’ were independent risk factors 
for CPO colonisation among general hospitalised patients. As the first national 
risk factor study for CPO infection and colonisation in a low incidence setting, 
this study sheds light on identifying patients at high risk of being infected or 
colonised by CPO among hospitalised patients and thus will help to inform and 
refine local screening and infection control policies for CPO. 
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Chapter 5 Discussion 
5.1 Overview 
Carbapenem resistance, mainly among Gram-negative bacteria including 
Enterobacteriaceae and non-fermenters, is an on-going global public health 
threat. Carbapenem resistance, especially when mediated by easily 
transferable carbapenemase-encoding genes, is increasing and spreading 
rapidly causing serious outbreaks and dramatically limiting treatment options 
(Nordmann, 2014; Meletis, 2016). Therefore, it is urgent and important to 
understand the epidemiology, including who is at risk of acquiring CRO 
including CPO. Compared with other antimicrobial resistant organisms (e.g., 
Methicillin-resistant Staphylococcus Aureus, vancomycin-resistant 
Enterococci) (Health Protection Scotland, 2014; Health Protection Scotland, 
2019b), CPO is still rare. However, as shown in this thesis CPO are increasing 
rapidly. In addition there are few published papers on CPO in Scotland (Toner 
et al., 2019; Trepanier et al., 2017). Yet there has been no critical review of the 
data in Scotland. Only with such a review can we assess the extent of the 
situation/problem in Scotland and offer suggestions to public health officials 
regarding the control of CPO. Therefore, there are two main aims in this thesis: 
(1) to summarise risk factors for CRO infection and colonisation in heathcare 
facilities from published work; (2) to describe and interpret the epidemiology 
patterns of CPO in Scotland.This thesis has two main parts accordingly. 
In the first part, a systematic review and meta-analyses was conducted to 
investigate risk factors for acquiring CRO in healthcare facilities worldwide 
using raw data extracted from published papers between 1986 and 2016 
(Chapter 2). Meta-regression analyses were performed to explore potential 
sources of heterogeneity for leading risk factors. The findings highlight leading 
risk factors for CRO infection and colonisation in healthcare settings and study 
characteristics accounting most for heterogeneity. 
The second part of the thesis focused on all CPO reported in Scotland since 
its first report in 2003 until 2016 by conducting a retrospective epidemiology 
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study using data extracted from multiple national datasets held by NHS 
National Services Scotland. The epidemiological analyses (Chapter 3) 
provided a comprehensive description of spatial and temporal epidemiological 
patterns of CPO and microbiological characteristics of CPO isolates. 
Additionally, this thesis evaluated the mortality of CPO and identified patients 
at higher 30-day mortality risk from CPO. Then hospitalised patients with CPO 
infection and colonisation between 2010 and 2016 were included in a matched 
case-control study to identify risk factors for CPO infection and colonisation 
using conditional logistic models and the clinical outcomes and antimicrobial 
susceptibility were also compared between cases and controls (Chapter 4). 
All the work done in this thesis has not been conducted and published by other 
researchers, therefore, the findings add new knowledge and implications to 
the existing literature and will hopefully help to inform and refine local 
screening and infection control policies for CPO to make a better structured 
and coordinated national plan in Scotland and elsewhere. Nonetheless, there 
are also some limitations regarding data and methodology which have 
implications for future research. These are discussed in the next sections of 
this chapter. 
 
5.2 Data and methodological critique 
5.2.1 Systematic review and meta-analysis 
Systematic reviews and meta-analyses have been widely used in the practice 
of evidence-based medicine since the 1970s (Mallett et al., 2012). They can 
inform both healthcare professionals in clinical practice and public health policy 
makers by summarising the findings from individual studies relating to a 
specific health‑related topic in both qualitative and quantitative ways. To 
summarise the risk factors for acquiring CRO in healthcare facilities, I 
conducted a systematic review and meta-analysis (Chapter 2). As the data 
were extracted from published papers, there is a risk of publication bias and 
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language bias (Higgins et al., 2019). To minimise these biases, I searched the 
three most widely used and largest Chinese databases in addition to the four 
main English databases and set no language restrictions for studies. I also 
contacted the authors when a full-text paper could not be accessed or the data 
needed in my study were not completely reported in the published text. Egger’s 
test is commonly used to detect the publication bias but the power of this 
method to detect bias will be low with small numbers of studies (Egger et al., 
1997), thereby I performed the test for risk factors being investigated in more 
than ten studies, and the indicators were significant for few risk factors (9/88), 
none of which were among the leading risk factors (Appendix 2-7).  
To maximise the number of studies included in the meta-analyses, study 
quality was not an exclusion criterion in my study which may introduce a risk 
of bias and misleading interpretation of results. The quality of a study reflects 
the strength of the evidence that can be drawn from it. In other words, it reflects 
the confidence that one can have that the results of a study reflect the ‘truth’ 
(Cochrane Consumers and Communication Review Group, 2013). Given that 
there is no acknowledged standards for interpretation of studies of high or low 
quality, I defined studies with the lowest scores as ‘low quality’. To examine 
whether including the low quality studies had significant impact on the pooled 
estimates, I performed sensitivity analyses for risk factors investigated by no 
less than five studies when the studies of low quality were included and 
excluded from meta-analyses and found that the results did not differ 
substantially (Appendix 2-9), i.e. the results are robust. 
A major limitation of the meta-analyses in this thesis is that the pooled 
estimates were generated from univariate analysis without accounting for any 
potential confounders, thereby the true association between the risk factors 
and acquiring CRO might be concealed. Furthermore, some risk factors might 
be correlated with other risk factors in practice, for example, patients with 
malignancy are usually treated by chemotherapy and patients in ICU usually 
require mechanical ventilation, CVC or urinary tract support. Such high 
correlation between risk factors was observed in Chapter 4 (Figure 4-6, Figure 
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4-7 and Figure 4-8). Given that the large number of included studies, 
contacting the authors to ask for individual data of each study would take 
considerable time, I did not endeavour to perform multivariate analysis for 
these risk factors in the meta-analysis. 
5.2.2 Data limitations 
The study of CPO in Scotland (Chapters 3 and 4) was based on data extracted 
from several national datasets. The limitations regarding the data integrity and 
availability of such data is discussed below. 
5.2.2.1 Clinical manifestations and laboratory tests 
The impact of antimicrobial resistant organisms on a patient’s prognosis will 
be different depending on whether the organism is associated with an infection 
or a colonisation as different intervention measures are required. As a result, 
from both clinical and public health perspectives, discrimination between 
infection and colonisation are crucial in antimicrobial resistance studies. 
Clinical manifestations (signs and symptoms) and results of laboratory tests 
are important components of infection diagnostics (Garner et al., 1988; Horan 
et al., 2008). Comorbidity data were extracted from Scottish Morbidity Record-
General Acute Inpatients/Day Cases (SMR 01), information regarding clinical 
manifestations and laboratory tests were recorded as a disease belonging to 
‘Symptoms, signs and abnormal clinical and laboratory findings’ according to 
International Classification of Diseases (Centers for Disease Control and 
Prevention, 2017). But the records were not recorded in detail and as a result 
were often not useful to define an infection (for example ‘other specified 
abnormal immunological findings in serum’ and ‘tendency to fall’). As a 
compromise, I worked closely with a consultant physician in infectious 
diseases and general internal medicine (Dr Meghan Perry, Western General 
Hospital, Edinburgh) to classify cases as infection and colonisation (Table 3-5) 
based on the source of specimen with positive cultures and diagnosis as 
suggested by other researchers (Khadem et al., 2017). Those patients that I 
could not definitely classify as either infection or colonisation are classified as 
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unclassifiable for the sake of clinical rigour and significance. Moreover, CPO 
cases from CPE screening programme (launched since August 2013) are 
expected to be more likely to be colonisations, but whether the reported CPO 
cases were from the screening programme is unknown. 
Survival analyses of all the 211 CPO cases by status (infection, colonisation 
and unclassifiable) (Figure 3-24) shows that the survival curve of 48 
unclassifiable (either infection or colonisation) cases is quite similar to that of 
211 cases regardless of status. This could partially demonstrate that the 
definitions are practically sensible and sound. 
5.2.2.2 Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing is important in the steps to identify a CPO 
as described in Chapter 1 (Section 1.3.3). However, the antimicrobial 
susceptibility testing results were not available for all CPO isolates 
(antimicrobial susceptibility testing results were available for only 54 of 243 
CPO isolates: 22.2%) which means that the specific carbapenem(s) which the 
CPO isolate was non-susceptible to was unknown. For the 54 CPO isolates 
with antimicrobial susceptibility testing results, they were not tested for the 
same agents (Table 3-11). A possible explanation is that the agents tested in 
antimicrobial susceptibility testing depends on sample type in Scotland 
(according to Dr Meghan Perry, personal communication by email, November 
15, 2019); for example, VITEK® 2 antimicrobial susceptibility testing-N382 
(Standard Urine Card) is used for Enterobacteriaceae isolates from urine and 
VITEK® 2 antimicrobial susceptibility testing-N381 (Standard 
Enterobacteriaceae Card) is used for Enterobacteriaceae isolates from other 
sites. 
The 54 CPO isolates involved in the analyses were from 14 hospitals located 
in 10 NHS Boards between 2008 and 2016 while isolates from culture positive 
controls were from 13 hospitals located in 8 NHS Boards between 2010 and 
2016 including both Enterobacteriaceae and non-fermenters. To exclude 
possible selection bias, I double checked whether the isolates were mainly 
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from some specific patients (such as older patients, patients in ICU/HDU and 
patients with infections), but no obvious bias was noted. Nonetheless, the 
antimicrobial susceptibility testing results were still not convincing and the 
results should be interpreted with caution due to the small number of isolates 
tested. 
5.2.2.3 Risk factors investigated for CPO infection and colonisation 
The results from the systematic review and meta-analysis in Chapter 2 show 
that prior administrations with specific antibiotics and longer duration of the 
presence of some invasive medical devices before CRO isolation were leading 
risk factors for acquiring CRO in healthcare facilities. However, information on 
antibiotics usage and length of exposure to invasive medical devices at 
individual patient level in hospitals were not available in Scotland until the end 
of 2016. In addition, data at individual level regarding medicines related to 
certain comorbidities like steroids which were also investigated widely by other 
risk factor studies were not available from the current national datasets until 
the end of 2016. 
The incompleteness, unavailability or inaccessibility of data mentioned above 
might generate overestimated associations between some variables 
investigated and CPO infection and colonisation. 
5.2.3 Statistical models selection 
Statistic models support medical research for antimicrobial resistance by 
facilitating individualized outcome prognostication conditional on independent 
variables or by estimating effects of risk factors adjusted for covariates (Heinze 
et al., 2018).To investigate CPO incidence in Chapter 3, two statistical models 
were considered, a nonlinear model (exponential model) and a generalised 
linear model. I performed analyses using both models and found the 
exponential model had a better fit (residual standard deviation: 0.091) than the 
generalised linear model (residual standard deviation: 1.316). To investigate 
risk factors for 30-day mortality of hospitalised CPO cases in Chapter 3, two 
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statistical models were considered, a Cox proportional-hazards model (Cox, 
1972) and a generalised linear mixed model (Breslow and Clayton, 1993). The 
former investigates the association between the survival time of individuals 
and predictors while the latter contains random effect(s) in addition to the fixed 
effects (i.e. predictors of interest). The outcome I am interested in is whether 
the patient died within 30 days after CPO isolation rather than how long the 
patient survived within 30 days after CPO isolation which a Cox proportional-
hazards model takes into account. Moreover, previous study specified that 
patients clustered within the same hospital were more likely to be similar to 
each other than similar to patients from another hospital (Khadem et al., 2017), 
and medical conditions varied across different hospitals in different NHS 
Boards. Given all the above factors, a generalised linear mixed model with the 
hospital where the patient with CPO was treated being a random effect was 
fitted to account for differences in study setting and geographic location. 
Although the CPO study in this thesis is the first and largest national-level study 
since its first report as of today, the number of patients enrolled is still relatively 
low compared with the number of variables of interest, thereby variable 
selection is necessary for multivariate analyses which attempts to find a simple 
and appropriate model. Variable selection techniques can be grouped into 
three categories: 1) filter methods which select variables by ranking them on 
how useful they are for the model via calculating the usefulness score based 
on their correlation with the dependent variable, like Chi-square, analysis of 
variance and Pearson's correlation (Saeys et al., 2007); 2) wrapper methods 
generates different subsets of variables, each subset is then used to build up 
a model and train the learning algorithm, the best subset is selected by testing 
the algorithm (Saeys et al., 2007). To select variables for the subsets different 
criteria are used, e.g. forward selection and backward selection; 3) embedded 
methods are combinations between the two previous methods including 
LASSO (Heinze et al., 2018). There are some advantages using LASSO 
method over other methods. First, it can provide a very good prediction 
accuracy since shrinkage and removal of the coefficients can reduce variance 
without increasing substantial bias. This is especially useful when there is a 
Epidemiology of CPO in Scotland 
204  Discussion 
 
small sample size investigated and a large number of variables. Second, it 
helps to increase the model interpretability by eliminating irrelevant variables 
that are not related with the response variable and thereby reduce overfitting 
(Fonti and Belitser, 2017). Therefore LASSO was adopted given its 
advantages in this scenario. 
For risk factor analyses in Chapter 3 and 4, a liberal P value criterion (0.10) 
was used rather than the conventional criterion (0.05) to identify independent 
variables included in multivariate analyses. It is argued that the traditional level 
of 0.05 can fail in identifying variables known to be important (Costanza and 
Afifi, 1979, Mickey and Greenland, 1989) and a liberal criterion could 
compensate by making it more likely that truly important predictors and 
confounders will be retained in the model when there are too many candidate 
predictors for the sample size (Steyerberg et al., 2001). A liberal 0.01≤P≤0.25 
often perform better (Costanza and Afifi, 1979) and 0.01 was chosen in this 
thesis given the relatively small sample size. 
 
5.3 Implications and future work 
The findings of this thesis answer some key questions regarding risk factors 
for acquiring CRO (including CPO) in healthcare facilities and epidemiology of 
CPO in Scotland. These findings have implications for the clinical and policy. 
Due to time and data constraints there were several questions that could not 
be answered by this thesis. These unanswered questions warrant more 
research work in the future. 
5.3.1 Who are going to acquire CRO in low income countries 
and high income countries with low CRO incidence? 
This thesis highlights the knowledge gap in risk factor studies for acquiring 
CRO since no relevant study has been reported from low income countries or 
high income countries with low CRO incidence (e.g. Canada, New Zealand). 
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However, high level of carbapenem resistance including CPO has been 
reported in some low income countries (Manenzhe et al., 2015; Ssekatawa et 
al., 2018) and rapid increases in CPO in high income countries with low CRO 
incidence had been noted currently (Australian Commission on Safety and 
Quality in Health Care, 2017; Ministry of Health New Zealand Goverment, 
2018; Government of Canada, 2016). Moreover, it is reported that many CPO 
in low CPO incidence settings have been imported from overseas (Blakiston 
et al., 2017) and travel and medical exchange between countries are becoming 
more frequent and increasing. Besides poor hygiene, there is a lack of financial 
support and a formal framework for surveillance programmes in low income 
countries. The above situations would facilitate a rapid spread of CRO across 
these countries or regions. Therefore, future work conducted in these countries 
or regions will help to fill the knowledge gap and contribute to combat the public 
health threat globally. This is also an important motivation for the work done in 
Chapters 3 and 4 of this thesis. 
5.3.2 What else can be done to widen the generalisability of 
the results of the systematic review and meta-analysis 
from clinical and epidemiological perspective? 
The methodological and data limitations of the systematic review and meta-
analysis conducted in this thesis were discussed above. Based on these, 
further research could be performed to address more clinical and 
epidemiological orientated questions. 
First, univariate analysis investigating one single risk factor without taking 
other factors (confounders) into account could lead to misleading results and 
conclusions. Future multivariate analysis considering potential confounding 
would provide more reliable estimates for risk factors of interest. 
Second, I applied modified study quality assessment scales tailored from the 
common used scales for systematic review and meta-analysis. However, 
these quality assessment scales did not address all aspects related to study 
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quality, such as risk of bias, sample size and analysis method. More detailed 
study quality assessment tools should be designed and applied to evaluate the 
quality of included studies focus on risk factors for antimicrobial resistance in 
the future. 
Third, I merged different types of bacteria (Enterobacteriaceae and non-
fermenter), patients (adults and the paediatric, ICU patient and non-ICU 
patients), infections (bloodstream infections, UTI, pneumonia) and resistance 
mechanisms (carbapenemase production and non-enzymatic mechanisms) in 
the analysis. Meta-regression analyses show that some of these 
characteristics accounted for most of the heterogeneity. Future research on 
these distinctions and stratifications is crucial to provide more meaningful 
guidance and data for further action by clinicians and public health 
epidemiologists. 
Finally, I evaluated antibiotic exposure as a dichotomous variable and did not 
fully address the complexities of previous antibiotic exposure such as duration, 
dosage and route of administration due to the limited number of studies 
included. Moreover, I did not specify and allow for the time line of risk factors 
of interest due to the huge variety across studies. The risk factors can be 
assessed during hospitalisation or within two weeks till one year of hospital 
admission or CRO isolation. Analyses detailing these variables and 
distinctions warrant future work. 
5.3.3 Does acute hospital admission screening programme for 
CPE in Scotland work? 
The national screening programme was launched in August 2013 (The 
Scottish Government, 2013). The observed CPO incidence after 2013 was 
higher than the extrapolations from the model in 2003-2013 (Figure 3-5), 
indicating that the introduction of CPE screening programme might have had 
an impact on CPO incidence. However, the number of reported CPO cases 
from the screening programme is unknown. Therefore, it is hard to tell exactly 
to what extent the screening programme has contributed to the increased 
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number of CPO cases. Better records or labels of CPO cases from the 
screening programme in the national dataset would enable the policy makers 
to evaluate the programme better. 
5.3.4 How many CPO infections developed from colonisation 
and what are risk factors for the progress from CPO 
colonisation to infection? 
The systematic review and meta-analysis highlights that prior colonisation by 
CRO was a leading risk factor for CRO infection. A previous systematic review 
reported an overall 16.5% risk of developing an infection with CRE among 
patients colonised by CRE and it was associated with a 10% overall mortality 
(Tischendorf et al., 2016). Given that the reported high risk of infection 
developing from colonisation, difficulty of treating CRO infections and 
associated high mortality, it is important to elucidate the CPO infection burden 
among patients with CPO colonisation in Scotland and the triggers for the 
progressions from colonisation to infection. Furthermore, the screening 
programme using urine and rectal swabs is supposed to identify CPO 
colonisation, and understanding the risk of infection developing from 
colonisation could help to assess the screening programme. However, I could 
not evaluate the risk of developing an infection amongst those colonised with 
CPO. The risk factors for the progress could be the scope of future research. 
Clear and practical definitions of CPO infection and colonisation should be 
developed and applied in the future to better address the question. 
5.3.5 Are antibiotics usage and duration of invasive devices 
presence before CPO isolation associated with acquiring 
CPO in Scotland? 
Prior antibiotics usage and duration of treatments with certain invasive medical 
devices were found to be leading risk factors for CRO presence in Chapter 2 
and have been reported as risk factors for unfavourable outcomes (Punpanich 
et al., 2012; Kim et al., 2012b). However, data for these variables in hospitals 
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at individual level are not available in Scotland. Although treatments with 
certain invasive medical devices as a dichotomous variable was included in 
the analysis, using the variables in a quantitative manner (i.e. taking the 
duration of exposure into account) would be more informative. Additionally, 
these variables may correlate with other variables (comorbidities, 
demographics and healthcare exposure). The true association between these 
variables and acquiring CPO/mortality risk from CPO should be investigated 
further in the future. 
5.3.6 Is there clonal persistence and spread of CPO in 
Scotland or between Scotland and elsewhere? 
The epidemiological data shows that some CPO cases with the same 
carbapenemase had been admitted to the same ward in the same hospital at 
similar time before CPO isolation. All the cases are VIM/IMP producers which 
are healthcare-associated. Is there clonal spread of CPO in these hospitals? 
Moreover, cases with NDM/OXA-48 producing isolates are more likely to be 
colonisation and community-associated and percentage of these isolates 
among all CPO isolates showed an upward trend over time. Where did the 
community-associated cases acquire CPO? Are they imported CPO cases? 
Given that whole-genome sequencing has been demonstrated as a useful 
approach to elucidate genetic modes of transmission (Martin et al., 2017), a 
future bioinformatic and phylogenetic study using such genomic data is 
essential to answer these questions and provide evidence or guidance for 
infection prevention control measures in both hospitals and the community. 
5.3.7 Are there other factors accounting for the impact of 
certain species or carbapenemases on patient survival? 
This thesis highlights that infection with or colonisation by carbapenemase-
producing non-fermenters (Pseudomonas spp. or Acinetobacter spp.) was 
independently associated with 30-day mortality and that the incidence of 
carbapenemase-producing non-fermenters increased over time. Cases with 
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NDM/OXA-48-producing isolates had significantly better survival than those 
with KPC/IMP-producing isolates (Figure 3-28). Half of IMP-producing isolates 
are non-fermenters (9/18, 50.0%) while the majority of NDM/OXA-48-
producing isolates are Enterobacteriaceae (97/101, 96.0%). The antimicrobial 
resistance profiles show no significant differences to nearly all antibiotics 
between Enterobacteriaceae and non-fermenters isolates (Table 3-11, Figure 
3-22). However, all the 8 OXA-48-producing isolates that underwent 
antimicrobial susceptibility testing remained susceptible to meropenem while 
all the 4 IMP-producing isolates that underwent antimicrobial susceptibility 
testing were resistant to meropenem or imipenem. Due to the sparse 
antimicrobial susceptibility testing data available, it is not possible to conclude 
that the antimicrobial susceptibility of NDM/OXA-48-producing isolates offering 
potential effective treatment options accounted for the better survival. 
Moreover, several studies specified that some mechanisms conferring biofilm 
formation, enhanced virulence and resistance to immunological responses 
could contribute to antimicrobial resistance and increased mortality (Chiang et 
al., 2016; Paauw et al., 2009; Xu et al., 2018; Cho et al., 2018). Therefore, a 
future molecular study offering a comprehensive understanding of the 
virulence, antimicrobial susceptibility and pathogenicity profiles of CPO 
isolates would help answer this question. 
5.3.8 Are the risk factors identified in this thesis specific for 
acquiring CRO/CPO? 
The results from both the systematic review and meta-analysis worldwide 
(Chapter 2) and risk factor analyses for CPO in Scotland (Chapter 4) show that 
severity of illness and extensive healthcare exposure (including prolonged 
hospitalization, HDU/ICU stay, exposure to invasive devices and exposure to 
antibiotics) were associated with CRO/CPO acquisition in healthcare settings. 
However, these factors were also reported by review studies as common risk 
factors for acquiring other antimicrobial resistant bacteria in hospitals 
comprising MRSA, VRE, ESBL-producing bacteria and Clostridium difficile 
(Detsis et al., 2017; Eze et al., 2017; Flokas et al., 2017; Li et al., 2017; Pano 
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Pardo et al., 2014; Sabbagh et al., 2019; Song and Kim, 2019). Although 
prolonged hospitalisation and HDU stay were identified as independent risk 
factors for CPO infection comparing with patients infected by non-CPO, no 
independent risk factor was noted when CPO colonisation cases were 
compared with patients colonised by non-CPO. Are the independent risk 
factors for CPO infection associated with exposure to antibiotics in hospitals? 
Will the independent association disappear when other variables (e.g. 
exposure to antibiotics, duration of antibiotics exposure, duration of exposure 
to invasive devices) are taken into account? Are risk factors the same when all 
cases and controls are selected in HDU/ICU since patients in these wards are 
usually very ill? This thesis cannot answer these questions. A well-designed 
prospective study with sufficient sample size conducted in HDU/ICU that take 
as many as potential risk factors into account and use logically matched 
controls who are free of colonisation by any antimicrobial resistant bacteria 
would address these questions. 
 
5.4 Concluding remarks 
This thesis made an endeavour to provide a comprehensive epidemiological 
understanding of CPO in Scotland since its first report. The traditional 
epidemiological triad model has three components: reservoir, mode of 
transmission and susceptible population (Centers for Disease Control and 
Prevention, 2011). The corresponding infection prevention and control 
measures should be developed based on the three components, including 
reservoir identification, cutting off transmission routes and susceptible 
population identification. 
First, reservoir identification, namely identification of CPO cases. CPO 
incidence (both CPO infection and colonisation) increased over time, indicating 
that: 1) CPO in Scotland is an increasing public health threat; 2) the acute 
hospital admission screening programme has an impact on finding CPO cases, 
thereby it is necessary to continue this surveillance. The percentage of some 
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CPO isolates (NDM/OXA-48 producers) related to community-associated 
source and colonisation rose over time, highlighting the presence and possible 
transmission of CPO in the community. In September 2017, HPS issued a 
guidance containing a set of recommendations and practical advice to reduce 
the spread of CPE in non-acute and community settings in Scotland (Health 
Protection Scotland, 2017). The findings of this thesis confirm the necessity of 
these measures. 
Given that all CPO attributed deaths were CPO infection cases, colonisation 
precedes infections and the high risk of developing an infection among 
colonised patients, clear and practical definitions of infection and colonisation 
of a CPO case should be developed at a national level and the patients who 
are suspected with CPO and underwent the screening programme should be 
flagged in the medical records. This would help clinicians and hospital infection 
control teams to notice, isolate and treat the cases and close contacts as 
quickly as possible. Also, it will help policy makers to accurately evaluate the 
local disease burden of CPO infection, colonisation and progression from 
colonisation to infection, thereby guiding efforts to develop more effective 
strategies for prevention and control CPO. 
Second, cut off transmission routes. Although the data shows that some CPO 
cases with the same carbapenemase had been admitted to the same ward in 
the same hospital at similar time before CPO isolation, no clonal transmission 
or spread can be identified without phylogenetic analyses using sequencing 
data. Additionally, the antimicrobial susceptibility testing results show that 
some non-CPO isolates were resistant to carbapenems (Table 4-4, Figure 
4-5), indicating that there are other carbapenem resistance mechanisms. 
Carbapenem resistant non-CPO are outside the scope of this thesis, but they 
are worthy of public health awareness as an important component of CRO. As 
discussed in Section 5.3, it is unknown whether antimicrobial resistance and 
virulence profiles contribute to the unfavourable outcomes of cases with non-
fermenters and KPC/IMP producers. Therefore, whole genome sequence data 
providing a wide range of genetic determinants comprising antimicrobial 
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resistance, non-carbapenemase producing resistance mechanisms and 
virulence factors (Turton et al., 2018; Martin et al., 2017), together with 
metadata will provide a whole picture of CRO in Scotland and inform possible 
transmission or spread of CRO within Scotland or between Scotland and 
elsewhere. This would help policy makers to determine if travel or hospital 
transfer information should be taken into account to refine the screening 
programme and infection prevention and control measures for nosocomial 
infections. 
Third, identification of the susceptible population, namely the population at 
high risk of acquiring CRO/CPO. Risk factors for CRO/CPO infection and 
colonisation identified in this thesis are markers of critical illness and extensive 
healthcare exposure which are the common risk factors for acquiring other 
multidrug-resistant organisms. Given that previous carriage of other multidrug-
resistant organisms was a leading risk factor for acquiring CRO, pre-emptive 
identification and isolation of individuals with such risk factors for colonisation 
and infection by any of these multidrug-resistant organisms would very likely 
reduce the spread of antimicrobial resistance in hospitals. Furthermore, future 
studies to identify specific risk factors for CRO/CPO are also important since 
the CPO study in Scotland shows that CPO infections were associated with 
prolonged hospital stay and higher in-hospital mortality compared with non-
CPO infections. 
Finally, my supervisors and myself worked together with HPS, electronic Data 
Research and Innovation Service and the university staff to apply for, analyse 
and release the results of the analyses of the data of CPO in Scotland (data 
used in Chapters 3 and 4). The whole process from application for the data 
until the acquisition of all the data I required took 14 months which is almost 
40% of my PhD programme (36 months). The unanswered questions in this 
thesis mainly resulted from the data limitations. Since combating antimicrobial 
resistance needs collaboration from multiple disciplines (human healthcare, 
epidemiology, environment ecology, food-producing animals and wildlife), 
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cooperative and efficient data sharing is essential to benefit both public health 
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Appendix 2-2. Search strategy of risk factors for the presence of 
carbapenem-resistant organisms (CRO) among patients in healthcare 
facilities 
Embase 
1. exp antibiotic resistance/ 
2. produc*.mp. 
3. (Multi-drug resistan* or Multidrug resistan* or MDR or non susceptib* or 
resistan*).mp. 
4. "not susceptible".mp. 
5. carbapenem*.mp. or exp carbapenem/ 
6. exp carbapenemase/ or carbapenemase*.mp. 
7. exp imipenem/ or imipenem.mp. 
8. exp meropenem/ or meropenem.mp. 
9. ertapenem.mp. or exp ertapenem/ 
10. doripenem.mp. or exp doripenem/ 
11. exp metallo beta lactamase/ or metallo beta lactamase*.mp. or 
MBL.mp. 
12. (KPC or Klebsiella pneumoniae Carbapenemase).mp. 
13. (SME or Serratia marcescens enzyme).mp. 
14. (IMI or imipenem hydrolyzing beta lactamase).mp. 
15. (NMC or not-metalloenzyme carbapenemase).mp. 
16. (IBC or integrin-borne cephalosporinase or GES or Guiana extended 
spectrum).mp. 
17. (IMP or active on imipenem).mp. 
18. (VIM or Verona integron encoded metallo beta lactamase).mp. 
19. (SPM or Sao Paulo metallo beta lactamase).mp. 
20. (GIM or German imipenemase).mp. 
21. (SIM or Seoul imipenemase).mp. 
22. (OXA or oxacillin hydrolysing).mp. 
23. (NDM or New Delhi metallo beta lactamase).mp. 
24. KHM.mp. 
25. 1 or 2 or 3 or 4 
26. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 
or 19 or 20 or 21 or 22 or 23 or 24 
27. 25 and 26 
28. exp risk factor/ or risk factor*.mp. 
29. exp prediction/ or predict*.mp. 
30. outbreak*.mp. 
31. exp association/ or associat*.mp. 
32. emergence.mp. 
33. exp bacterial transmission/ or transmission*.mp. 
34. protect*.mp. 
35. exp prevalence/ or exp epidemiology/ or epidemiolog*.mp. 
36. age/ 
37. exp "gender and sex"/ or sex.mp. 
38. (underlying disease* or underlying condition*).mp. or exp comorbidity/ 
  Epidemiology of CPO in Scotland 
Appendices 219 
 
39. exp hospitalization/ or previous hospitalization.mp. 
40. exp intensive care unit/ or previous ICU stay.mp. 
41. exp patient transport/ or patient transport.mp. 
42. exp invasive procedure/ or invasive intervention*.mp. 
43. exp catheter/ or catheter.mp. 
44. ventilation.mp. 
45. exp dialysis/ or dialysis.mp. 
46. drainage.mp. 
47. endoscopy.mp. or exp endoscopy/ 
48. parenteral nutrition.mp. or exp parenteral nutrition/ 
49. exp surgical technique/ or surgical procedure*.mp. 
50. transplantation*.mp. or exp transplantation/ 
51. blood transfusion.mp. or exp blood transfusion/ 
52. exp intubation/ or intubation.mp. 
53. travel history.mp. 
54. antibiotic exposure*.mp. 
55. quinolones.mp. or exp quinolone derivative/ 
56. extended spectrum cephalosporins.mp. or exp cephalosporin/ 
57. 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 
40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 
52 or 53 or 54 or 55 or 56 
58. 27 and 57 
59. Limit 58 to (human and yr=”1986 – 2016”) 
 
MEDLINE 
1. (Multi-drug resistan* or Multidrug resistan* or MDR).mp. or exp drug 
resistance, bacterial/ or exp drug resistance, multiple, bacterial/ or "not 
susceptible".mp. or non susceptib*.mp. or resistan*.mp. 
2. (producer* or producing or production).mp. 
3. 1 or 2 
4. exp Carbapenems/ or carbapenem*.mp. 
5. imipenem.mp. or exp Imipenem/ 
6. (meropenem or ertapenem or doripenem).mp. 
7. (carbapenemase* or metallo beta lactamase* or MBL).mp. 
8. (KPC or Klebsiella pneumoniae Carbapenemase).mp. 
9. (SME or Serratia marcescens enzyme).mp. 
10. (IMI or imipenem hydrolyzing beta lactamase).mp. 
11. (NMC or not-metalloenzyme carbapenemase).mp. 
12. (IBC or integrin-borne cephalosporinase or GES or Guiana extended 
spectrum).mp. 
13. (IMP or active on imipenem).mp. 
14. (VIM or Verona integron encoded metallo beta lactamase).mp. 
15. (SPM or Sao Paulo metallo beta lactamase).mp. 
16. (GIM or German imipenemase).mp. 
17. (SIM or Seoul imipenemase).mp. 
Epidemiology of CPO in Scotland 
220  Appendices 
 
18. (OXA or oxacillin hydrolysing).mp. 
19. (NDM or New Delhi metallo beta lactamase).mp. 
20. KHM.mp. 
21. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 
or 18 or 19 or 20 
22. 3 and 21 
23. exp Risk Factors/ or risk factor*.mp. 
24. (predict* or determinant*).mp. or exp Disease Outbreaks/ or 
outbreak*.mp. or exp Epidemiology/ or epidemio*.mp. or spread*.mp. 
or exp Prevalence/ or prevalen*.mp. or occurrenc*.mp. or 
emergenc*.mp. or exp Association/ or associat*.mp. or 
transmission*.mp. or exp Disease Transmission, Infectious/ or 
protect*.mp. 
25. age.mp. or exp Sex/ or sex.mp. or exp Ethnic Groups/ or ethnic.mp. 
26. (underlying disease* or underlying condition*).mp. or exp Comorbidity/ 
27. (ICU stay or hospitalization).mp. or exp hospitalization/ or exp "length 
of stay"/ or exp patient readmission/ or exp patient transfer/ 
28. invasive intervention*.mp. or exp catheters/ or exp cannula/ or exp 
catheters, indwelling/ or exp urinary catheters/ or exp vascular access 
devices/ or exp cardiac catheters/ or exp central venous catheters/ 
29. ventilation.mp. or exp Ventilation/ or exp Dialysis/ or dialysis.mp. or 
drainage.mp. or exp Drainage/ 
30. endoscopy.mp. or exp Endoscopy/ 
31. parenteral nutrition.mp. or exp Parenteral Nutrition/ 
32. surgical procedure*.mp. or exp surgical procedures, operative/ 
33. transplantation*.mp. or exp transplantation/ 
34. blood transfusion.mp. or exp Blood Transfusion/ 
35. intubation.mp. or exp intubation/ or exp intubation, gastrointestinal/ or 
exp intubation, intratracheal/ 
36. travel history.mp. 
37. antibiotic exposure*.mp. 
38. quinolones.mp. or exp quinolones/ or exp fluoroquinolones/ 
39. exp Carbapenems/ or carbapenem*.mp. or imipenem.mp. or exp 
Imipenem/ or meropenem.mp. or ertapenem.mp. or doripenem.mp. 
40. extended spectrum cephalosporins.mp. or exp Cephalosporins/ or 
cephalosporins.mp. 
41. 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 
35 or 36 or 37 or 38 or 39 or 40 
42. 22 and 41 
43. limit 42 to yr="1986 - 2016" 
44. limit 43 to humans 
 
Global Health 
1. (carbapenemase* or metallo beta lactamase* or MBL).mp. 
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2. (KPC or Klebsiella pneumoniae Carbapenemase or SME or Serratia 
marcescens enzyme or IMI or imipenem hydrolyzing beta 
lactamase).mp. 
3. (NMC or not-metalloenzyme carbapenemase).mp. 
4. (IBC or integrin-borne cephalosporinase or GES or Guiana extended 
spectrum).mp. 
5. (IMP or active on imipenem or VIM or Verona integron encoded metallo 
beta lactamase or SPM or Sao Paulo metallo beta lactamase or GIM or 
German imipenemase or SIM or Seoul imipenemase or OXA or oxacillin 
hydrolysing or NDM or New Delhi metallo beta lactamase or KHM).mp. 
6. exp carbapenems/ or exp doripenem/ or exp ertapenem/ or exp 
imipenem/ or exp meropenem/ or carbapenem*.mp. or imipenem.mp. 
or meropenem.mp. or ertapenem.mp. or doripenem.mp. 
7. 1 or 2 or 3 or 4 or 5 or 6 
8. exp drug resistance/ or resistan*.mp. 
9. "not susceptible".mp. 
10. "non susceptib*".mp. 
11. (producer* or producing or production).mp. 
12. 8 or 9 or 10 or 11 
13. exp risk factors/ or risk factor*.mp. 
14. predict*.mp. or epidemiology.sh. or prediction.sh. 
15. outbreak*.mp. or exp outbreaks/ 
16. prevalen*.mp. or disease incidence.sh. or disease prevalence.sh. 
17. exp transmission/ or transmission*.mp. 
18. age.mp. or exp age/ 
19. sex.mp. or exp sex/ 
20. ethnic group*.mp. or ethnic groups.sh. 
21. (underlying disease* or underlying condition* or comorbidit*).mp. 
22. previous hospital stay.mp. or hospital stay.sh. 
23. ICU stay.mp. or intensive care units.sh. 
24. patient transfer.mp. 
25. (invasive procedure* or invasive intervention*).mp. 
26. catheter*.mp. or exp catheters/ or catheterization.sh. 
27. ventilation.mp. or exp ventilation/ 
28. dialysis.mp. or exp dialysis/ 
29. exp drainage/ or drainage.mp. 
30. endoscopy.mp. or exp endoscopy/ 
31. parenteral nutrition.mp. or exp parenteral feeding/ 
32. surgical procedure*.mp. or surgical operations.sh. 
33. transplantation*.mp. or exp transplantation/ 
34. blood transfusion.mp. or exp blood transfusion/ 
35. intubation.mp. 
36. travel history.mp. 
37. antibiotic exposure*.mp. 
38. quinolones.mp. or exp quinolones/ 
39. extended spectrum cephalosporins.mp. or cephalosporins.sh. 
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40. 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 
25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 
37 or 38 or 39 
41. 7 and 12 and 40 
42. limit 41 to yr="1986 - 2016" 
 
Web of Science 
1. TOPIC: (multidrug resistan* or multiple drug resistan* or multidrug 
resistan* or MDR) 
2. TOPIC: (producer* or producing or production) 
3. TOPIC: (resistant or resistance) 
4. TOPIC: (“not susceptib”) 
5. TOPIC: (“non susceptib*) 
6. TOPIC: (carbapenem* or imipenem or meropenem or ertapenem or 
doripenem) 
7. TOPIC: (carbapenemase* or metallo beta lactamase* or MBL) 
8. TOPIC: (KPC or Klebsiella pneumoniae Carbapenemase or SME or 
Serratia marcescens enzyme or IMI or imipenem hydrolysing beta 
lactamase) 
9. TOPIC: (NMC or not-metalloenzyme carbapenemase) 
10. TOPIC: (IBC or integrom-borne cephalosporinase or GES or Guiana 
extended spectrum) 
11. TOPIC: (IMP or active on imipenem or VIM or Verona integrin encoded 
metallo beta lactamase or SPM or Sao Paulo metallo beta lactamase 
or GIM or German imipenemase or SIM or Seoul imipenemase or OXA 
or oxacillin hydrolysing or NDM or NEW Delhi metallo beta lactamase 
or KHM) 
12. 11 OR 10 OR 9 OR 8 OR 7 OR 6 
13. 5 OR 4 OR 3 OR 2 OR 1 
14. 12 AND 13 
15. TOPIC: (risk factor* or predict* or determinant* or outbreak* or 
epidemiolog* or prevalence or associate* or transmission* or protect*) 
16. TOPIC: (age or sex or ethnic or underlying disease* or underlying 
condition* or comorbidity or ICU stay or hospitalization or hospital stay 
or patient transfer or invasive intervention* or invasive procedure* or 
catheter* or ventilation or dialysis or drainage or endoscopy or 
parenteral nutrition or surgical procedure* or transplantation* or blood 
transfusion or intubation or travel history or antibiotic exposure* or 
quinolones or cephalosporin*) 
17. 16 OR 15 
18. 17 AND 14 
19. limit 18 to Timespan=1986-2016 
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China National Knowledge Infrastructure 
Topic: carbapenem (vague) 
OR        Topic: carbapenemase (vague) 
AND      Topic: risk factor (vague) 
Publication time: 1st January 1986-31st December 2016 
 
Chongqing VIP databases 
Title/Key word: carbapenem 
OR        Title/Key word: carbapenemase 




Topic: carbapenem (vague) 
OR        Topic: carbapenemase (vague) 
AND      Topic: risk factor (vague) 
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HI, high income; UMI, upper-middle income; LMI, lower-middle income; TCH, tertiary care hospital; SCH, secondary care 
hospital; PACH, post-acute care hospital; ICU, intensive care unit;  CARB, carbapenem resistance; CP, carbapenemase 
production; CR-CS, carbapenem resistance-carbapenem susceptible; CR-no CR, carbapenem resistance-no carbapenem 
resistance; CR-no, carbapenem resistance-no organisms; CRinf-CRcol, carbapenem resistance infection-carbapenem 
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SD-Wan, standard deviation estimated from Wan’s method; SD-Walter, standard deviation estimated from Walter’s method; 
SMD (95%CI)-Wan, standardised mean difference (95% confidence interval) calculated with standard deviation estimated from 
Wan’s method; SMD (95%CI)-Walter, standardised mean difference calculated with standard deviation estimated from Walter’s 
method; ICU, intensive care unit; CCI, Charlson Comorbidity Index; APACHE II, Acute Physiology, Age and Chronic Health 
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¶, the rank ordered by percentage of being a risk factor (i.e. percentage significant) from high to low; 
§, the rank ordered by pooled OR estimates from high to low, factors with different interpretations of results in bold; 
na, not applicable; OR (95%CI), odds ratio (95% confidence interval); CRO, carbapenem-resistant organisms; ICU, intensive 
care unit; ESBL, extended-spectrum beta-lactamases; COPD, chronic obstructive pulmonary disease; HIV, human 
immunodeficiency virus; CVC, central venous catheter; AMC, amoxicillin-clavulanate; AMS, ampicillin-sulbactam; SCF, 
cefoperazone-sulbactam; TZP, piperacillin-tazobactam; I, first generation cephalosporins; II, second generation cephalosporins; 
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OR, odds ratio; 95%CI, 95% confidence interval; na, not applicable; ICU, intensive care unit; CR-CS, carbapenem resistance-
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Individuals named on the form have read and approved its submission 
Please note that submitted applications may be circulated to panel members, 
administrative colleagues, NHSScotland information governance and 
information security colleagues, Caldicott Guardians, the CHI Advisory Group 
and, where appropriate, non-NHS Scotland colleagues from a variety of 
participating partner bodies, in the course of processing. You must make your 
eDRIS application coordinator aware of any confidential or sensitive 
information contained in your application which you would consider 
inappropriate for circulation in such a manner. Your application could be 
subject to disclosure or partial disclosure under the Freedom of Information 
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1.5.01 Full Name: Gail Robertson 
1.5.02 Title: Ms. 
1.5.03 Position: Statistical Epidemiologist 
1.5.04 Professional Registration 
No.: 
n/a 
1.5.05 Organisation Name: University of Edinburgh 
1.5.06 Address (incl. postcode):  
1.5.07 Email: 




1.5.09 Provide details of the most recent information governance training 
undertaken - a list of training courses is included at Appendix A of 
guidance notes 
 Name and institution of 
course: 
MRC Research Data and 
Confidentiality online module  
 Date completed: 4/5/17 
1.5.01 Full Name: Sharon Kennedy 
1.5.02 Title: Ms. 
1.5.03 Position: Principle Analyst/Statistician 
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Please provide details, include the 
reference number of the original 
application, and summarise the 
changes requested 
3.1.03 Does this proposal require updates of 
information or to be repeated at regular 
intervals? If yes please advise of the 
frequency 
No 
3.1.04 What is the substantive purpose of the proposal? (please choose 
one option from below that best matches your proposal) 
   Patient Care   Research 
   Audit   Performance 
Monitoring/Management 
   Service 
Planning/Improvement 
  Health/Social Care 
Administration 
   Systems 
Implementation/Testing 
  Training/Education 
   Other  
 If other clearly defined purpose, please give details: 
 
3.1.05 Access is being requested to data from which sources? (tick as 
many as are relevant) 
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     A single NHS Scotland Board (excluding NSS) including any 
system/database 
    NHS National Services Scotland  
    More than one NHS Scotland Board including any 
system/database 
    Community Health Index (CHI) database 
    NHS Central Registry 
    Other 
 If other, please give details: 
 
 
3.1.06 Provide a full, clear concise lay outline of the proposal (max. 500 
words) 
As β-lactam antibiotics, carbapenems provide enhanced Gram-
negative coverage as compared with other β-lactams and stability 
against extended-spectrum β-lactamases (ESBLs). Accordingly, 
carbapenems are often used as last resort antibiotics for 
treatment of multi-drug resistant (MDR) infections caused by 
Gram-negative bacilli (GNB). Carbapenemase producing is the 
main mechanism of carbapenem resistance. The rates of 
carbapenemase producing organisms (CPOs) have been 
gradually increasing worldwide over the last 10 years, leaving few 
effective therapeutic options available to MDR infections. In 2017, 
The World Health Organization developed a global priority 
pathogens list (global PPL) of antibiotic-resistant bacteria and 
carbapenem-resistant Acinetobacter baumannii/Pseudomonas 
aeruginosa/Enterobacteriaceae were listed as the top three 
pathogens of critical priority. Increases in carbapenemase 
producers among GNB can be attributed to multiple potential risk 
factors. Notably, antibiotic exposure has been reported as a factor 
independently associated with CPOs acquisition in healthcare 
facilities worldwide. Nevertheless, risk factors for CROs 
acquisition have not been completely characterized and conflict 
results are reported in various studies owing to the great 
heterogeneity between these studies conducting in different 
countries.  
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In Scotland, the first carbapenemase was identified in an 
Enterobacter cloacae complex blood culture isolate in 2003, 
carrying KPC-4. Afterwards, more and more CPOs were reported 
from nearly all parts of Scotland, showing a worrying upward 
trend. Additionally, there has been a 9.3% increase in 
carbapenem usage in Scottish acute hospitals since 2012. The 
epidemiology of Scottish CPO isolates, however, remains unclear. 
To date, no relevant data is available to the public in terms of 
morbidity and mortality rates, prescribing rates of clinically routine 
used antibiotics and risk factors for acquisition of CPOs in 
Scotland.   
 
This study aims to provide an indepth epidemiological analysis of 
CPOs in Scotland hence to provide a comprehensive 
understanding of characteristics underlying factors and related 
morbidity and mortality associated with CPOs. Insights based on 
these findings will further the development of effective and 
appropriate prevention and infection control strategies, thus 
curbing future emergence and spread of carbapenem resistance 
in Scotland. We intend to conduct a retrospective study of 
epidemiology of CPOs (as listed in Appendix II) among inpatients 
in Scotland between 2003 and 2016. This study will involve 
descriptive analysis of the temporal and spatial patterns of all 
CPOs cases in terms of morbidity and mortality and association 
between antibiotic prescription and morbidity from 2003 to 2016 
as well as a matched case-control study to identify risk factors 
associated with CPOs acquisition among inpatients between 
2010 and 2016. 
 
3.1.07 Provide a description of the aims and objectives of the proposal  
The proposal has 5 aims: 
1. To evaluate morbidity and mortality associated with CPOs 
acquisition in Scotland and to compare temporal trends of 
both rates at national, NHS board and hospital level and 
spatial trends of both rates between NHS boards from 2003 
to 2016. 
2. To evaluate risk factors for CPOs acquisition among 
inpatients from 2010 to 2016 in Scotland. 
We will conduct a matched 3:1 case-control study with two 
control groups (test control and demographic control). Cases 
will be inpatients carrying CPOs isolates, control group 1 (test 
control) will be a random selection of inpatients carrying non-
CPOs isolates matched with cases by participating hospital, 
admission date (± 2 months), specimen site and organism 
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species, control group 2 (demographic control) will be a 
random selection of all inpatients without CPOs isolation 
matched with cases by participating hospital and admission 
date (± 2 months). Variables of all cases and controls during 
study period, including demographic characteristics (age, 
sex), underlying diseases/comorbidity, exposure to 
operations and interventions, exposure to antibiotics in both 
the present indexing and 12 months prior to present indexing 
(listed in section 4.3) will be analysed using a regression 
model to identify independent risk factors for CPOs 
acquisition. 
3. To compare antimicrobial resistance rates to routine clinical 
tested antimicrobials (as listed in Appendix II) among cases 
and control group 1 isolates from 2010 to 2016. 
1) Results of antimicrobial susceptibility test (AST) of  
CPOs and non-CPOs   isolates will be used to calculate 
resistance rates;  
2) Differences of resistance rates between CPOs and 
non-CPOs isolates will be evaluated. 
4. To examine temporal and spatial trends of relevant 
antimicrobial (as listed in Appendix II) prescribing rates in 
primary and secondary care from 2003 to 2016. 
1) At Scottish national level and NHS board level, yearly 
prescribing rates of each antimicrobial in primary 
(2003-2016) and secondary care (2007-2016) will be 
calculated; in addition, at hospital level, in hospitals 
where CPOs isolates were identified, prescribing rates 
of each relevant antimicrobial will be calculated  (2007-
2016). 
2) At NHS board level, temporal trends of each relevant 
antimicrobial prescribing rates in primary (2003-2016) 
and secondary care (2007-2016) will be examined and 
temporal trends of each antimicrobial prescribing rate 
in different hospitals (2007-2016) will be examined. 
3) Trends of each antimicrobial prescribing rate between 
NHS boards in primary (2003-2016) and secondary 
care (2007-2016) will be examined.  
5. To investigate associations between antimicrobial prescribing 
rates in primary and secondary care and CPOs morbidity and 
antimicrobial resistance from 2003 to 2016. 
1) Associations between antimicrobial prescribing rates 
and morbidity of CPOs acquisition in primary care by 
year and NHS board will be examined from 2003 to 
2016; 
2) Associations between antimicrobial prescribing rates 
and morbidity of CPOs acquisition in secondary care 
by year and NHS board will be examined from 2007 to 
2016; 
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3) Associations between antimicrobial prescribing rates 
and antimicrobial resistance rates in primary care by 
year and NHS board will be examined from 2003 to 
2016; 
4) Associations between antimicrobial prescribing rates 
and antimicrobial resistance rates in secondary care by 
year and NHS board will be examined from 2007 to 
2016; 
5) Associations between antimicrobial prescribing rates 
and antimicrobial resistance rates at hospital level by 
year will be examined from 2007 to 2016. 
3.1.08 Provide a description of the envisaged benefits to the public 
and/or patients 
The intended study will provide an in-depth epidemiological 
analysis of CPOs in Scotland hence to provide a comprehensive 
understanding of characteristics underlying factors and related 
morbidity and mortality associated with CPOs. Better knowledge 
of risk factors and association between antibiotic prescription and 
morbidity and mortality of CPOs will help Scottish healthcare 
workers to identify cases and take corresponding precautions 
among patients of high risk for CPOs carriage and to optimise 
stewardship of clinical antibiotics. These will help local healthcare 
workers and public health policy makers to assess the impact of 
carbapenem resistance on disease burden and then to develop 
effective and appropriate prevention and infection control 
strategies, thus curbing future emergence and spread of 
carbapenem resistance in Scotland. 
3.1.09 Provide a concise description of: the research study design 
(sample size, inclusion criteria, time period); data collection; data 
processing or other means required to achieve the aims of your 
proposal.  
We intend to conduct a retrospective study of epidemiology of 
CPOs (as listed in Appendix II) among patients hospitalised in 
Scotland between 2003 and 2016. 
Study 1: epidemiology of CPOs (2003-2016) 
Inclusion criteria: 
All patients hospitalized in Scottish hospitals (including travel 
related cases) from whom a CPO was isolated from any type of 
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samples (i.e. isolation sites) during hospitalization from 2003 to 
2016.  
Exclusion criteria: 
If two or more CPO isolates of the same species were isolated 
from the same patient during the same hospitalisation, only the 
first isolate and corresponding episode will be included. Where 
more than one organism were present in a sample (a rare event) 
each organism will separately represent a case. 
Study 2: case-control study (2010-2016) 
For the 3:1 matched case-control study, controls are matched to 
cases of CPOs by participating hospital, admission date (± 2 
months), specimen site and organism species as appropriate. 
Admission date will be identified by comparison with specimen 
date within two weeks pre/post.  
Inclusion criteria:  
Cases (n=x): These are a subset of patients that were identified 
for study 1. Patients hospitalized in Scottish hospitals testing 
positive for CPOs isolated from any site from January 2010 to 
December 2016. 
Controls are defined as: 
Control Group 1 (n=3x): Randomly selected patients hospitalized 
in Scottish hospitals testing positive for organisms that did not 
produce carbapenemases from January 2010 to December 2016. 
These controls match with cases by participating hospital, 
admission date (± 2 months), specimen site and organism 
species. 
Control Group 2 (n=3x): Randomly selected patients hospitalized 
in Scottish hospitals who did not have CPOs isolated during their 
hospital stay from January 2010 to December 2016. These 
controls match with cases by participating hospital and admission 
date (± 2 months). 
Exclusion criteria:  
If two or more CPOs isolates of the same species were isolated 
from the same patient during the same hospitalisation, only the 
first isolate and corresponding episode will be included. Where 
more than one organism were present in a sample (a rare event) 
each organism will separately represent a case. 
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Data sources: 
1. SMR01 Inpatients and Day Cases: variables of potential 
risk factors of our interest, including demographic 
characteristics, underlying diseases/comorbidity, exposure 
to operations and interventions, hospital admission, 
separate hospital episode records of admission to 
Intensive Care Unit (ICU) and hospital transfer in both the 
present indexing and all previous records during 12 months 
prior to indexing from 2010 to 2016. 
2. PIS (Prescribing Information System):  
1) quarterly and yearly prescribing data of antimicrobials 
dispensed in the community at both national and NHS 
board level from 2003 to 2016 
2) quarterly and yearly prescribing data of antimicrobials 
dispensed in the community at individual patient level 
from 2009 to 2016 in the course of preceding 12 months 
prior to indexing.  
3. HMUD (Hospital Medicines Utilisation Database): quarterly 
and yearly prescribing data of antimicrobials dispensed in 
hospitals at national/NHS board/hospital level from 2007 to 
2016. 
4. ECOSS (The Electronic Communication of Surveillance in 
Scotland): CPO records including organism, specimen 
date, specimen site and results of AST from January 2003 
to December 2016. 
5. NRS Deaths Data: date and causes of death for all cases 
and controls from 2003 to 2016. 
6. ISD(S)1 (Hospital Activity Statistics): Quarterly and yearly 
data of total occupied bed days at national/NHS 
board/hospital level from 2003 to 2016. 
7. Publicly available data being added to Safe Haven for 
statistic analysis: NRS Health Board Population Estimates-
midyear population estimates from 2003 to 2016 by NHS 
board, age and sex. 
3.1.10 Provide a clear and concise outline of any statistical methods that 
will be used in the project (if applicable) 
1. Spatial trends of morbidity and mortality rates between 
NHS boards will be evaluated with appropriate regression 
analysis or analysis of variance (ANOVA). Temporal and 
spatial trends of routine clinical tested antimicrobials (see 
Appendix III) prescribing rates in primary and secondary 
care will be evaluated with ANOVA. Additionally, 
associations between antimicrobial prescribing rates in 
primary and secondary care and CPOs morbidity and 
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antimicrobial resistance will be evaluated with linear 
regression analysis. 
2. For the case-control study, univariate analysis will be 
performed: chi-square or Fisher’s exact test for 
dichotomous variables will be used to test the significance 
of categorical covariates. Parametric (ANOVA) and non-
parametric test, the Wilcoxon signed-rank test, will be used 
to assess the significance of continuous covariates. 
Logistic regression analysis was used to examine the 
independent risk factors associated with CPOs acquisition. 
3.1.11 Provide a diagram/description to illustrate the data flow or data 
linkage process envisaged (if applicable) 
Data linkage 
Linkage of datasets held at Health Protection Scotland (HPS) for 
all inpatients testing positive for CPOs confirmed by AMRHAI 
reference unit PHE and Information Services Division (ISD) held 
datasets providing information on hospitalizations, deaths, and 
relevant risk factors will be performed via HPS/PHI’s HPS 
Statistics Support Team. Community Health Index (CHI) number 
will be replaced with an anonymised patient identifier in the file 
made available for analysis.  
Age at admission would be derived from date of birth and hospital 
admission dates. Sex would be retained for analysis. Age and sex 
are potential risk factors of our interest and would be used as 
adjust factors as well while performing risk factor analysis. 
Please also find a flow chart attached (Appendix I). 
3.1.12 Does the proposal have implications for, or target, sensitive 
groups or vulnerable populations? Please give details. 
No 
3.1.13 Does the proposal seek to use information exclusively about 
deceased persons? Please give details 
No 
3.1.14 Describe how you have included public input / lay representation 
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ECOSS Date of Birth For all cases and 
controls 
 
ECOSS Sex For all cases and 
controls 
 
ECOSS Specimen site For all cases and 
controls 
 
ECOSS Specimen date For all cases and 
controls 
 
ECOSS Result of 
antimicrobial 
suseptibillity test 
For all CPOs from 
2003 to 2016, for 
control group 1 from 
2010 to 2016 
No 
ECOSS Organism For all cases and 
controls 
No 
ECOSS Specimen For all cases and 
controls 
No 
ECOSS Enzyme For all cases and 
controls 
No 
SMR01 CIS marker For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
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SMR01 Location (of 
treatment 
For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 NHS Board of 
treatment and 
residence 
For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Admission date For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Admission type For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
No 
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and admission date for 
control group 2 
SMR01 Admission/ transfer 
from - location 
For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SM01 Admission transfer 
from 
For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Specialty For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Significant facility For the present 
indexing record and all 
records during 12 
No 
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months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
SMR01 Discharge date For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Discharge type For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Discharge/ transfer 
to 
For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 





For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Main condition For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Other condition 
(all) 
For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Other condition 
(all) 
For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
No 
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and admission date for 
control group 2 
SMR01 Main Operation For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Date Main 
Operation 
For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Other Operation 
(all) 
For the present 
indexing record and all 
records during 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 
control group 2 
No 
SMR01 Date Other 
Operation (all) 
For the present 
indexing record and all 
records during 12 
No 
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months prior to 
specimen date for 
cases/control group 1 
and admission date for 









Quarterly and yearly 

















NRS- deaths Date of Death For all CRGNB 
carriers from 2003 to 
2016 and control 
group 1 
No 
NRS- deaths Causes (all) of 
Death 
For all CRGNB 
carriers from 2003 to 






and group- at 
patient level 
Records in the 12 
months prior to 
specimen date for 
No 
Epidemiology of CPO in Scotland 




cases/control group 1 
and admission date for 






doses (DDDs)- at 
patient level 
Records in the 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 






NHS Board (HB)- 
at patient level 
Records in the 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 






Date, and calendar 
year and quarter 
dispensed - at 
patient level 
Records in the 12 
months prior to 
specimen date for 
cases/control group 1 
and admission date for 








Quarterly and yearly 







Quarterly and yearly 
data from 2003 to 
2016 
No 









NHS Board (HB) Quarterly and yearly 







Calendar Year Quarterly and yearly 







Calendar Quarter Quarterly and yearly 










Quarterly and yearly 










Quarterly and yearly 






NHS Board (HB) Quarterly and yearly 
data from 2007 to 
2016 
No 
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Hospital Quarterly and yearly 








Calendar Year Quarterly and yearly 








Calendar Quarter Quarterly and yearly 







Please justify your need for identifiable or potentially identifiable 
variables 
An ECOSS extract will be provided from HPS to PHI’s HPS 
Statistical Support Team for all organisms as defined in the 
appended list from 2003-2016 and will include all available patient 
identifiers (CHI, forename, surname, date of birth, sex, 
address/postcode) in order to facilitate CHI seeding, linkage and 
identification of matched cases/controls. 
All linkage and identification of cases/controls will be performed by 
PHI’s HPS statistical Support Team and required variables (e.g. 
age, DDDs) will be derived prior to the file being anonymised and 
made available for analysis via eDRIS in the safe haven identified.  
For the aggregated study covering 2003-2016, an ECOSS extract 
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Complete the following section if you answered ‘No’ to question 3.4.1 
5.1.01 At what location is identifiable or potentially identifiable data 
being accessed? 
 
5.1.02 Please provide details of security policy/procedure  governing 
access to this physical and technical environment – append 
supporting documentation referencing appropriate sections  
 
5.1.03 Does this policy/procedure cover password policy in detail? 
Please provide details/ append supporting documentation 
referencing appropriate sections 
 
5.1.04 Does this policy/procedure cover user account management, 
including review or removal of access to sensitive/personal data, 
in detail? Please provide details/ append supporting 
documentation referencing appropriate sections 
 
5.1.05 Will individuals with access to data have individual or shared 
accounts? 
 
5.1.06 Will the data be accessed by staff working 
off site eg staff working from home at any 
time during the duration of the proposal?  
Choose an item.  
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5.2.06 Does this policy/procedure cover access control and auditing of 
system administrator activity? Please provide details/ append 
supporting documentation referencing appropriate sections 
 
5.2.07 Does this policy/procedure cover the production of backups and 
the controls in place around these? Please provide details/ 
append supporting documentation 
 
5.2.08 Does this policy/procedure describe the controls in place to 
prohibit unauthorised copying of data? Please provide details/ 
append supporting documentation referencing appropriate 
sections 
 
5.2.09 Does this policy/procedure describe physical and site controls? 
Please provide details/ append supporting documentation 
referencing appropriate sections 
5.2.10 Does this policy/procedure cover hardware repair, replacement 
or disposal and protection of data from inappropriate access 
during such procedures? Please provide details/ append 
supporting documentation 
 
5.2.11 Describe the systems, software and security used to store and 
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5.6.03 Describe the breach reporting mechanisms to be invoked in the 
event of any inappropriate access to data or other information 
security incident 
As per the eDRIS User Agreement (section 2.1), researchers 
will inform the safe haven research co-ordinator of any 
breaches. 
Section 6 – Declaration 
 I DECLARE THAT this application is accurate, and that, should it be 
successful, any health data made accessible will be used for no 
other purpose, and in no other way, than as described above.  
 I UNDERTAKE TO notify the Public Benefit and Privacy Panel of any 
future changes to the purpose or manner in which data is processed 
in accordance with this application. 
 I UNDERSTAND THAT any future applications by me, or my 
employing or sponsoring organisation, may be refused should any 
health data made accessible be used for any other purpose or in any 
other way than that described above.   
 I CERTIFY THAT all those who have access to health data in this 
proposal are aware of the requirements of confidentiality and 
understand that any breach (eg disclosure of confidential information 
to a person not authorised to receive it) will be reported to the data 
controller, and in the case of NHS Scotland originated data to 
Scottish Government eHealth division. 
 I GUARANTEE THAT no publication will appear in any form in which 
an individual may be identified without the written permission of that 
individual, and that I will apply appropriate disclosure control when 
planning publications involving the data requested. 
 I UNDERSTAND THAT the Data Controller, and agents acting on its 
behalf, reserves the right to inspect the data on the sites where it is 
being processed. 




To be signified by the APPLICANT 
Name (in Capitals):    
  
SHENGYUAN ZHAO 
Date:    
08/06/2017 
 
To be signified by the PhD SUPERVISOR (if applicable) 




 I DECLARE THAT (the applicant named above) is a bona fide worker 
engaged in a reputable project and that the data he/she asks for can 
be entrusted to him/her in the knowledge that he/she will 
conscientiously discharge his/her obligations, including in regard to 
confidentiality of the data, as stated in the declaration above. 
 
To be signified by the INFORMATION CUSTODIAN named in Section 
1.4 above (where the Information Custodian is not the applicant). 
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Appendix I. Flow chart of the study 
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Appendix II. Carbapenemase Producing Organisms (CPOs) of interest 
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§, Number of survivors/non-survivors with the characteristics (percentage of survivors/non-survivors with the characteristics 
among all the survivors/non-survivors investigated), unless stated otherwise; 
¤, median (interquartile range); 
OR (95%CI), odds ratio (95% confidence interval); aOR (95%CI), adjusted odds ratio (95% confidence interval); CPO, 
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Appendix 4-2. Forest plots of results of univariate analyses of risk factors 
for carbapenemase-producing organisms (CPO) infection by comparing 
cases and culture positive controls/demographic controls. (A) 
Demographics and comorbidities related variables; (B) Healthcare 
exposure and invasive procedures related variables. 
 
(A) 
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Appendix 4-3. Forest plots of results of univariate analyses of risk factors 
for carbapenemase-producing organisms (CPO) colonisation by 
comparing cases and culture positive controls/demographic controls. 
(A) Demographics and comorbidities related variables; (B) Healthcare 
exposure and invasive procedures related variables. 
 
(A) 
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